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Abstract
Hsp104 is a protein remodeling factor from Saccharomyces cerevisiae which couples the energy released
from ATP hydrolysis to the disaggregation of amyloid and amorphous protein aggregates. Hsp104
assembles into a hexamer with a central channel through which aggregated substrates are threaded. The
exact mechanistic details of how Hsp104 accomplishes disaggregation have not been fully articulated. In
this work, our goal was to determine the role of inter-subunit communication in amyloid and amorphous
substrate disaggregation and to resolve the function of the distal loop of the Middle Domain of Hsp104.
Using a mutant subunit doping analysis, we determined whether Hsp104 subunits work in concert to
accomplish substrate disaggregation. We found that during amorphous substrate disaggregation,
Hsp104 subunits act independent from each other. In contrast, when Hsp104 encounters more stable
substrates, like amyloid, the subunits collaborate to hydrolyze ATP and to bind substrate to accomplish
disaggregation. The amount of inter-subunit collaboration was found to be commensurate with the
stability of the aggregated substrate: more stable aggregates required more subunit collaboration.
Furthermore, we found two Hsp104 mutants, L462R and D704N, which specifically impaired inter-subunit
communication, indicating that the regions containing these mutations may be critical for relaying intrasubunit signals.
To disaggregate amorphous aggregates, Hsp104 must work in concert with the chaperone pair Hsp70
and Hsp40. How Hsp104 interfaces productively with Hsp70 and Hsp40 is undetermined. Recently, it has
become apparent that the coiled coil Middle Domain (MD) of Hsp104 and ClpB play a key role in
collaboration with Hsp70 and Hdp40. Here, we determine that the distal loop portion of the MD is
especially important for collaboration with Hsp70 and Hsp40, as mutations in this region specifically
ablate the functional interaction with Hsp70. Furthermore, the distal loop of Hsp104 appears to be
involved in an interface with the second nucleotide binding domain (NBD2) of Hsp104 as shown by
tryptophan fluorescence, hydroxyl radical foot-printing, and disulfide cross-linking. We hypothesize that
the distal loop interaction with NBD2 is inhibitory to productive collaboration with Hsp70 and Hsp40.
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ABSTRACT
DEFINING THE MECHANISM OF HSP104-MEDIATED PROTEIN
DISAGGREGATION
Morgan Elizabeth DeSantis
James Shorter, Ph.D.
Hsp104 is a protein remodeling factor from Saccharomyces cerevisiae which
couples the energy released from ATP hydrolysis to the disaggregation of amyloid and
amorphous protein aggregates. Hsp104 assembles into a hexamer with a central channel
through which aggregated substrates are threaded. The exact mechanistic details of how
Hsp104 accomplishes disaggregation have not been fully articulated. In this work, our
goal was to determine the role of inter-subunit communication in amyloid and amorphous
substrate disaggregation and to resolve the function of the distal loop of the Middle
Domain of Hsp104.
Using a mutant subunit doping analysis, we determined whether Hsp104 subunits
work in concert to accomplish substrate disaggregation. We found that during amorphous
substrate disaggregation, Hsp104 subunits act independent from each other. In contrast,
when Hsp104 encounters more stable substrates, like amyloid, the subunits collaborate to
hydrolyze ATP and to bind substrate to accomplish disaggregation. The amount of intersubunit collaboration was found to be commensurate with the stability of the aggregated
substrate: more stable aggregates required more subunit collaboration. Furthermore, we
found two Hsp104 mutants, L462R and D704N, which specifically impaired inter-subunit
communication, indicating that the regions containing these mutations may be critical for
relaying intra-subunit signals.
v

To disaggregate amorphous aggregates, Hsp104 must work in concert with the
chaperone pair Hsp70 and Hsp40. How Hsp104 interfaces productively with Hsp70 and
Hsp40 is undetermined. Recently, it has become apparent that the coiled coil Middle
Domain (MD) of Hsp104 and ClpB play a key role in collaboration with Hsp70 and
Hdp40. Here, we determine that the distal loop portion of the MD is especially important
for collaboration with Hsp70 and Hsp40, as mutations in this region specifically ablate
the functional interaction with Hsp70. Furthermore, the distal loop of Hsp104 appears to
be involved in an interface with the second nucleotide binding domain (NBD2) of
Hsp104 as shown by tryptophan fluorescence, hydroxyl radical foot-printing, and
disulfide cross-linking. We hypothesize that the distal loop interaction with NBD2 is
inhibitory to productive collaboration with Hsp70 and Hsp40.
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CHAPTER 1: Introduction
Sections of this chapter are based on the review DeSantis and Shorter, 2012 [1]. Required
permissions were obtained.

1.1 Protein misfolding can lead to disease
Proteins are macromolecules that perform remarkable functions inside the cell.
They are involved in activities as diverse as catalyzing myriad metabolic reactions,
regulating and facilitating gene expression, providing intra-cellular scaffolds, generating
force and movement, and promoting immunity [2]. The function of each protein is
fundamentally tied and dependent on its three-dimensional structure; a protein that does
not assume the correct fold may not function properly, which can result in pathology [3,
4]. Furthermore, misfolded or aggregated proteins can be intrinsically toxic to cells [5, 6].
As such, protein misfolding and aggregation are often associated with disease [7-9]. In
fact, aggregation can be so deleterious to fitness that every living organism has elaborate
and complex systems in place to ensure proper protein folding. These systems include
chemical and molecular chaperones to usher the nascent protein into the correct fold [10,
11], protein-remodeling factors which can rearrange or disassemble pre-formed
aggregates [12, 13], and degradation machinery to remove protein aggregates that cannot
be re-folded [14, 15].
There are two broad classes of protein aggregates that are implicated in disease
[16-18]. Amorphous type aggregates are hypothesized to be involved in cystic fibrosis
[19], cancer [20], and some neurodegenerative diseases, including Amyotrophic Lateral
Sclerosis (ALS) [21, 22]. Amorphous aggregates, which will also be referred to as
1

disordered aggregates, can be induced with heat or high protein concentration in vitro,
are largely unstructured and appear granular when viewed via Electron Microscopy [16,
22], but contain β-sheet character when examined with x-ray diffraction and Infrared (IR)
spectroscopy [16]. Amorphous aggregates are typically soluble in chemical denaturants,
like SDS or urea [16].
Amyloid aggregates comprise the other class of disease-associated protein
misfolding products [8, 23-25]. Many neurodegenerative diseases, like Parkinson’s or
Alzheimer’s Disease, contain hallmark amyloid plaques that can be located intra-cellular
or extra-cellular [5, 7, 26]. Amyloid refers to a self-templating protein conformation that
can covert native protein structure to the amyloid fold [27],which is characteristically βsheet rich, and assembles into fibers where the β-strands run perpendicular to the fiber
axis [28-30]. The fibers are SDS-resistant, insoluble, and spontaneous dissociation is rare
[31].
The relationship between protein aggregation and toxicity is not well defined in
all cases. However it is hypothesized that toxicity associated with protein aggregation
could be caused by loss of function of the aggregating protein [32, 33], insolubility and
aggregation in the cytoplasm or extracellular matrix [6, 34], or due to sequestration of
molecular chaperones and metastable proteins with unstructured regions [35, 36].
Recently it has been hypothesized that in some cases amyloid fibers may actually serve to
protect the cell from potentially toxic pre-amyloid oligomeric species [5, 37]. Whatever
the cause of toxicity, protein aggregation is at the root of many human diseases and is
only becoming a more pressing problem as our population ages. In fact, the single biggest
2

risk factor for many protein-misfolding diseases is aging. Because the onset of the disease
is often late in life, polymorphisms that might contribute to protein-misfolding diseases
are not purged from the gene pool by natural selection [9, 38]. Furthermore, there are few
biomarkers for the majority of these diseases, which makes preventative treatment
difficult to execute [39, 40]. An ideal therapeutic strategy would include treatments that
reverse protein aggregation [41]. The protein Hsp104 is a very promising therapeutic
because it has evolved to reverse amorphous and amyloid aggregation in yeast [12, 4244].

1.2 Hsp104 is a bifunctional protein disaggregase
Hsp104 is a protein disaggregase found in yeast [12, 42, 45]. As a protein
disaggregase, Hsp104 facilitates the unfolding of protein aggregates such that they can
assemble into the correct, native fold [12]. Hsp104 was first identified in genetic studies
to confer selective advantage to yeast exposed to high temperatures [42], low
temperatures, or chemical stressors, like ethanol and arsenite [45]. Deletion of Hsp104
results in yeast that cannot clear heat induced aggregates. Instead, dense aggregates,
which can be visualized by Electron Microscopy (EM), remain littered throughout the
cytoplasm even 2 hours post heat shock [43]. Pure protein biochemistry using model
amorphous aggregates of luciferase [12] and GFP [46] revealed that Hsp104 functions
unlike other protein chaperones by actively disaggregating amorphous aggregates and not
by simply inhibiting aggregation [12]. Genetic interactions were detected between
Hsp104 and the chaperone Hsp70, indicating that Hsp104 requires Hsp70 for activity
[47]. This result was confirmed in vitro and it was also observed that Hsp40, a regulator
3

of Hsp70 ATPase activity, is required for robust disaggregation activity [12, 48]. In fact,
Hsp104 has no activity towards amorphous aggregates without some activating co-factor.
In cells and in vitro, Hsp70 and Hsp40 collaborate to promote Hsp104-mediated
disaggregation [12, 49]. The details of the collaboration between Hsp104 and the Hsp70
system will be discussed more in subsequent sections. The in vivo chaperone network
also includes other factors which may enhance Hsp104 disaggregation activity. These
include small heat shock proteins (sHsps) which co-precipitate with aggregated proteins
[50] and may promote Hsp104-mediated disaggregation [51] as well as Hsp110 proteins,
which act as nucleotide exchange factors (NEFs) for Hsp70s and may increase
disaggregation by the Hsp104, Hsp70, and Hsp40 system [51, 52].
Hsp104 is required for prion maintenance and inheritance in yeast [53-55]. Prions,
which are infectious amyloids, are harnessed by yeast for beneficial purposes [56]. Yeast
can employ prions as non-nucleic acid based, heritable elements that confer selective
advantage in certain environments [57]. An excellent example of this phenomenon is
found in the S. cerevisiae prion protein, Sup35 which, by accessing an infectious amyloid
structure, acts as the protein determinant for the prion phenotype [PSI+] [44, 58-61]. In
the soluble, native structure Sup35 functions as a component of the translation
termination factor which prevents ribosomes from reading through nonsense codons [62].
However, in the [PSI+] state Sup35 does not function as proficiently and novel protein
products are generated from read-through of stop codons, which reveals hidden genetic
variation [44, 58, 61, 63]. In response to environmental stressors, like peroxide or high
salt , Sup35 can convert from the native fold to the amyloid conformation [64, 65], thus
4

allowing yeast to exploit cryptic genetic variation to survive in adverse conditions [66].
Intermediate concentrations of Hsp104 are absolutely required for inheritance of [PSI+]:
overexpression and deletion of Hsp104 yields yeast that are [psi-] (i.e. all Sup35 is
soluble and not in the amyloid state) [53, 63, 67]. This observation can be explained by
the unique relationship between [PSI+] and Hsp104. Low concentrations of Hsp104 can
nucleate soluble Sup35 to form prions and sever pre-formed Sup35 amyloids into
nucleating seeds [54, 55, 68], thus allowing the prion phenotype to be propagated to
daughter cells. High concentration of Hsp104 inhibits prion assembly and completely
disaggregates pre-formed Sup35 amyloid, which results in daughter cells that are [psi-]
[54, 55, 68, 69]. Deletion of Hsp104 results in [psi-] yeast because large pre-existing
fibers cannot be severed into small, heritable elements or because new prion fibers cannot
be nucleated in the absence of Hsp104, ensuring that existing Sup35 prions are not passed
from mother to daughter cells [54].
Hsp104 is also responsible for the maintenance and heritability of the yeast prions
[URE3] and [RNQ+], whose protein determinants are Ure2 and Rnq1, respectively [70,
71]. Soluble Ure2 is regulator of nitrogen uptake and metabolism [72, 73]. In the prion
state [URE3], yeast preferentially use a poorer nitrogen source, even in the presence of
ideal nitrogen sources [74]. There is no distinct phenotype associated with the [RNQ+]
prion [71]. Instead, it appears that yeast must be [RNQ+] in order to induce [PSI+] [75].
Low concentrations of guanidine HCl (5mM), which is a specific inhibitor of Hsp104
ATPase activity, results in clearance of [PSI+] and [URE3] [76-79]. While overexpression
or deletion of Hsp104 is required for [PSI+] clearance, only deletion of Hsp104 results in
5

curing most [URE3] or [RNQ+] phenotypes [70, 71, 80]. It is not entirely clear why
inheritance of [PSI+], [URE3] and [RNQ+] are governed differentially by Hsp104.
As with amorphous substrate aggregation, Hsp70 and Hsp40 can collaborate with
Hsp104 to alter activity towards amyloid [67]. For example, overexpression of the Hsp70
family member Ssa1 buffers [PSI+] yeast from losing the prion phenotype upon over
expression of Hsp104 [67]. Moreover, high levels of Ssa1 induce spontaneous [PSI+]
induction in [psi-] cells, indicating that Ssa1 might promote the amyloid form of Sup35
[81]. Ssb1, another yeast Hsp70, has the reverse effect on [PSI+]; overexpression of Ssb1
and Hsp104 promotes [PSI+] curing [82]. Curiously, elevated levels of Ssa1 can cure the
[URE3] phenotype [83, 84]. The relationship between Hsp104, Hsp70 and prions is very
complicated in vivo. The results are not so disparate in vitro. Both Ssa1 and Ssa2, as well
as the Hsp40 family members, Sis1 and Ydj1, inhibit assembly of the truncated prion
domains (NM) of the Sup35 protein [49]. Remarkably, pure protein biochemistry has
revealed that Hsp70 and Hsp40 are not necessary for amyloid remodeling [54]. Unlike
disordered substrates, Hsp104 can remodel amyloid in the absence of the Hsp70 system.
This finding suggests that Hsp104 may use subtly different mechanism to disassemble
amorphous and amyloid aggregates.

1.3 ClpB and Hsp104 are homologues with different functional repertoires
Hsp104 has two different primary activities in vivo: thermotolerance and prion
maintenance. Within the category of prion maintenance, Hsp104 can function to
propagate prions to daughter cells or, as with [PSI+], completely cure the prion
phenotype. These cellular activities originate from the ability of Hsp104 to remodel
6

different types of aggregated substrate, as has been shown in numerous in vitro studies
[12, 49, 54, 55] (Figure 1). In thermotolerance, Hsp104 disaggregates disordered
substrates and this activity requires Hsp70 and Hsp40 [12]. To propagate prions, Hsp104
either fragments pre-existing fibers or nucleates the formation of new fibers [54, 85]. In
[PSI+] curing, Hsp104 completely disaggregates prions, which results in solubilized,
monomeric Sup35 [54]. These two activities do not strictly require Hsp70 and Hsp40 [49,
55] (Figure 1a, b)
While animal cells possess a weak disaggregase activity that is powered, in part,
by an Hsp110 protein [51, 52] there is no functional homologue of Hsp104 in metazoan
lineages. Bacteria, plants, protozoa, chromista, and fungi all have protein disaggregases
which function to promote stress tolerance by unfolding aggregated proteins [41].
Interestingly, Candida albicans Hsp104 is able to cure by overexpression and propagate
the prion [PSI+] when expressed in Hsp104-deletion strains of S. cerevisiae [86]. This
indicates that C. albicans Hsp104 can nucleate and disaggregation the Sup35 amyloid
[86]. However, it is unclear whether Hsp104 in organisms other than budding yeast
possess robust amyloid disaggregation capacity. Recently, it has been demonstrated that
Schizosaccharomyces pombe and Eschericia coli homologues of Hsp104 can support and
propagate [PSI+] in S. cerevisiae if Hsp70 and nucleotide exchange factors from each
organism are also co-expressed [87, 88]. While this activity was very weak for the E. coli
homologue [88], these experiments indicates that both homologues have the capacity to
remodel amyloid aggregates of Sup35 in a way that promotes nucleation of more fibers.
However, the S. pombe homologue was not capable of curing [PSI+] via overexpression,
7
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Figure 1: In vitro disaggregase activity of Hsp104 and ClpB. (a) Hsp104 remodels
amorphous aggregates via collaboration with Hsp70 and Hsp40, while ClpB remodels
these types of aggregates via collaboration with DnaK, DnaJ, and GrpE (KJE). The
product of disaggregation of amorphous aggregates is natively folded protein. Hsp104
or ClpB hexamer is shown in gray with the front half cutaway to reveal the axial
channel running down the length of the structure. Four pore loops with conserved
tyrosines residues are shown in orange. These pore loops are important for substrate
binding and threading through the axial channel. (b) Only Hsp104 is able to remodel
amyloid aggregates and in vitro this can proceed without the aid of Hsp70 and Hsp40.
Products of amyloid disaggregation are soluble natively folded protein and fragmented
amyloids. However, for some amyloids (e.g. Sup35 prions) remodeling can continue to
generate disordered-type aggregates that Hsp104 cannot remodel and which lack the
seeding activity of amyloid.
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which indicates that Hsp104 from S. pombe does not have the capacity for robust amyloid
disaggregation, which would result in fully solubilized Sup35 monomers [87]. This
experiment was not attempted for the E. coli homologue [88].
The bacterial Hsp104 that was used in the study outlined above is named ClpB
and is one of the best studied Hsp104 homologues. Despite sharing over ~50% identity
with Hsp104, the bacterial protein ClpB does not appear to possess the same dual
functionality as Hsp104. Like Hsp104, ClpB is able to disaggregate amorphous substrates
in response to environmental stresses that induce widespread protein aggregation [13, 8992]. However, unlike Hsp104, ClpB appears to be ineffective at disaggregating amyloid
conformers in vitro [54, 93-95] (Figure 1a).

1.4 The structures of Hsp104 and ClpB are still unresolved
Hsp104 and ClpB are in the Clp/Hsp100 family of proteins. Members of this
family, which includes ClpC, ClpA, and ClpX, are all protein remodeling machines [96,
97]. Most of these proteins are involved in protein degradation and work in tandem with
the chambered protease, ClpP [98-100]. Hsp104 and ClpB are unique within this family
in that they do not contribute to protein degradation pathways but instead aid in aggregate
refolding. The Clp/Hsp100 sub-group is categorized within the AAA+ (ATPases
Associated with various cellular Activities) super-family [96, 101-103]. AAA+ proteins
are functionally diverse, with members involved in cellular processes as varied as DNA
replication, protein degradation, microtubule severing, and membrane fusion [101]. All
AAA+ proteins function by coupling the energy released by ATP binding and hydrolysis
to chemo-mechanical work on some macromolecular target [101]. The unifying structural
9

feature of this family is the canonical AAA+ domain, which harbors conserved motifs
that enable ATP binding and hydrolysis [104] (Figure 2a). For an excellent review see
Hanson and Whiteheart [104]. The Walker A motif (with a consensus sequence
GXXXXGK[T/S]) enables nucleotide binding. The P-loop of the Walker A motif (Figure
2a) directly interacts with the phosphates in ATP [104]. The lysine residue in this motif is
invariant and mutation of it (typically to Ala or Thr) inhibits ATP binding [104]. The
Walker B motifs (consensus: hhhhDE) is involved in nucleotide hydrolysis (Figure 2a,b).
The Asp residue coordinates Mg2+ that is important for ATP hydrolysis and the Glu
residue is hypothesized to activate water for nucleophillic attack during hydrolysis [104,
105]. Mutation of the Walker B Glu residue (typically to Gln) results in a protein that can
bind ATP, but not hydrolyze it [104]. The pore loop (consensus: YVG) has been shown
to directly engage substrate [106-108]. This loop undergoes ATP-dependent
conformational changes and is thought to thread substrate through the central pore of the
AAA+ machine as the enzyme hydrolyzes ATP (Figure 2a,b) [104]. Mutations that
disrupt the pore loop (typically Tyr to Ala) result in a protein which cannot bind
substrate, but is still able to hydrolyze ATP and oligomerize properly [104, 107]. The
Arginine Finger (RF) motif allows for cooperativity during hydrolysis [104]. While not
conserved in all AAA+ proteins, in most obtained crystal structures, the RF from one
subunit reaches into the ATP binding site of the adjacent subunit and engages nucleotide
there [104, 109]. The Sensor I residue is usually a conserved Asn or Thr which interacts
with the Walker B motif and the γ-phosphate of ATP [110] (Figure 2a,b). Finally, the
Sensor II residue (usually a conserved Arg) is also involved in nucleotide binding and/or
10
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Figure 2: AAA+ domains and conserved motifs. (a) Typical AAA+ domain as
described by Hanson and Whiteheart[104]. Shown here is the homology modeled
NBD2 domain of Hsp104 (modeled on the T. thermophilus ClpB structure, PDB ID:
1QVR). Conserved motifs are highlighted in color and key residues in each domain
are shown in stick format. The Walker A motif is shown in red with an arrow pointing to the P-loop, Pore loop in magenta, Walker B in green, Sensor I (S1) in dark
blue, Arginine finger (RF) in purple, and Sensor II (S2) in orange. (b) Organization
of conserved motifs in a typical AAA+ domain. Color and naming convention as
detailed in part (a). Key residues which are shown as sticks in part (a) are shown in
color.
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hydrolysis and also engages the γ-phosphate of ATP to promote hydrolysis [101, 104]
(Figure 2b).
Most known AAA+ proteins form higher-order oligomers [101]. Hsp104 and
ClpB are functional as hexamers and assemble into a three tiered barrel structure with a
central channel that runs down the center axis [96, 111, 112]. These proteins are thought
to drive disaggregation by directly translocating aggregated substrates through their
central channel in a way that is coupled to ATP hydrolysis [107, 113-117]. The exact
mechanistic details of disaggregation are not elucidated, in large part because of a lack of
high resolution structural information.
Each Hsp104 or ClpB monomer contains an N-terminal domain, two AAA+
nucleotide-binding domains (NBD1 and NBD2), and a predicted coiled-coil middle
domain (MD) that is inserted toward the C-terminal end of NBD1 (Figure 3a) [96, 118121]. Additionally, Hsp104 contains a short C-terminal extension, absent from ClpB, that
is required for Hsp104 hexamerization [122]. The tertiary structure of the individual
domains was largely resolved in 2003 when a 3.0Å crystal structure of ClpB (TClpB)
from the thermophilic eubacterium, Thermus thermophilus, was solved by Tsai and
colleagues (Figure 3b) [123]. These studies revealed that both NBDs adopt a canonical
AAA+ fold [123]. The structure of NBD1 agreed with a previously solved structure of
this isolated domain [124]. The N-terminal domain, which is the least conserved domain
in the Hsp100 disaggregase family, was also structurally similar to the isolated E. coli
ClpB N-terminal domain [125]. The MD was revealed as a broken anti-parallel coiledcoil (Figure 3b, for naming nomenclature refer to Figure 4b) [123]. The MD is less well
12
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Figure 3: Predicted structures and hexameric models of Hsp104 and ClpB. (a)
Domain organization of monomer of Hsp104 and ClpB. N-terminal domain (N)
shown in purple, Nucleotide binding domain 1 (NBD1) shown in cyan, Middle
domain (MD) in yellow, Nucleotide binding domain 2 (NBD2) in dark blue. Only
Hsp104 has the short C-terminal extension (C) shown in green. Sequence numbering
for ClpB is shown on top and for Hsp104 is shown on the bottom. (b) TClpB crystal
structure PDB ID: 1QVR [123]. Domain coloring corresponds with part (a). A 180°
rotation about the vertical axis is shown on the right. (c) The Tsai model for the
hexameric quaternary structure of TClpB. The Tsai model, which was initially based
on Cryo-EM envelopes generated with TClpB is shown on left [139]. (d)The Saibil
model, which used Hsp104 to generate Cryo-EM density, is shown in the middle
[134] (e) The 6.93Å crystal structure of hexameric, full length ClpC is shown on the
right. The adaptor protein MecA was omitted for clarity. A side view is shown on top
and a view down the axial channel from the N-terminus is shown on the bottom. In
(c-e) one subunit is colored as described in part (a). The other five subunits are in
gray.
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Figure 4: Middle domain nomenclature. (a) An alignment of the MD from E. coli
ClpB, T. thermophilus ClpB, and S. cerevisiae Hsp104. Helix 1 is colored in green,
helix 2 is colored in purple, helix 3 is colored in light blue, and helix four is colored
in yellow. Motif 1 (also called wing 2) is boxed in black while motif 2 (also called
wing 1) is boxed in orange . (b) Close up of the MD in the TClpB crystal structure.
Each helix and motif is colored as indicated in part (a). NBD2 is omitted for clarity.
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conserved, with Hsp104 and ClpB sharing only ~36% identity. Unfortunately, full length
TClpB did not crystallize in its functional hexameric structure, but in a trimeric spiral
with protomer-protomer interactions that might, at least in part, reflect crystal contacts
rather than native protomer interfaces. In a dynamic, multi-domain molecular machine
like Hsp104/ClpB, understanding the relative domain positioning and protomer
organization is absolutely critical to understanding the mechanism of action.
The overall quaternary structure of Hsp104 and ClpB has been investigated
primarily by Cryo Electron Microscopy (Cryo-EM), which has led to debate. It is
generally agreed that Hsp104 and ClpB are native hexamers and that oligomerization is
promoted by increased protein concentration [120], low salt [120, 126], and the presence
of ADP or ATP [111, 112, 126-128]. Curiously, however, while nucleotide binding to
NBD1 is critical for ClpB hexamerization [126], this situation is reversed in Hsp104
where nucleotide binding to NBD2 is key [111, 128, 129]. NBD1 and NBD2 both
contribute the overall observed ATPase activity in ClpB [126], whereas NBD1 primarily
fulfils this role in Hsp104 [111, 128, 129]. The underlying reason for this switch between
NBDs is unknown and continues to remain puzzling and unaddressed. Gross domain
position and the protomer-protomer interfacial packing of Hsp104 and ClpB hexamers
still remain uncertain. Of particular interest is the position of the coiled-coil MD, which is
necessary for disaggregase activity and is unique to the Hsp100 chaperones that function
primarily in disaggregation [1, 123, 126, 130]. In the TClpB crystal structure, this domain
was jutting obliquely from the axis of the other domains [123] (Figure 3b). Thus, in the
original cryo-EM reconstructions of TClpB in the presence of AMP-PNP (a non15

hydrolyzable ATP analog) the MD was assigned to protrusions that appeared to emanate
from one tier of the hexamer [123] (Figure 3c, Tsai model).
In subsequent studies, to determine any conformational reorganizations that take
place through the ATPase cycle, Cryo-EM envelopes of TClpB in the ADP and apo state
were reconstructed as well as the envelope of the Double Walker B TClpB mutant
(E271A:E668A) in the presence of ATP [131]. This mutant binds but does not hydrolyze
ATP at both NBDs and has increased affinity for substrate [131, 132]. In all states, a twotiered hexamer with an axial channel running down the center was clearly visible [131].
However, the N-terminal domain was not visible as electron density [131]. In the AMPPNP bound state, the TClpB envelope shows clear, well defined protrusions on the
outside of the hexamer, which, when the TClpB monomeric crystal structure was rigid
body fit into the density, overlapped partially with predicted MD density [123, 131]. All
the other nucleotide states (ATP, ADP, and apo) do not have such large protrusions that
could correlate with an MD projection. The authors ascribe this to inherent mobility of
the coiled coil MD [131]. Indeed, the main difference between the different nucleotide
states were the length of these radially extending protrusions [131]. By contrast, the
positions of the AAA+ domains remained almost identical in the various nucleotide states
[131]. Consequently, these reconstructions do not clarify the mechanochemical coupling
events that drive substrate translocation through the central channel.
This structural model of the hexamer was challenged by cryo-EM reconstructions
of Hsp104 by Saibil and colleagues [133-135]. In these studies, cryo-EM reconstructions
were generated of Hsp104 lacking its N-terminal domain, ∆N-Hsp104, and an NBD2
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sensor-1 Hsp104 mutant, Hsp104N728A, which has slowed hydrolysis in NBD2 and is able
to catalyze disaggregation of disordered aggregates in the absence of Hsp70 and Hsp40,
but is unable to remodel amyloid [46, 136]. Contrary to the TClpB reconstruction,
Hsp104N728A had a structured N-terminal domain and presented as a three-tiered hexamer
with no oblique MD protrusion [133-135]. The central cavity of Hsp104N728A was also
much larger than observed with TClpB and the modeled protomer-protomer packing was
unlike that of typical AAA+ structures [133-135]. It was hypothesized that the enlarged
cavity might serve as an adaptation necessary to remodel large aggregated structures
[133-135]. A TClpB-homology model of Hsp104 was rigid-body fit into the electron
density with each domain connected by a flexible linker (Figure 3d, Saibil model) [133135]. The resulting fits placed the MD intercalated within NBD1 and NBD2, rather than
projecting out into solution (Figure 3d) [133-135]. This physical proximity of the MD to
both NBDs, which is also partially supported by fluorescence proximity studies of ClpB
[137], might help explain how the MD mediates communication pathways between
NBD1 and NBD2 [120].
The cryo-EM reconstruction of Hsp104N728A with ATPγS (a slowly hydrolysable
ATP analog), ATP and ADP was also reconstructed [134, 135]. Hsp104N728A displayed
large nucleotide-dependent domain reorganizations, with the ATPγS state having the
most expanded central cavity [134, 135]. These domain movements displaced the
substrate-binding tyrosine loops in the central channel and triggered a peristaltic motion
that provides a structural basis for N- to C-terminal substrate translocation [134, 135].
Asymmetric reconstructions of Hsp104N728A with ATPγS and ATP provided
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unprecedented insight into disaggregase activity [134, 135]. These reconstructions
suggested a sequential mechanism of ATP hydrolysis in NBD1 coupled to clockwise
handover of substrate in the NBD1 ring and a coordinated handover between NBD1 and
NBD2 [134, 135]. Thus, the first detailed structural picture of the mechanochemistry that
underpins protein disaggregation emerged [134, 135, 138].
It remains unclear why the Cryo-EM reconstructions of TClpB and Hsp104N728A
would be so disparate. Could the differences simply reflect a fundamental difference in
hexamer architecture for the prokaryotic and eukaryotic enzymes? Or could the different
reconstructions reflect the different protein preparations for the Cryo-EM? For example,
glutaraldehyde fixation was employed for the TClpB studies [123, 131], whereas rapid
freezing in liquid ethane was employed for the Hsp104 studies [133, 134]. The story
takes another twist when Tsai and colleagues presented Cryo-EM reconstructions of a
double Walker B Hsp104 mutant (E285A:E687A) in the presence of ATP and ∆NHsp104 in the presence of ATPγS with and without glutaraldehyde [139]. Both sets of
envelopes appeared very similar, indicating that fixation might not be an issue [139].
Intriguingly, and in contrast to their prior TClpB reconstructions, there was a striking
absence of additional mass density on the outside of the ∆N-Hsp104 or Hsp104E285A:E687A
hexamer [139]. Indeed, the Cryo-EM envelopes of the different Hsp104 variants
constructed by the different groups are remarkably similar, particularly for ∆N -Hsp104
plus ATPγS (especially when either reconstruction is subjected to a 180° vertical
rotation) [133, 134, 139]. This similarity among Hsp104 envelopes might even suggest
that TClpB hexamers possess a subtly distinct architecture. After all, Hsp104 is equipped
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to remodel amyloid, whereas ClpB is not [54, 93-95], so perhaps subtle structural
differences might be anticipated. However, despite the absence of lateral projections
emanating from the Hsp104 hexamer, the authors placed the MD outside of the hexamer
walls in their atomic structure fitting as with TClpB [139]. Thus, it is still unclear
whether the MD of Hsp104 and ClpB is located inside or outside of the hexamer. It
should also be noted that no reconstructions have been presented with full-length wildtype Hsp104.
In an effort to visualize the MD during Cryo-EM, an Hsp104 chimera was
generated with T4 lysozyme inserted into the MD [139]. Because the lysozyme was
visible as density on the outside of the hexamer, it was suggested that the MD must also
be located on the exterior [139]. However, density corresponding to the MD on the
outside of the hexamer could still not be readily visualized even with this highly artificial
construct [139]. It is extremely probable that this large-scale (19kDa) insertion disrupts
the native quaternary structure of Hsp104, especially since the insertion was located in
helical region of the MD (between residues N467 and E468 of helix 2 (Figure 4b)) and
not in a predicted loop region. Indeed, although this chimera possesses some
disaggregation activity against non-native substrates in vitro, it should be noted that its
ATPase activity was elevated, hexamerization was perturbed, disaggregase activity was
dysregulated and the functionality was not assessed in vivo [139]. Thus, it is not clear
whether the two models can really be distinguished with this contrived insertion variant
despite it displaying partial functionality in restricted settings. Rather, the ability of the
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Hsp104 to accommodate such a large insertion and retain some activity indicates an
extraordinary plasticity of the hexamer.
A number of biochemical techniques have been used to attempt to differentiate
which, if either, of the two models is correct. Close proximity of motif 2 in the MD to
NBD1 is well supported. Engineered disulfide cross-links in ClpB that covalently link
NBD1 to motif 2 of the MD have shown that these two domains are closely associated
and that movement of the MD is crucial for disaggregation [123, 140]. Unfortunately,
these cross-links do not differentiate between the two models because the MD is closely
associated with NBD1 in both proposed structures [123, 131, 133-135, 139]. Importantly,
the MD is inaccessible to three monoclonal antibodies that recognize native MD epitopes
in Hsp104 hexamers, but is exposed in Hsp104 monomers [120, 133]. These data suggest
that the MD becomes shielded upon hexamerization but remains accessible and solvated
when Hsp104 is monomeric [134]. This observation might explain why monomeric
TClpB crystallized with the MD jutting away from the axis of the NBDs. However, in
contrast to these results, Lee et al. inserted a short StrepII tag (WSHPQFEK) into the MD
(between residues N467 and E468 of helix 2 (Figure 4a, b)) of Hsp104 and employed dot
blots to determine whether the tag was exposed in monomeric and hexameric Hsp104
[139]. These studies suggested that the StrepII tag was accessible in monomeric and
hexameric forms of Hsp104 [139]. Unfortunately, however, it is uncertain whether this
epitope tag is truly innocuous or partially disruptive. Moreover, these data are difficult to
assess because it is not clear whether monomeric and hexameric Hsp104 were spotted on
the same dot blot. Thus, one cannot be certain from the presented data whether the signal
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intensities for monomeric and hexameric conformers are directly comparable [139].
Recently, using hydrogen/deuterium exchange (H/X), Oguchi and colleagues observed
that key regions of the MD show slowed hydrogen exchange upon hexamerization. These
regions map to helix 1 in motif 1 and helices 2 and 3 in motif 2. The authors note that the
H/X protection patterns are distributed in an asymmetric way across the MD. To test
whether the H/X protection of the MD results due to association with the outside of the
ring or because the MD becomes intercalated between NBDs, the authors introduce sitespecific cysteine residues and attempt to PEGylate them to probe solvent accessibility.
They find that one side of the MD (the side furthest away from the ring in Figure 3c)
remains solvent accessible in the hexameric conformation while the other face of the MD
(the face closest to the ring in Figure 3c) is nestled against the NBD1 ring [141]. The
authors suggest that the regions of the MD become protected from PEGylation and H/X
because of an interaction between the NBD1 ring and the inside face of the MD. Their
data does not support either Cryo-EM model in that the MD does not appear to be
intercalated within two AAA+ domains as suggested by the Saibil group [133, 134] or
jutting out into solution as suggested by the Tsai laboratory [123, 131, 139] (Figure 3c,
d).
Another major difference between the hexameric models is the positioning of the
putative arginine fingers [123, 131, 133-135, 139]. Typically, an arginine finger is an
arginine residue that coordinates the γ-phosphate of a bound nucleotide and is a recurring
characteristic of AAA+ family members [104]. In many AAA+ proteins the arginine
residue is located distal to the nucleotide-binding site and is provided by the adjacent
21

subunit of the oligomer [104, 109, 142]. Arginine fingers contribute to ATP hydrolysis
through stabilization of the transition state [104]. When the MD is positioned on the
exterior of the hexamer the arginine-finger residues are positioned in a canonical position
reaching into the nucleotide-binding site of an adjacent protomer [104, 123, 131, 139].
By contrast, when the MD is intercalated between NBDs the arginine fingers are in a
non-canonical position [133, 134]. However, it should be noted that the arginine finger is
not conserved in all members of the AAA+ family, and it is not clear if the position of
this motif in the oligomeric structure is stringently conserved among all the different
clades of the family [143]. For example, in some crystal structures, the predicted arginine
finger of HslU, an Hsp100 and AAA+ family member with only one NBD, is roughly 8Å
from the nucleotide binding site [144]. In this regard, it is interesting to note that the
missense mutation R444M in the distal loop region between helices 1 and 2 in the MD
reduces ATPase activity of Hsp104 and impairs thermotolerance in a dominant-negative
manner and disrupts amyloid remodeling functionality [133]. This deficiency may
suggest a close contact between the distal loop of the MD and the NBD2 [133]. Thus, it is
possible that other conserved arginines might fulfill the role of the arginine finger in
Hsp104.
Finally, a crystal structure of another Hsp100 family member from Bacillus
subtilis, ClpC, was solved and has weighed in on the debate [145]. Like ClpB and
Hsp104, ClpC is a AAA+ disaggregase involved in modulation of stress response [146]
and protein quality control [147]. Typically, ClpC passes disaggregated substrates to the
chambered protease, ClpP, for degradation [145-148]. While ClpC is natively a hexamer,
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it requires an adaptor protein, MecA, to oligomerize and form an active enzyme [149,
150]. By employing a ΔNBD2 variant, a 3.65Å crystal structure of hexameric ClpC 1-485
(which contains the N-terminal domain, the NBD1, and the MD) in complex with the
adaptor protein MecA was obtained [145]. In that same study, they authors crystallized a
hexamer of the full length ClpC-MecA complex at a resolution of 6.9Å. Interestingly,
the packing within the NBD1 ring corresponded well with that proposed for TClpB [123,
131, 145], while the packing of the NBD2 ring in the full length structure was loose and
very asymmetric [145]. Additionally, the MD of ClpC, which is roughly half the length
of the MD of ClpB [150], was also jutting out away from NBD1 and was distinctly
located on the outside of the hexamer [145]. These data provide independent support for
the TClpB hexameric model. However, the coiled-coil domain of ClpC is considerably
shorter than that of Hsp104 or ClpB and in further contrast must interact with MecA so
that ClpC can hexamerize [145]. Thus, the MD of ClpC plays a very different role to the
MD of ClpB or Hsp104 where it is dispensable for hexamerization [126, 151].

1.5 Mechanistic Models of Hsp104 Activity
Many elements of Hsp104 activity are well established. For instance it has been
shown that nucleotide binding to Hsp104 and low salt concentrations promote
hexamerization [111, 127, 128]. It is also clear that ATP binding in either domain results
in large conformational changes of the Hsp104 hexamer [134]. Similar to other proteinremodeling factors, Hsp104 and its homologues most likely translocate substrates
through their axial channels along the N- to C-terminal vector [115, 152, 153]. ATP
hydrolysis appears to lower substrate affinity for Hsp104 and ClpB, presumably because
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ATP hydrolysis triggers substrate release [107]. Slowing down or halting hydrolysis
allows a stable interaction between substrate and Hsp104 or ClpB. For example, Hsp104
double walker B mutants (which can bind, but not hydrolyze ATP) in the presence of
ATP, as well as WT Hsp104 in the presence of ADP and AMPPMP (a non-hydrolyzable
ATP analog) can support peptide binding within the axial channel [107]. Similarly, a
double walker B mutant of ClpB, as well as WT ClpB saturated with ATPγS can bind to
substrates [131]. Interestingly unlike with Hsp104, ADP and AMPPNP do not promote
ClpB binding to substrate peptides [131].
Mutational and photo-reactive cross-linking analysis has shown that conserved
pore-loops in each NBD interact with substrate on the inside of the channel and are very
important for substrate recognition and disaggregation [107, 115, 154, 155] Mutation of
conserved residues in these loops (Y257A in NBD1 and Y662A in NBD2) prevents the
binding of substrate without affecting ATP binding or hydrolysis [95, 107]. Additionally,
movement of the pore loops is coupled to ATP hydrolysis [134]. Upon substrate binding,
hydrolysis might reorient the pore loops in a manner that results in substrate translocation
though the axial channel [134].
Hsp104 absolutely requires Hsp70 and Hsp40 to promote thermotolerance [12,
43, 47, 115]. However, the mechanism by which Hsp104 collaborates with Hsp70 and
Hsp40 is still largely unresolved. Hsp104 cannot co-operate with prokaryotic Hsp70 and
Hsp40 [12, 156, 157], which indicates the proteins form a functional disaggregating
complex. Additionally, mixing of ClpB and DnaK, a bacterial homologue of Hsp70, has
been shown to result in a synergistic increase in ATP hydrolysis in the presence of
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substrate [158]. Recently, it has become clear that functional interaction between
disaggregase and the Hsp70 chaperone may be mediated by the loop region in the MD
between helices 3 and 4 (Fig. 1c) [140], which will be discussed more below.

1.6 The function of the MD
Despite the ambiguity in MD orientation within the hexamer, several studies have
probed MD function. For instance, in ClpB, deletion of the MD causes a loss of
thermotolerance [126, 159]. Furthermore, partial truncations in ClpB MD cause a
decreased ATPase activity, hexamerization defects, and impaired disaggregation [160].
Even point mutations along the MD have been implicated in altered ATPase activity, loss
of thermotolerance activity, and/or destabilization of the hexamer [130, 133, 140, 161].
The dynamic mobility of the MD is also critical for Hsp104/ClpB function, as crosslinks
that hinder MD flexibility reduce or ablate disaggregation activity of ClpB [123, 140].
Additionally, the MD appears to be involved in facilitating NBD1 and NBD2
communication: when motif 2 is covalently attached to NBD1, ATPase activity in NBD2
increases by ~30-fold [120, 137]. Clearly, the structural integrity and mobility of the MD
must be maintained for full disaggregase functionality.
At first glance, the MD appears to differentiate Hsp100 proteins that possess
disaggregase activity from other Hsp100s. Hsp104 homologues in bacteria, yeast, and
plants, ClpC in bacteria, and Hsp78 in yeast are the only known AAA+ proteins with the
coiled-coil insertion toward the C-terminal end of NBD1 [140, 147, 156, 162-169].
However, even though various Hsp100 proteins like ClpX lack disaggregase activity
[158] it is not quite so straightforward. ClpA, another Hsp100 and AAA+ protein with
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two NBDs per monomer found in E. coli (but not in yeast), also displays disaggregase
activity against disordered aggregates but does not harbor a coiled-coil MD [46, 170].
Indeed, in collaboration with its adaptor protein, ClpS, ClpA disaggregates substrates and
delivers them to ClpP for degradation [170]. ClpA disaggregates substrates without any
need for the Hsp70 chaperone system [158, 170], indicating that Hsp70 is not absolutely
required for disaggregation per se. Importantly, however, the Hsp70 chaperone system
inhibits protein disaggregation by ClpA [170]. In this way, Hsp70 prevents degradation
of aggregated substrates by ClpAP and permits their disaggregation and reactivation by
ClpB [170]. Since the MD is a major distinguishing feature of ClpB compared to ClpA,
these studies provided the first hint that the MD might contribute to collaboration with
Hsp70 [170].
Hsp104 and ClpB require collaboration with Hsp70 and Hsp40 chaperones for
successful disaggregation of amorphous aggregates, both in vitro and in vivo [12, 43, 47,
89, 91, 171]. Hsp70 and Hsp40 can also ameliorate the amyloid-remodeling activity of
Hsp104 [49, 172]. In yeast, members of the Hsp70 chaperone family (e.g. Ssa1, Ssb1)
and Hsp40 family (e.g. Ydj1 and Sis1) have been identified as being able to collaborate
with Hsp104 [12, 49]. In bacteria, the homologous DnaK and DnaJ (along with the
nucleotide exchange factor GrpE) (KJE) collaborate with ClpB [13, 90, 91]. The exact
mechanisms by which Hsp70 and Hsp40 collaborate with Hsp104 are largely unresolved.
However, two key functions are commonly ascribed. First, Hsp70 is proposed to act
upstream of Hsp104 or ClpB by interacting with the aggregate and shuttling substrate
into the axial channel of Hsp104 or ClpB [12, 115, 140, 152, 153, 173, 174]. Second,
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Hsp70 is proposed to act downstream of Hsp104 and promotes refolding of unfolded
polypeptides once they emerge from axial channel [12, 46, 91, 132].
However, the Hsp70 chaperone system may fulfill a third role by modulating the
ATPase activity of Hsp104/ClpB in a manner that promotes the successful disaggregation
of disordered aggregates [46, 121, 158]. Indeed, mixing of ClpB with KJE results in a
synergistic increase in global ATPase activity [158]. Moreover, the requirement for
Hsp70 to disaggregate certain disordered aggregates can be bypassed altogether by
addition of specific mixtures of ATP:ATPγS (3:1 for Hsp104 and 1:1 for ClpB), or by
introducing specific Walker A (e.g. K620T in Hsp104), Walker B (e.g. E279Q or E678Q
in ClpB) or sensor-1 (e.g. N728A in Hsp104) mutations into either NBD1 or NBD2 [46,
158, 175-177]. Thus, part of the function of Hsp70 might be to set Hsp104 ATPase
activity in a mode in which predominantly one NBD is rapidly hydrolyzing ATP, which
can be sufficient to promote the disaggregation of disordered aggregates [46, 134, 158,
176]. However, this mode of ATPase activity precludes amyloid remodeling by Hsp104
[46]. Further studies are needed to define the precise mechanisms by which Hsp70
promotes protein disaggregation by Hsp104. Moreover, it has long remained unclear how
the functional interaction between Hsp104 and Hsp70 is mediated and what domains of
either protein are required. Recent studies, however, ascribe a critical role for the MD in
promoting communication with the Hsp70 system [159, 178].

1.7 The role of the MD in Hsp70 Chaperone Collaboration
Interestingly, it has long been clear that Hsp104 is unable to collaborate with the
bacterial Hsp70 chaperone system [12]. Likewise, ClpB is unable to collaborate with the
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yeast Hsp70 chaperone system [156]. This situation is often referred to as the ‘speciesspecific’ interaction between Hsp104 and Hsp70 [121, 151, 178]. However, the term
‘species specific’ should not be taken too literally. Hsp104 is able to collaborate
effectively with the mammalian Hsp70 chaperone system [172, 177, 179] and multiple
eukaryotic Hsp104 homologues can complement the thermotolerance function of Hsp104
in yeast (but interestingly not always the prion propagation function of Hsp104) [86, 180182], whereas ClpB cannot unless DnaK and GrpE are also co-expressed [88, 93, 183].
Rather, it seems that eukaryotic Hsp100s are unable to collaborate with prokaryotic
Hsp70, and likewise prokaryotic Hsp100s cannot collaborate with eukaryotic Hsp70.
Within prokaryotes, TClpB cannot collaborate with DnaK from E. coli [184]. Moreover,
Ssa1 and DnaJ can collaborate with Hsp104 [12]. Thus, the key determinant of this
specificity is the Hsp70 chaperone rather than Hsp40.
The first functional evidence for the interaction between the MD and the Hsp70
chaperone system was uncovered by characterization of specific helix 3 MD mutants (e.g.
Y503D) [140]. ClpBY503D was unable to collaborate with KJE in protein disaggregation.
However, ClpBY503D formed hexamers, had elevated ATPase activity and translocated
unfolded polypeptides [140]. The specific defect in ClpBY503D was pinpointed to an
inability of KJE to shuttle aggregated substrates to the NBD1 channel loop [140]. Thus, it
was concluded that the MD functions to couple the interaction with Hsp70 to
translocation of aggregated substrates [140]. Yet, a direct interaction between helix 3 of
the MD and DnaK was not observed [140]. Rather, helix 3 of the MD displays
conformation flexibility that is necessary to regulate a direct interaction between helix 3
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of the MD and NBD1 [140]. Mutations in helix 3 (e.g. Y503D) cause this interaction to
become dysregulated and consequently ATPase activity becomes elevated to such an
extent that substrate handover from KJE to the ClpB channel can no longer be coordinated [140]. Thus, these studies revealed that helix 3 of the MD indirectly controls
the interaction with Hsp70.
The established connection between the MD and Hsp70 [140] stimulated efforts
to utilize chimeras of Hsp104 and ClpB to determine which domain(s) of Hsp104 would
enable ClpB to function in yeast [93, 159, 178]. Each study constructed various chimeras
of Hsp104 and ClpB and tested the constructs in various assays to discern the role of each
domain. Briefly, chimeras containing ClpB-MD were able to collaborate with bacterial
DnaK (i.e. Hsp70) and DnaJ (i.e. Hsp40) to disaggregate substrates, while chimeras
containing Hsp104-MD could functionally interface with yeast Hsp70 and Hsp40 [93,
159, 178], indicating that the MD is the domain determinant of ‘species specificity’. It is
worth noting that chimeras containing ClpB-MD were not as robust in disaggregation
with the bacterial DnaK system as were chimeras containing Hsp104-MD with the Hsp70
system. It was necessary to include a portion of ClpB-NBD1 in addition to the ClpB-MD
in order to fully recapitulate WT-ClpB collaboration with DnaK and DnaJ [1, 159, 178].
The reasons for this are unclear.
Yet, pinning down the exact region of Hsp104 that interacts with Hsp70 has
historically proven difficult. Initial evidence suggested that Hsp104
coimmunoprecipitates with Ydj1 (an Hsp40), but not Sis1, from yeast extracts [12].
Using pure proteins, a weak physical association was observed between hexameric ClpB
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and DnaK [184]. In another study, DnaJ was found not to interact with ClpB, whereas the
substrate-binding domain of DnaK was required for an interaction with ClpB that was
disrupted by deletion of the N-terminal domain of ClpB and was partially disrupted by
deletion of portions of the coiled-coil MD of ClpB [185]. These data indicated that DnaK
may interact with ClpB at the N-terminal domain and the MD [185]. However, it is
difficult to know whether these interactions reflected specific functional interactions
between ClpB and DnaK that are required for protein disaggregation, or whether they
reflected the chaperone activity of DnaK that would presumably recognize and bind
transiently unfolded portions of ClpB.
Very recently, a number of studies have been published which end the ambiguity
of where and how ClpB and Hsp104 interact with Hsp70. Within months of each other,
three separate labs identified that motif 2 of the MD of Hsp104 and ClpB interact with
Hsp70 [186-189]. Seyffer and colleagues [187] have observed a direct interaction
between residues in ClpB motif 2 of the MD and DnaK. To visualize this, they performed
a cysteine scan of many residues in the MD and attached a thiol-reactive photoactivatable
crosslinking agent to each introduced Cys residue. By mixing the modified ClpB Cys
mutants with DnaK and exposing to UV light, DnaK-ClpB covalent products were
observed when the photo-crosslinker was attached to Q481, K483, Q488, and E500C of
the MD [187] (Figure 5a & b). No interaction was detected between DnaK and any other
region of the MD. Aspects of these studies have been recapitulated in the yeast system.
Using a peptide array library, Lee and colleagues have identified that Hsp70 binds a
number of peptides derived from the Hsp104 [186]. These include peptides that
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Figure 5: Proposed interface between ClpB and DnaK. Model of the interface
between DnaK (green) and ClpB (NBD1, cyan; MD, yellow; NBD2, dark blue;
N-terminal domain is omitted) (PDB ID: 1QVR) as proposed by Rosenzweig et al
[189]. Inset is a magnification of boxed portion. Red sticks are TClpB residues
discussed in Rosenzweig et al. [189], purple sticks are ClpB residues highlighted in
Seyffer et al. [187], and orange sticks are Hsp104 residues discussed in Lee et al.
[186] Note how all key residues are located in motif 2.
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correspond with Hsp104 residues 28-45, 91-111, 178-192, 238-252, 435-448, 471-488,
603-617, 618-638, 678-692. The authors were particularly interested in the peptides
which encompass a region of the MD (from 411-538) and focused subsequent analysis on
this region. By introducing cysteine residues throughout the MD and conjugating a
photoactivatable cross-linker to the cysteines, the authors were able to observe specific
cross-linking between Hsp70 and R496C in helix 2 of the MD [186] (Figure 5a & b),
which confirms the results observed with ClpB [187].
Finally, in a ground breaking study, Rosenzweig and colleagues confirmed that
residues in helices 2 and 3 in motif 2 of T. thermophilus ClpB (TClpB) interact with
DnaK [189]. Using methyl-transverse relaxation-optimized nuclear magnetic resonance
(NMR) spectroscopy, the authors found that chemical shift perturbations were found
throughout helices 2 and 3 of the MD of TClpB in the presence of DnaK. Key TClpB
residues in helix 2, Y494, Y484, and K499 were found to impair Hsp70 and Hsp40
collaboration when mutated to alanine, confirming the NMR results (Figure 5a, b).
Furthermore, the authors resolved the question of whether DnaK engages ClpB as it
would substrate, that is, in the substrate binding domain. The authors show that DnaK
engages TClpB with the IB and IIB subdomains of the nucleotide binding domain and not
the substrate binding domain (Figure 5a, b).
It is still unclear exactly how the interaction with Hsp70 results in activation of
Hsp104, however recent work indicates that the MD is a very mobile element that
controls or titers Hsp104 and ClpB activity in response to Hsp70. To accomplish
activation, Hsp70 may break inhibitory intra-Hsp104 contacts between the motif 2 of the
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MD and NBD1. Oguchi and colleagues used H/X to show that helix 1 and the portion of
helix 2 that lies in motif 2 becomes protected from solvent upon oligomerization in the
presence of ATP [141]. To confirm the solvent accessibility of these regions, they
attempted to PEGylate introduced cysteine mutants throughout the MD. The authors
found that residues in helix 1 (L4224C, E425C, and Q427C) as well as residues in motif
2 (K483C, S499C, E500C and Q502) were protected from PEGylation upon
oligomerization [141], confirming the H/X results These residues are all modeled to be
on the same face of their respective helices. Fluorescence resonance energy transfer
(FRET) and cysteine cross-linking revealed that L424 (in MD- motif 1) was in close
proximity to E344 (in NDB1) of the adjacent protomer [141] and that Y503 (in helix 3 of
motif 2) is in close proximity to N255 (in NBD1) of the same protomer [141]. In other
words, this suggests that motif 2 of the MD interacts with NBD1 of the same protomer
while the distal end of the MD interacts with NBD1 of the adjacent protomer.
Furthermore, the authors identified that a number of MD mutants alter ClpB activity in
non-predictable ways. For example, the variants E432A and E480A are inactive in
disaggregation yet retain the ability to thread unfolded substrate through the channel. At
the other end of the spectrum lie the MD variants K476C and Y503D, which have greater
disaggregation activity than even WT ClpB. Interestingly, though the authors were
unable to prime facie predict how a mutation would alter ClpB activity, they could
differentiate activating from inactivating mutations in their H/X experiments. All
inactivating mutants resulted in less relative hydrogen exchange of motif 2 of the MD,
which indicates that this region is less solvent exposed in these variants. All the
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activating mutants increased the amount of hydrogen exchange in motif 2, as compared to
WT ClpB, which indicates that these mutants cause increased solvent accessibility of
motif 2. In sum, these results suggest that when motif 2 is tightly associated with NBD1,
ClpB activity is repressed, however mutants that alleviate this interaction activate the
disaggregase functionality. The authors suggest that DnaK traps Hsp104 in the active
conformation and prevents the inhibitory interaction between NBD1 and motif 2.
Lipińska and colleagues have also observed that disrupting the interaction
between motif 2 and NBD1 with a charged residue yielded a hyperactive Hsp104 mutant
that could operate independently from Hsp70 [188]. A compensatory charged mutation
that introduced a salt bridge rescued the hyperactive phenotype [188]. This work also
suggests that the role of Hsp70 could be to break or inhibit the intra-Hsp104 interface by
interacting with motif 2 of the MD.
Our understanding of how Hsp104 communicates and collaborates with Hsp70 is
beginning to become elucidated. Remarkably, each study probing the role of the MD has
largely ignored the distal loop region of the MD, presumably because there is no
interaction between this portion of the MD and DnaK. One goal of this thesis is to
elucidate the function of the distal loop of the MD.

1.8 Inter-subunit cooperativity in AAA+ machines
Each Hsp104 hexamer contains six individual subunits and a total of twelve
nucleotide-binding sites. Structural studies have revealed that the identity of the
nucleotide bound to the Hsp104 hexamer imparts unique structure to the axial channel
[133, 134] suggesting that Hsp104, like other known AAA+ machines, couples cycles of
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ATP hydrolysis to movement of pore lining residues to promote substrate translocation
[190]. Furthermore, Cryo-EM has indicated that the Hsp104 hexamer is not symmetric
[134], which signifies that each nucleotide binding site may not be saturated with the
same nucleotide. For instance, because WT Hsp104 can hydrolyze ATP, any given
nucleotide binding site in an active Hsp104 hexamer could be occupied by ATP, ADP, or
remain apo. But how can identical binding sites be occupied by different nucleotides? If
Hsp104 operated in a collaborative or cooperative way, in which the fate of nucleotides
in one subunit influenced hydrolysis in other subunits, each binding site could potentially
have different affinities for nucleotides. One can imagine then, that the identity of the
binding site with higher or lower affinity for ATP, for example, could rotate around the
ring as Hsp104 cycles through ATP hydrolysis.
Since Monod, Wyman, and Changuex published their first seminal paper on
allostery in 1965 [191], inter-subunit collaboration has been an important and
fundamental area of research in the biosciences. How individual subunits collaborate and
communicate to promote the remodeling of substrate is an outstanding question for all
NTP-fueled hexameric ring-translocases, including Hsp104 [190, 192]. Several different
models of intersubunit collaboration have been proposed for different AAA+ machines.
A probabilistic model in which individual subunits within the hexamer function non-cooperatively and independently has been suggested for the protein unfoldase ClpX [193195]. Models of subglobal co-operativity where a subset of subunits around the ring must
co-operate have been proposed for the helicase MCM [196] and the 20S component of
the 26S eukaryotic proteasome [197]. Finally, models of global cooperation where all
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subunits co-operate in sequence or in concert have been observed for the T7 DNA
helicase, the viral E1 helicase, and the E. coli Rho transcription termination factor [198201]. Typically, these models focus on how ATPase events are co-ordinated and much
less consideration has been given to how individual subunits within the hexamer
contribute to substrate binding and translocation across the channel [193, 195, 196, 198,
202, 203]. Importantly, a key unresolved issue concerns whether subunits of a single
ring-translocase possess the plasticity to implement different modes of inter-subunit
collaboration to remodel diverse substrates that impose disparate mechanical demands
[190].
One goal of this research was to determine the mode of inter-subunit cooperativity
utilized by Hsp104 to disaggregate amorphous and amyloid aggregates. It is not clear if
Hsp104 uses the same mechanism to disaggregate amyloid and non-amyloid clients.
Specific mutations in Hsp104 differentially affect its ability to catalyze remodeling of
prions and disordered aggregates respectively, as does ATPγS [46, 204, 205], suggesting
a mechanistic dichotomy or plasticity. This might reflect the ability of subunits within
Hsp104 hexamers to collaborate differently to promote the dissolution of diverse
aggregated structures. Specifically, we hypothesized that Hsp104 may operative
differently when acting on the two different types of aggregates.
There is evidence that Hsp104 hydrolyzes ATP in a cooperative manner in the
absence of substrate. Hattendorf and Lindquist found that WT Hsp104 has at least two
different types of nucleotide binding sites: a lower ATP-affinity site with high ATPase
activity (Km = 170±12µM, kcat = 75.5±4.5min-1) and a higher ATP- affinity site with
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slower turnover (Km = 4.7±1.1µM, kcat = 0.27±0.05min-1) [110]. Both low and high
affinity sites operate during hydrolysis in an allosteric manner, with Hill coefficients of
2.3 and 1.6, respectively [110]. In this same study, sensor-1 mutants were employed to
study the basal ATPase rates of one NBD at a time. Sensor-1 mutations halt hydrolysis,
allowing the authors to study ATPase activity in one NBD, while the other NBD
remained saturated with ATP. Here, the sensor 1 mutant T317A (in NBD1) was
employed to monitor ATPase in NBD2, while the sensor 1 mutant N728A (in NBD2)
was used to monitor ATPase activity only in NBD1. The T317A mutation in NBD1 did
not alter the properties of the higher affinity binding site significantly. However, the
lower affinity and higher turnover site had much slower ATPase activity and a reduced
affinity for ATP. The N728A mutant was more deleterious to hydrolysis, yielding a
protein with a greatly diminished ATPase activity, increased affinity for ATP, and no
discernible ‘high affinity’ type of ATP binding site [110]. This led the authors to
conclude that NBD2 possess a higher affinity and slower turnover, while NBD1 binds
ATP less tightly and hydrolysis it more rapidly. Both NBDs operate with cooperativity,
as both sensor mutants showed Hill coefficients greater than 1. Additionally, it appears as
if ATP binding in NBD2 allosterically promoted hydrolysis in NBD1.
While hinting at inter-subunit cooperativity, this study was performed in the
absence of substrate. Furthermore, by simply monitoring ATPase activity, the authors
could not ask questions about subunit collaboration with respect to substrate binding or
translocation.
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1.9 Purpose of Study Section

The aim of this thesis was to:
(1) Determine how the inter-subunit cooperativity present in basal ATP hydrolysis
manifests during disaggregation of amorphous and amyloid aggregates. Additionally, we
endeavored to determine the role of cooperativity in substrate binding and handling. We
also aimed to determine if ClpB could remodel amyloid. Our final goal was to establish if
Hsp104 and ClpB operated with inter-subunit collaboration during disaggregation
(Chapter 2).
(2) Elucidate the function of the distal loop of the MD. Specifically, our goal was
to determine how mutation in the distal loop affected Hsp104 activity. We also wanted to
determine where the distal loop was located within the Hsp104 hexamer in order to aid in
resolving the debate about Hsp104 structure (Chapter 3).
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CHAPTER 2: Operational plasticity enables Hsp104 to disaggregate
diverse amyloid and non-amyloid clients
This chapter is based in its entirety on DeSantis, et al., 2012 [95]. Required permission
was obtained
2.1 Overview
It is not understood how Hsp104, a hexameric AAA+ ATPase from yeast,
disaggregates diverse structures encompassing: stress-induced aggregates, prions, and αsynuclein conformers connected to Parkinson’s disease. Here, we establish that Hsp104
hexamers adapt different mechanisms of intersubunit collaboration to disaggregate stressinduced aggregates versus amyloid. To resolve disordered aggregates, Hsp104 subunits
collaborate non-co-operatively via probabilistic substrate binding and ATP hydrolysis. To
disaggregate amyloid, several subunits co-operatively engage substrate and hydrolyze
ATP. Hsp104 variants with impaired intersubunit communication dissolve disordered
aggregates but not amyloid. Unexpectedly, prokaryotic ClpB subunits collaborate
differently to Hsp104, which enhances disordered aggregate dissolution, sensitizes ClpB
to inhibition, and diminishes amyloid disaggregation. Hsp104 hexamers deploy more
subunits to disaggregate Sup35 prion strains with more stable ‘cross-β’ cores. Thus,
operational plasticity enables Hsp104 to robustly dissolve amyloid and non-amyloid
clients, which impose distinct mechanical demands. Similar adaptable mechanochemical
coupling could underpin other multimeric NTPases with structurally diverse substrates.

2.2 Mutant doping strategy and experimental logic
We employed a mutant doping strategy to investigate the contribution of
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individual Hsp104 subunits toward protein disaggregation and thereby define the
mechanochemical coupling mechanism employed by Hsp104 hexamers. In this approach,
mutant subunits defective in ATP hydrolysis or substrate binding are mixed with wildtype (WT) subunits at various concentrations to yield heterohexamer ensembles
containing different ratios of WT and mutant protein (Figure 6a). Assuming
heterohexamers assemble randomly according to a binomial distribution (Figure 6a).
Using this distribution, we can predict how disaggregase activity would be inhibited at
various mutant:WT ratios if the hexamer were inactivated by a specified number of
incorporated mutant subunits (Figure 6b). For example, if all 6 subunits must work
together, the presence of just one mutant subunit would be predicted to abolish activity
(Figure 6b, dark blue curve). On the other hand, if the activity of an individual subunit
within the hexamer is sufficient, then some activity would still be observed with 5 mutant
subunits per hexamer and 6 mutant subunits per hexamer would be required to abolish
activity (Figure 6b, orange line). By comparing experimental data with theoretical plots
(Figure 6b), we can determine whether subunit collaboration within Hsp104 hexamers is
probabilistic (6 mutant subunits abolish activity), subglobally co-operative (2-5 mutant
subunits abolish activity), or globally co-operative (1 mutant subunit abolishes activity)
[196, 198, 206]. This strategy has yielded key mechanistic insights for other NTP-fueled
ring-translocases, but is contingent upon random mixing of mutant and WT subunits at
the monomer level [176, 196, 198, 206].

2.3 Hsp104 subunits exchange rapidly and randomly between hexamers
We employed several methods to assess whether WT Hsp104 forms
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a.

b.

Figure 6: Doping analysis reveals inter-subunit coordination. (a)Theoretical
ensembles of Hsp104 hexamers containing no mutant (black), one mutant subunit
(blue), two (green), three (orange), four (red), five (purple) and six mutant subunits
(yellow) as a function of the percentage of mutant subunits present. See Experimental
Procedures for more details. (b) Theoretical activity curves for mutant doping experiments. The activity varies as a function of the percentage of mutant subunits present
assuming that hexamer activity is proportional to the number of active subunits and all
subunits in a hexamer are inactive when a specified number of mutant subunits per
hexamer is breached. Curves are shown for situations where one or more mutant
subunits (blue), two or more mutant subunits (red), three or more mutant subunits
(green), four or more mutant subunits (purple), five or more mutant subunits (light
blue), or six mutant subunits (orange) are required to eliminate hexamer activity. See
Methods section for more details.
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heterohexamers with mutant subunits. First, to test if there is an equilibrium between
monomer and hexamer, we first employed a fluorescence resonance energy transfer
(FRET) based assay. Here, we labeled separate batches of Hsp104 (either WT or mutant)
with Alexa-Fluor 488 (AF488), which would act as a donor or with Alexa-Fluor 546
(AF546), which would act as a fluorescence acceptor (Figure 7a). Hsp104 has 6 native
cysteines which could possibly be modified by the thiol reactive dyes, however mass
spectroscopy revealed that only Cys643 and Cys876 and were routinely labeled during
our procedure (Figure 7b). Because these dyes function as a FRET pair with a Förster
radius of 65Å, only hexamers that are comprised of AF488- and AF546-labeled subunits
will result in energy transfer. A similar strategy has been employed to demonstrate the
formation of mixed oligomers by ClpB [206] and MCM helicase, another AAA+ protein
[207, 208]. AF588-Hsp104 and AF546-Hsp104 formed mixed hexamers, as mixing of
two separate pools of AF488-Hsp104 and AF546-Hsp104 for 15min on ice resulted in an
increase in acceptor fluorescence and a decrease in donor fluorescence with an apparent
FRET efficiency of 45% (Figure 7c, j). The FRET signal evolved rapidly over the course
of 15min and could be rapidly reversed by addition of unlabeled Hsp104 (Figure 7d, e).
Thus Hsp104 subunits rapidly exchange between hexamers on the minute timescale.
Next, we performed the mixing experiments under conditions which destabilize the
Hsp104 hexamer. High salt, low Hsp104 concentration, and the absence of ATP are all
known to promote monomerization of Hsp104 [111, 128, 136, 209]. At high salt
concentrations (1M NaCl) and low Hsp104 concentration (0.5µM), minimal FRET signal
was observed when donor and acceptor labeled subunits were mixed (FRET efficiency of
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Figure 7: Hsp104 forms dynamic hexamers that exchange monomers on the minute
timescale. (a) Schematic of subunit mixing assayed by FRET. Separate pools of Hsp104
were labeled with Alexa-Fluor 488 (AF488) to serve as a donor and Alexa-Fluor 546
(AF546) to serve as an acceptor. In mixed hexamers, the donor (AF488) and acceptor
(AF546) labels come into close enough proximity to elicit FRET. (b) Hexameric model
of Hsp104 in the ATPgS state based on single-particle cryo-EM of the Hsp104N728A
hexamer[134]. A single subunit is colored blue. Note the position of Cys643 (orange) and
the C-terminal end of the hexamer where Cys876 would be located (which is not present
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in this model).(c) AF488-Hsp104 (donor), AF546-Hsp104 (acceptor), or unlabeled WT
Hsp104 were mixed in the presence of ATP (5mM) at a 1:1 molar ratio to a final Hsp104
concentration of 1µM. Samples were allowed to equilibrate on ice for 15min. Mixed and
equilibrated samples were excited at the donor excitation wavelength of 475nm. To monitor FRET, fluorescence was observed from 500nm-650nm. Note the increase in acceptor
fluorescence at 572nm in the presence of donor (compare purple and black traces) and the
concomitant decrease in donor fluorescence at 525nm (compare green and purple traces)
indicative of FRET and the assembly of mixed hexamers with subunits within the range of
the Förster distance. (d) AF488-Hsp104 (donor) and AF546-Hsp104 (acceptor) were
mixed in the presence of ATP (5mM) at a 1:1 molar ratio to a final Hsp104 concentration
of 1µM. The increase in acceptor fluorescence (575nm) and was then monitored for
30min. Values represent means±SEM (n=3). (e) AF488-Hsp104 (donor) and AF546Hsp104 (acceptor) were mixed for 15min in the presence of ATP (5mM) at a 1:1 molar
ratio to a final Hsp104 concentration of 1µM. Unlabeled WT Hsp104 (1µM) was then
added and the increase in donor fluorescence (525nm) was then monitored for 30min.
Values represent means±SEM (n=3). (f) AF488-Hsp104 (donor) and AF546-Hsp104
(acceptor) were mixed at a 1:1 molar ratio to a final Hsp104 concentration of 1µM for
15min on ice in buffer with 300mM NaCl in the absence (orange trace) or presence of
5mM ATP (green trace). Alternatively, AF488-Hsp104 (donor) and AF546-Hsp104
(acceptor) were mixed at a 1:1 molar ratio to a final Hsp104 concentration of 0.5µM for
15min on ice in buffer with 1M NaCl (blue trace). To monitor FRET, fluorescence was
observed from 500nm-650nm after excitation at 475nm. Note the increased FRET signal
at 575nm in the presence of ATP (green trace) and the reduced signal in the absence of
ATP (orange trace) or at high salt (blue trace). (g) AF488-Hsp104 and AF546-Hsp104
were mixed at a 1:1 molar ratio to a final Hsp104 concentration of 0.067µM for 20min on
ice in buffer in the absence (purple trace) or presence of 5mM ATP (red trace). Note the
increase in fluorescence at 575nm and concomitant decrease in fluorescence at 525nm in
the presence of ATP (red trace), a condition that promotes hexamerization. (h, i) AF488Hsp104, AF546-Hsp104, or unlabeled WT Hsp104 were mixed in the presence of ATP
(1mM) at a 1:1 molar ratio to a final Hsp104 concentration of 8.3µM. Samples were
allowed to equilibrate on ice for 15min. Mixed and equilibrated samples were then fractionated by TSK4000 size-exclusion chromatography and the elution profile was followed
by absorbance at 280nm (h) and fluorescence at 572nm (excitation 475nm) to follow
Alexa-Fluor 546 (acceptor) (i). Note that labeled Hsp104 preparations elute with a very
similar profile to unlabeled Hsp104 (h), indicating that AF488-Hsp104 and AF546Hsp104 are hexameric. Importantly, fluorescence is greatly increased in the hexameric
peak of AF488-Hsp104 mixed with AF546-Hsp104 (D+A, blue trace), indicating that
FRET occurs in Hsp104 hexamers (i). Very little acceptor fluorescence is observed in the
controls (green and red trace) as expected. (j) FRET efficiency after mixing AF488Hsp104 with AF546-Hsp104, AF546-Hsp104DPL, AF546-Hsp104DWA, AF546-Hsp104DWB
or AF546-Hsp104DPLDWB for 15min in the presence of ATP (5mM) at a 1:1 molar ratio
with a final Hsp104 concentration of 1µM. As a negative control the FRET efficiency of
mixing AF488-Hsp104 with AF546-Hsp104 at high salt (1M NaCl) is also shown.
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15%) (Figure 7f,j). Furthermore, at moderately high salt concentrations (300mM NaCl),
we observed an increase in FRET upon addition of ATP, indicating that the equilibrium
was being shifted towards the hexamer (Figure 7f). At low Hsp104 concentrations at
physiological salt concentration (150mM potassium acetate) in the absence of ATP,
Hsp104 is largely monomeric, but forms hexamers upon addition of ATP. Accordingly,
under these conditions, we observed increased FRET in the presence of ATP (Figure 7g).
To confirm that FRET occurred in the hexamer and not some lower oligomeric species,
we subjected mixed pools of AF488-Hsp104 and AF546-Hsp104 to size exclusion
chromatography and measured fluorescence in hexameric fractions with an inline
fluorimeter. AF488-Hsp104 and AF546-Hsp104 had similar elution profiles to unlabeled
Hsp104, indicating that they form hexamers like WT Hsp104 (Figure 7h). Acceptor
fluorescence was greatly increased in hexameric fractions of mixed AF488-Hsp104 and
AF546-Hsp104, but not in controls with either donor or acceptor mixed with unlabeled
Hsp104 (Figure 7h & i ). Taken together, these data strongly suggest that observed FRET
is an accurate reporter of hexamer formation and that Hsp104 hexamers are in dynamic
equilibrium. Finally, we assessed whether any of the Hsp104 mutants we employed in
our mutant doping experiments affected subunit exchange when they were mixed with
WT subunits. Importantly, none of the introduced mutations (Hsp104DPL, Hsp104DWA,
Hsp104DWB, or Hsp104DPLDWB; see section 1.4, and 2.4-2.6 for explanation of mutant
nomenclature and phenotype) affected subunit exchange, as measured by FRET (Figure
7j). Thus these variants are suitable for doping experiments.
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To confirm that incorporation of mutant subunits occurred according to a
binomial distribution, we used two different approaches. First, we labeled purified
Hsp104 variants with NHS-LC-biotin to obtain an average of 1-2 biotin moieties per
Hsp104 monomer as determined with the HABA (2-[4’-hydroxyazobenzene]-benzoic
acid) reagent (Pierce). Addition of the biotin moiety had no effect on ATPase activity
(Figure 8a) or disaggregase activity (Figure 8b). These data suggest that Hsp104 hexamer
functionality was unaffected by the biotinylation. We then mixed biotinylated Hsp104
(bio-Hsp104) variants with WT Hsp104 in various proportions for 5min on ice in the
presence of ATP (5mM) (Figure 8c). We rapidly depleted bio-Hsp104 with neutravidin
sepharose and then determined the amount of unlabeled WT Hsp104 in the unbound
fraction (Figure 8c). We confirmed that bio-Hsp104 had been depleted from unbound
fractions using the HABA reagent and by Western blot using neutravidin-HRP (Figure
8c). We then compared the amount of unlabeled Hsp104 in the unbound fraction to the
amount that would be predicted (hexamers with 0 mutant subunits) by the binomial
distribution (Figure 6b) [206]. For all the Hsp104 variants used here (Hsp104DPL,
Hsp104DWA, Hsp104DWB, or Hsp104DPLDWB) we observed a remarkable similarity
between the predicted and experimental values for the amount of unbound Hsp104, i.e.
the amount of Hsp104 hexamers devoid of biotinylated subunits (Figure 8d). This
agreement suggests that like its prokaryotic orthologue, ClpB [176, 206, 210], Hsp104
hexamers rapidly exchange subunits on the minute timescale. Moreover, these data
suggest that the Hsp104DPL, Hsp104DWA, Hsp104DWB, and Hsp104DPLDWB variants are
highly suitable for our doping experiments because they incorporate in WT hexamers just
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Figure 8: Hsp104 hexamers rapidly and randomly exchange monomers. (a)
Hsp104 or bio-Hsp104 (0.2µM monomer) were incubated for 0–20 min at 25°C with
ATP (1mM). At various times the amount of ATP hydrolysis was determined. Values
represent means±SEM (n=3). (b) NM25 fibers (2.5µM monomer) were incubated for
30min at 25°C in the presence of Ssa1 (1µM), Sis1 (1µM), and Hsp104 or bioHsp104 (0-2µM) plus ATP (10mM). Disassembly was assessed by ThT fluorescence.
Values represent means±SEM (n=3). (c) WT Hsp104 was mixed for 5min on ice with
various fractions of bio-Hsp104DWA while keeping the total amount of Hsp104
constant at 5µM. Bio-Hsp104DWA was then depleted using neutravidin sepharose and
the amount of unlabeled Hsp104 in the unbound fraction was determined by immunoblot. Top panels show inputs and lower panels show unbound fractions. Note the
absence of bio-Hsp104DWA in the unbound fraction and the depletion of unlabeled
Hsp104 even at 33.3% bio-Hsp104DWA. (d) WT Hsp104 was mixed for 5min on ice
with various fractions of either WT bio-Hsp104, bio-Hsp104DPL, bio-Hsp104DWA,
bio-Hsp104DWB, or bio-Hsp104DPLDWB while keeping the total amount of Hsp104
constant at 5µM. Bio-Hsp104 was then depleted using neutravidin sepharose and the
amount of unlabeled Hsp104 (Hsp104 hexamers without any biotinylated subunits) in
the unbound fraction was determined by immunoblot. Note the similarity between
values predicted by the binomial distribution (Figure 6a) and experimental values.
Values represent means±SEM (n=3).
47

as well as WT Hsp104 and heterohexamers assemble according to a binomial
distribution.
In a second approach, we mixed His6-tagged and untagged Hsp104 subunits in a
1:1 ratio for 5 min. The ensemble was then quickly mixed with Ni-sepharose and allowed
to bind. Using an empirically determined imidazole gradient with a 20mM step size, we
eluted Hsp104 hexamers containing 1, 2, 3, 4, 5, and 6 His6-tagged Hsp104 subunits. The
ratio of His6-tagged Hsp104 and untagged Hsp104 in each step were determined by SDSPAGE analysis and was found to be in agreement with the ratios predicted by the
binomial distribution (Figure 6a). For example, the binomial distribution predicts that, at
a molar ratio of 1His6-tagged Hsp104 : 1untagged Hsp104, gradient step 2 (which elutes
hexamers with 1 His tags) would only contain 5% of the initial protein while gradient
step 4 (which elutes hexamers with 3 His tags) will contain 31% of the total protein
(Figure 9a). We repeated this with each of the untagged variants we planned to use in the
doping experiment (Hsp104DPL, Hsp104DWA, Hsp104DWB, and Hsp104DPLDWB) (Figure
9b-e). We observed mixing of tagged and untagged Hsp104 according to the binomial
distribution. These data agree with the results found in the biotinylation experiment
outlined above and we concluded that the mutant subunits exchange freely and randomly
with WT Hsp104 subunits.
To show that subunit mixing occurs very rapidly, we assessed how real time
disaggregation of GFP [46] by WT Hsp104 was affected by addition of a 5-fold excess of
Hsp104DPL, Hsp104DWA, Hsp104DWB or Hsp104DWBDPL. Importantly, GFP disaggregation
was inhibited almost immediately (within 2min), whereas addition of buffer had no effect
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Figure 9: Hsp104 heterohexamers assemble according to the binomial distribution. His-tagged WT Hsp104 was mixed with untagged WT Hsp104 (a), Hsp104DPL
(b) Hsp104DWA (c), Hsp104DWB (d), or Hsp104DPLDWB (e) at a 1:1 ratio for 5min. The
mixture was then applied to Ni-sepharose and the flow through fraction (20mM
imidazole) was collected. Hsp104 was eluted using a step gradient of imidazole
(concentration indicated on x-axis). Protein was then TCA precipitated from each
fraction and the amount of untagged (cyan bars), his-tagged (purple bars), and total
Hsp104 (green bars) in each fraction was determined. This value was compared to
the amount of Hsp104 predicted to be in each fraction by the binomial theorem (red
bars). 20mM imidazole will elute hexamers with no His tagged subunits and
240mM imidazole will remove hexamers with all subunits His-tagged.
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(Figure 10). These data are consistent with the rapid incorporation of mutant subunits into
WT Hsp104 hexamers leading to an immediate cessation of disaggregase activity.

2.4 Hsp104 utilizes a non-cooperative, probabilistic mechanism to resolve stressinduced aggregates
To determine the role of individual Hsp104 subunits with respect to substrate
binding, we employed a Hsp104 mutant that is defective in substrate binding, termed
Hsp104DPL. Hsp104DPL harbors Y257A and Y662A mutations in channel lining poreloops of NBD1 and NBD2 respectively, which severely impairs substrate binding and
disaggregation [107, 113, 211]. Importantly, Hsp104DPL forms hexamers, has WT levels
of ATPase activity (Figure 11a), incorporates into WT hexamers just as well as WTHsp104 (Figure 7j, 8d, 9b, 10), and has minimal effect on total ATPase activity when
mixed with WT-Hsp104 (Figure 11a,b, grey markers).
We assembled various heterohexamer ensembles of WT-Hsp104 and Hsp104DPL
and measured their ability to disaggregate disordered aggregates comprised of ureadenatured firefly luciferase [12]. Dilution of WT-Hsp104 with buffer had minimal effect
on luciferase reactivation (Figure 11c). By contrast, addition of Hsp104DPL caused an
approximately linear decrease in Hsp104 disaggregase activity (Figure 11d). This
tolerance of WT-Hsp104 hexamers to inclusion of Hsp104DPL subunits suggests that for
disordered aggregates, Hsp104 translocates substrate in a probabilistic manner, with a
single WT subunit per hexamer being sufficient to catalyze disaggregation. Thus,
disaggregation does not invariably require a sequential ‘bucket-brigade’ handover of
substrate between neighboring monomers around the hexameric ring [134].
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Figure 10: Hsp104 subunits incorporate very rapidly into hexamers. Heat
aggregated GFP (0.45µM) was incubated at 23°C with Hsp104 (1µM), Ssa1
(1µM) and Sis1 (1µM). After 8min, either buffer or a five-fold excess of
Hsp104DPL, Hsp104DWA, Hsp104DWB or Hsp104DPLDWB (5µM) were added and the
reaction was allowed to proceed for a further 22min. Note that the addition of
Hsp104DPL, Hsp104DWA, Hsp104DWB or Hsp104DPLDWB rapidly inhibits disaggregase activity. Values represent means±SEM (n=3).
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Figure 11: Hsp104 exploits a probabilistic mechanism to dissolve stress-induced
disordered aggregates. (a) WT or mutant Hsp104 ATPase activity. Values represent
means ±SEM (n = 3–5). (b) Hsp104 was mixed with increasing fractions of mutant
Hsp104 proteins or buffer, andATPase activity was assessed. Values represent means
±SEM (n = 3–5). Orange line indicates expected ATPase activity if six mutant
subunits are needed to ablate hexamer activity. (c-g) Luciferase aggregates were
treated with Hsp104 (gray markers), Hsc70 (an Hsp70), and Hdj2 (an Hsp40) plus
increasing fractions of buffer (c), Hsp104DPL (d),Hsp104DWA (e), Hsp104DWB (f), or
Hsp104DPLDWB (g). Alternatively, luciferase aggregates were treated with ClpB (blue
markers), DnaK, DnaJ, and GrpE plus increasing fractions of buffer (c), ClpBDPL (d),
ClpBDWA (e), ClpBDWB (f), or ClpBDPLDWB (g). Luciferase reactivation (% WT
activity) was then assessed. Values represent means ±SEM (n = 3–4). Theoretical
disaggregase activity if six (orange line [d and e]), two or more (red line [e–g]), or
one or more mutant subunits (blue line [f and g]) ablate hexamer activity. Pink line
(g) indicates simulated activity if a mutant subunit stimulates an adjacent WT
subunit 1.4-fold but is inhibitory if adjacent to a mutant subunit.(h) Adjacent pairs of
WT-WT or WT mutant subunits determine hexamer activity, whereas adjacent
mutant subunits have no activity. Each adjacent WT-WT pair has an activity of 1/6.
By contrast, adjacent WT mutant pairs have a stimulated activity (s), and the effect
of various values of s is depicted. Brown markers indicate experimental luciferase
disaggregation data obtained with Hsp104DPLDWB.
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This probabilistic mechanism of substrate handling is conserved over 2 billion years of
evolution to E. coli ClpB. ClpB also displayed an approximately linear decline in
luciferase disaggregation activity in response to a substrate binding defective variant,
ClpBDPL (ClpB with mutations: Y251A and Y653A) [115, 154], whereas buffer had no
effect (Figure 11 c, d). Thus, probabilistic substrate binding appears to be a conserved
strategy for protein disaggregases, which stands in contrast to hexameric AAA+
unfoldases like ClpX, where two substrate-binding defective subunits are sufficient to
poison the entire hexamer [203]. These data might help explain why ClpX has very
limited disaggregase activity [212].
This non-cooperative mechanism of substrate handling was surprising considering
previous reports that Hsp104 hydrolyzes ATP in a co-operative manner [120, 213]. To
determine the role of individual Hsp104 subunits in disaggregation with respect to ATP
hydrolysis, we employed the ATPase-defective Hsp104DWA variant, which harbors
K218T and K620T mutations in the Walker A motifs of NBD1 and NBD2 respectively.
These mutations severely impair ATP hydrolysis (Figure 11a) by reducing affinity for
ATP, but do not impair hexamerization at the high protein concentrations employed here
[213-215]. Indeed, Hsp104DWA incorporated into WT hexamers just as well as WTHsp104 (Figure 7j, 8d, 9c, 10). Mutant doping revealed that Hsp104DWA subunits
inhibited total ATPase activity slightly less than predicted by a linear response (Figure
11b, compare purple markers to orange line). This result was surprising because similar
experiments with ClpB revealed a sharp decline in total ATPase activity consistent with 1
or 2 subunits poisoning the hexamer [206]. Strikingly, Hsp104DWA subunits elicited an
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approximately linear decline in the disaggregation of luciferase by WT Hsp104 (Figure
11e). These data strongly suggest that Hsp104 couples probabilistic ATPase activity and
substrate handling to the disaggregation of disordered aggregates. Moreover, they suggest
that for disordered aggregate dissolution the Hsp104 power stroke can be generated by
ATP hydrolysis in a single subunit.

2.5 ClpB hexamers are tuned differently to Hsp104 hexamers
These observations with Hsp104 were surprising because mutant doping studies
with ClpB previously suggested a highly co-operative mode of ATP hydrolysis enabled
disaggregation of various disordered aggregates [176, 206, 210]. Consistent with these
reports and in stark contrast to Hsp104, we observed that the ATPase-defective ClpBDWA
variant (ClpB K212T:K611T) caused a sharp non-linear decline in ClpB disaggregase
activity (Figure 11e), consistent with a mechanism in which 2 mutant subunits abolish
hexamer activity (Figure 6b). We corroborated these findings using another ATPasedefective ClpB mutant, ClpBDWB, bearing E279Q and E678Q mutations in the Walker B
motifs of NBD1 and NBD2. This mutant forms hexamers that bind but do not hydrolyze
ATP [132]. In doping studies, ClpBDWB elicited a sharp non-linear decline in luciferase
disaggregase activity (Figure 11f), consistent with a mechanism in which 1-2 mutant
subunits abolish hexamer activity (Figure 6b). Taken together these data strongly suggest
that in contrast to Hsp104, ClpB subunits couple highly collaborative ATPase activity to
probabilistic substrate handling to promote the disaggregation of stress-induced
aggregates.
One caveat of employing ClpBDWB is that this variant is a substrate ‘trap’ and fails
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to release substrate [132]. Thus, ClpBDWB might poison hexamer function by failing to
release substrate rather than by perturbing intersubunit co-ordination of ATP hydrolysis
per se. To address this potentially confounding issue and to assess the importance of
substrate binding and ATP hydrolysis by individual subunits toward hexamer
functionality, we constructed ClpBDPLDWB in which both the substrate-binding pore loops
and Walker B motifs are mutated (Y251A:E279Q:Y653A:E678Q). In mutant doping
studies, ClpBDPLDWB, also caused a sharp decline in luciferase disaggregation such that 12 mutant subunits abolished activity (Figure 11g). These data suggest that substrate
binding by ClpBDWB does not contribute to the ability of this mutant to inactivate the
hexamer. Rather, five or six ClpB subunits per hexamer must hydrolyze ATP to drive
protein disaggregation. Surprisingly, this highly co-ordinated ATPase pattern of ClpB
hexamers (Figure 11f, g) is coupled to stochastic substrate binding (Figure 11d). To the
best of our knowledge, this is the first example of a AAA+ protein operating in this way.

2.6 Hsp104 hexamers tolerate multiple subunits defective in ATP hydrolysis and
substrate binding.
We obtained markedly dissimilar results with Hsp104. We confirmed that
Hsp104DWB (E285Q:E687Q) and Hsp104DPLDWB (Y257A:E285Q:Y662A:E687Q) had
little ATPase activity in isolation (Figure 11a) and incorporated into WT hexamers as
predicted (Figure 7j, 8d, 9d & e, 10). Hsp104DWB subunits elicited an approximately
linear decline in total ATPase activity similar to Hsp104DWA subunits (Figure 11b,
compare red markers to orange line). By contrast, Hsp104DPLDWB had little effect on total
ATPase activity unless the fraction of mutant subunit exceeded 50%, in which case the
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inhibition was similar to Hsp104DWB subunits (Figure 11b, compare green to red
markers). Similar to observations with ClpBDWB, 1-2 Hsp104DWB subunits per hexamer
abolished Hsp104 disaggregase activity (Figure 11f). In vivid contrast to ClpB, however,
this inhibitory effect was partially rescued by the substrate-binding loop mutations in
Hsp104DPLDWB (Figure 11g). These data suggest that the ‘substrate-trapping’ activity of
Hsp104DWB [107, 214] poisons the Hsp104 hexamer, rather than the ATPase defect.
Indeed, Hsp104DWA confers a similar ATPase defect to Hsp104DWB (Figure 11b), but
cannot interact with substrate [214] and consequently does not elicit such a sharp decline
in disaggregase activity. Thus, the higher affinity of a single Hsp104DWB subunit for
substrate is sufficient to poison a hexamer with five WT subunits.
The response to Hsp104DPLDWB subunits was unusual (Figure 11g). Rather than
the linear decline predicted by a probabilistic model (Figure 6b), we observed little effect
on disaggregase activity at low fractions of Hsp104DPLDWB. However, a sharp decline in
disaggregase activity was observed when the fraction of Hsp104DPLDWB subunit exceeded
66.7% (Figure 11g). We could mathematically model this behavior if we imposed rules
whereby a mutant subunit stimulates the activity of an adjacent WT subunit by ~1.4-fold,
but exerts an inhibitory effect if it is adjacent to another mutant subunit [196] (Figure
10g, compare pink line to grey markers; Figure 11h). Collectively, these data reveal that
Hsp104 hexamers operate via principles distinct to those of ClpB hexamers. The Hsp104
hexamer displays greater plasticity. It can tolerate a wider variety of subunit inactivating
events without gross perturbations in disaggregase activity . For example, an Hsp104
subunit that: (a) binds but cannot hydrolyze ATP, and, (b) is unable to engage substrate,
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can stimulate the disaggregase activity of an adjacent subunit. In ClpB, a single subunit
with these properties ablates the activity of the entire hexamer. We suggest that the
enhanced plasticity of the Hsp104 hexamer likely reflects an adaptation that ensures a
robust disaggregase activity able to accommodate the distinctive demands presented by
the aggregated proteome of yeast.

2.7 Hsp104 remodels diverse amyloid conformers, whereas ClpB has limited
activity.
What are the distinctive demands of the yeast aggregated proteome? One
possibility is that yeast exploit Hsp104 disaggregase activity to ensure the cytoplasmic
inheritance of numerous beneficial prions [56, 216-220]. By contrast, although E. coli
exploits functional amyloid on the cell surface [221], it is not known to harbor
cytoplasmic prions and can only very inefficiently support the formation of infectious
Sup35 amyloid [222]. Moreover, WT ClpB is unable to remodel Sup35 prions [54, 88,
223]. However, it is unknown whether this inability extends to other amyloid conformers.
We tested whether Hsp104 and ClpB could disaggregate a variety of amyloid
conformers formed by proteins with highly divergent primary sequences, encompassing
yeast prion proteins: Sup35, Ure2 and Rnq1 [224]; proteins connected with Alzheimer’s,
Parkinson’s, and Huntington’s Diseases, or type II diabetes: Aβ42, tau (and K18 a
fibrillogenic tau fragment), α-syn (WT, and PD-linked variants: A53T, A30P, and
E46K), polyglutamine (Q62 and Q81) and amylin [225-227]. As expected, a negative
control, Hsp104DWA, displayed no activity against these amyloid forms (Figure 12a, b).
Remarkably, Hsp104 was able to remodel the vast majority of these amyloid conformers
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Figure 12: Hsp104 disaggregates diverse amyloid conformers, whereas ClpB
does not. (a-d) Amyloid forms of Sup35, Ure2, Rnq1 (2.5µM monomer) or Aβ42,
tau, K18, α-synWT, α-synA53T, α-synA30P, α-synE46K, Q62, Q81 and amylin
fibers (1µM monomer) were incubated with the indicated combination of Hsp104
(20µM), Ssa1 (6µM), Sis1 (6µM), or Hsp104DWA (20µM) (a,c) or ClpB (20µM),
DnaK (3.33µM), DnaJ (0.67µM) and GrpE (0.33µM) for 6h at 37°C (b,d). Fiber
integrity was then determined by either ThT fluorescence (a,b) or sedimentation
analysis (c,d). Values represent means means±SEM (n=3).
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in a manner that was slightly enhanced by the presence of Hsp70 (Ssa1) and Hsp40
(Sis1), which were inactive alone (Figure 12a,c). Rnq1 prions were an exception that
absolutely required Hsp70 and Hsp40 for Hsp104-catalyzed remodeling (Figure 12a, c).
Even in the presence of Hsp70 and Hsp40, some amyloid forms were more refractory
including α-synE46K, Aβ42 and Q81 (Figure 12a, c). In sum, these data suggest that
Hsp70 and Hsp40 are not always essential for Hsp104 to remodel diverse cross-β
structures. Thus, we suggest that a generic structural feature of the amyloid form likely
enables Hsp104 activity in the absence of Hsp70 and Hsp40. The ability of Hsp104 to
remodel such a diverse collection of amyloid forms is unprecedented and could hold
therapeutic potential for various neurodegenerative disorders as well as for the improving
the purification of diverse recombinant proteins for valuable basic and therapeutic
purposes.
In marked contrast, ClpB had very limited ability to disaggregate any of these
amyloid forms with or without Hsp70 (DnaK) and Hsp40 (DnaJ) (Figure 12b,d). Indeed,
we performed an exhaustive set of experiments to try and establish conditions where
ClpB could effectively disaggregate amyloid. We varied ClpB concentration (0-50µM),
DnaK, DnaJ, and GrpE concentrations (0-20µM), incubation time (0-96h), and the
amount of ATP (0-25mM) over a wide range of conditions and could still not establish a
single condition where ClpB effectively disaggregated any of the amyloid forms in
Figure 12. These data indicated that ClpB has diminished activity against amyloid.
We were concerned that the inability of ClpB to disaggregate amyloid might
simply reflect a reduced affinity of ClpB for amyloid substrates. However, the Kd of ClpB
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and Hsp104 for all the amyloid substrates and disordered aggregates used in this study
was remarkably similar and ranged from ~30-100nM (Figure 13a). Thus, ClpB and
Hsp104 appear to recognize and engage amyloid with similar affinity indicating that
some character of the amyloid substrate antagonizes ClpB but not Hsp104 after initial
engagement.
The ClpB hexamer is more sensitive than the Hsp104 hexamer to subunits with
reduced ATPase activity (Figure 11e,f). Thus, one possibility was that the amyloid form
inhibited the ATPase activity of sufficient ClpB subunits to ablate activity. Indeed, all the
amyloid substrates tested inhibited the steady state ATPase activity of ClpB by ~30%,
whereas disordered aggregates stimulated ClpB ATPase activity by ~20% (Figure 13b).
The ATPase activity of Hsp104 was also stimulated by disordered aggregates (Figure
13b). Importantly, none of the amyloid substrates inhibited Hsp104 ATPase activity to
the same extent as ClpB was inhibited (Figure 13b). Indeed, several amyloid substrates
slightly stimulated Hsp104 ATPase activity, whereas others had little effect (Figure 13b).
These data suggest that amyloid specifically inhibits the ATPase activity of the ClpB
hexamer, which might help explain why ClpB has limited ability to disaggregate these
substrates.

2.8 ClpB reactivates stress-induced aggregates more effectively than Hsp104
When ClpB and Hsp104 were titrated against the same model disordered
aggregates, ClpB was consistently more effective than Hsp104 at lower concentrations
(Figure 14). These data indicate that ClpB and the prokaryotic Hsp70 chaperone system
is more adapted to remodel disordered aggregates that accrue upon protein-folding stress,
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Figure 13: Hsp104 and ClpB both bind amyloid but only ClpB ATPase is
inhibited. (a) Apparent Kds for ClpB (blue bars) or Hsp104 (green bars) binding
Sup35, Ure2, Rnq1, Aβ42, tau, K18, α-synWT, α-synA53T, α-synA30P,
α-synE46K, Q62, Q81 or amylin fibers in the presence of 1mM ATPγS as determined by sedimentation analysis. (b) ATPase activity of ClpB or Hsp104 in the
presence of Sup35, Ure2, Rnq1, Aβ42, tau, K18, α-synWT, α-synA53T,
α-synA30P, α-synE46K, Q62, Q81 or amylin fibers. Values represent means
±SEM (n =3).
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Figure 14: ClpB reactivates disordered aggregates more effectively than
Hsp104.Chemically denatured luciferase aggregates were treated with ClpB
(0.03-1.2µM), DnaK (0.2µM), DnaJ (0.04µM) and GrpE (0.02µM) or Hsp104
(0.03-1.2µM), Ssa1 (0.2µM) and Sis1 (0.04µM) for 60min at 25°C. The
reactivation of luciferase was then determined and converted into reactivation
yield (% of total recoverable activity). Values represent means means±SEM
(n=3).
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but is ineffective against amyloid. By contrast, Hsp104 can remodel amyloid (Figure 12a,
b). Although this apparent adaptation enables yeast to exploit prions for beneficial
purposes [56, 216, 217, 219, 220, 224], it also incurs a slight penalty in the ability of
Hsp104 to resolve stress-induced disordered aggregates. We suggest that the ability of
Hsp104 to remodel amyloid is likely conferred by the enhanced plasticity of the hexamer.

2.9 Hsp104 utilizes a distinct mechanism to resolve amyloid conformers
Hsp104 couples probabilistic ATPase activity and substrate handling to the
disaggregation of stress-induced, disordered aggregates. By contrast, Hsp104 switches to
co-operative mechanisms to disaggregate more ordered aggregated structures, such as
preamyloid oligomers and amyloid conformers. We used the mutant doping approach to
analyze Hsp104-catalyzed disassembly of toxic preamyloid oligomers and amyloid
conformers formed by the PD-linked α-syn mutant, α-synA30P [172] and Ure2 prions.
Remarkably, disassembly of α-synA30P oligomers, α-synA30P amyloid, and Ure2 prions by
Hsp104 was extremely sensitive to doping with mutant Hsp104 subunits, including
Hsp104DPL (Figure 15a, b, c), Hsp104DWA (Figure 15d, e, f) and Hsp104DPLDWB (Figure
15g, h, i). In contrast to the results shown in Figure 11, Hsp104’s ability to disassemble
α-SynA30P oligomers was severely compromised by ~2 mutant subunits per hexamer
(Figure 15a, d, g), whereas α-SynA30P fiber and Ure2 prion disassembly was eliminated
by 1 mutant subunit per hexamer (Figure 15b, c, e, f, h, i). Thus, more subunits must
work together to disrupt amyloid conformers (Figure 15b, c, e, f, h, i) compared to stressinduced aggregates (Figure 11d, e, g). Moreover, the response to mutant subunits
(Hsp104DPL, Hsp104DWA, and Hsp104DPLDWB) is relatively invariant for amyloid
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Figure 15: Hsp104 exploits a distinct mechanism to remodel preamyloid
α-synA30P oligomers, α-synA30P amyloids, and Ure2 prions. (a-i) α-synA30P
oligomers (1µM monomer) (a, d, g), α-synA30P fibers (1µM monomer) (b, e, h),
or Ure2 prions (c, f, i) were incubated with Hsp104 (10µM), Ssa1 (3µM) and Sis1
(3µM) for 1h at 37°C in the presence of increasing fractions of buffer (a, b, c) or
mutant Hsp104 subunits: Hsp104DPL (a, b, c), Hsp104DWA (d, e, f), or
Hsp104DPLDWB (g, h, i). Oligomer remodeling was monitored by filter trap assay
and amyloid remodeling was monitored by ThT fluorescence (grey or black markers) or sedimentation analysis (purple or yellow markers). Observed activity was
converted to % WT activity (activity of 10µM WT Hsp104). Values represent
means±SEM (n=2-3). Blue line (a-i) denotes expected disaggregase activity if one
or more mutant subunits eliminate hexamer activity. Red line (a-i) denotes
expected disaggregase activity if two or more mutant subunits eliminate hexamer
activity.
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remodeling, whereas the same mutant subunits elicit diverse responses in the
disaggregation of disordered aggregates (e.g. compare Figure 15b, e, h to Figure 11d, e,
g). These observations suggest that amyloid conformers make more stringent demands on
the precise way in which Hsp104 subunits must collaborate to promote disaggregation.
Taken together, these data suggest that Hsp104 hexamers switch to a highly cooperative mode of ATP hydrolysis and substrate handling to disassemble preamyloid
oligomers and amyloid substrates. A cooperative, sequential mechanism of substrate
handling has been suggested by cryo-EM reconstructions of Hsp104 hexamers [134].
Thus, the operational plasticity of the Hsp104 hexamer could enable a switch between
radically distinct mechanisms of intersubunit mechanochemical coupling to resolve
structures of grossly different chemical stability. Stress-induced disordered aggregates,
which are typically of limited stability and detergent-soluble [16], are resolved via a
probabilistic mechanism. Amyloid structures, which are among the most stable protein
structures in nature and detergent-insoluble [16, 228], elicit a globally co-operative
mechanism of Hsp104 subunit collaboration. This switch in operating mode (e.g.
compare Figure 11d to Figure 15b) likely enables Hsp104 to exert the increased
mechanical force necessary to remodel the extremely stable amyloid form.

2.10 Hsp104 switches reaction mechanism to remodel distinct Sup35 prion strains
Amyloidogenic proteins typically fold into multiple structurally distinct amyloid
structures or ‘strains’, which can vary in stability and confer distinct phenotypes [229].
We hypothesized that Hsp104 subunits might collaborate differently to remodel distinct
amyloid strains of different stabilities formed by the same protein. Hence, we exploited
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the well-defined paradigm provided by the translation termination factor and [PSI+] prion
protein, Sup35, which readily forms distinct prion strains [230-234]. Pure NM, the prion
domain of Sup35 (Figure 16), spontaneously assembles into different prion strain
ensembles at different temperatures [230-234]. Synthetic NM prions formed at 4°C,
termed NM4, possess a shorter, less stable amyloid core (Tm~54°C) with distinctive
intermolecular contacts and give rise to ‘strong’ [PSI+] prion strains in vivo (Figure 16)
[231, 232, 234]. Here, ‘strength’ refers to the magnitude of the translation termination
defect caused by depletion of soluble, functional Sup35 by self-templating Sup35 prions
[224]. Synthetic NM prions formed at 25°C or 37°C, termed NM25 and NM37, harbor
longer, more stable amyloid cores (Tm~81°C for NM25 and Tm~86°C for NM37) with
intermolecular contacts distinct from NM4, and give rise to ‘weak’ [PSI+] prion strains in
vivo (Figure 16) [231, 232, 234]. These different prion strains provide an unparalleled
opportunity to assess Hsp104 activity against alternative prion structures with distinct
chemical stabilities formed by the same primary sequence. Hence, we employed mutant
doping studies to assess the mechanism by which Hsp104 subunits collaborate to remodel
NM4, NM25 and NM37.
Remarkably, remodeling of each NM prion strain required a different mode of
intersubunit collaboration by Hsp104. Thus, NM4 remodeling was less sensitive than
NM25 or NM37 to Hsp104DPL (Figure 17a, d, g), Hsp104DWA (Figure 17b, e, h), or
Hsp104DPLDWB (Figure 17c, f, i). Very similar results were obtained with Hsp104DWB
(data not shown). Indeed, NM4 remodeling was eliminated by ~3-4 mutant subunits per
hexamer, whereas NM25 remodeling was eliminated by 1 mutant subunit per hexamer
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Figure 16: Sup35 NM can form different strains. Sup35 is composed of a
C-terminal GTPase domain (amino acids 254–685, black) that confers translation
termination activity, a highly charged middle domain (M, amino acids 124–253, dark
grey) and a prionogenic N-terminal domain (N, amino acids 1–123, light grey)
enriched in glutamine, asparagine, tyrosine and glycine. Within N, prion recognition
elements termed the ‘Head’ (red) and ‘Tail’ (green), which flank a ‘Central Core’
(blue), play important roles in prionogenesis [230]. Prion recognition elements within
N make homotypic intermolecular contacts such that Sup35 prions are maintained by
an alternating sequence of Head-to-Head (red) and Tail-to-Tail (green) contacts [230,
234]. The Central Core (blue) is sequestered by intramolecular contacts. Different
prion strains can form depending on the environmental conditions [230, 232, 234].
Thus, NM4 fibers form at 4°C, NM25 fibers form at 25°C and NM37 fibers form at
37°C. Note that the Central Core (blue) and Tail (green) are comprised of different
amino acids in the NM4, NM4 and NM37 fiber conformations . NM25 and NM37
have an extended central core and have a higher melting temperature (Tm) in 2% SDS
than NM4 [230, 232, 234]. These are our working models of Sup35 prion strain
structure, but we note that the atomic structures of Sup35 prion strains remain
unknown and several alternative models have been advanced [29, 233].
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Figure 17: Hsp104 switches reaction mechanism to remodel distinct Sup35 prion
strains. (a-i) Preformed NM4, NM25 or NM37 (1µM monomer) were incubated for
1h at 25°C with Hsp104 (10µM), Ssa1 (3µM) and Sis1 (3µM) in the presence of
increasing fractions of buffer (a, d, g) or mutant Hsp104 subunits: Hsp104DPL (a, d, g),
Hsp104DWA (b, e, h), or Hsp104DPLDWB (c, f, i). Remodeling was monitored by ThT
fluorescence (grey or black markers) or sedimentation analysis (purple or yellow
markers). Observed activity was converted to % WT remodeling activity (activity of
10µM WT Hsp104). Values represent means±SEM (n=2-4). Purple line denotes
expected disaggregase activity if four or more mutant subunits eliminate hexamer
activity (a-c). Green line denotes expected disaggregase activity if three or more
mutant subunits eliminate hexamer activity (a-c). Blue line (d-i) denotes expected
disaggregase activity if one or more mutant subunits eliminate hexamer activity.
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(see Figure 11b). Taken together, these data suggest that as the length of the cross-beta
core of the NM fiber increases (Figure 16) the mechanism by which Hsp104 subunits
must collaborate becomes increasingly co-operative. For NM4, a subglobal co-operative
mechanism will suffice, whereas NM25 requires a global co-operative mechanism.
NM37 remodeling is extremely sensitive to mutant subunits (Figure 17g-i), which might
even indicate that more than one Hsp104 hexamer is required to remodel this amyloid
structure. Thus, as the amyloid core of NM prions increases in size and encroaches
further into more C-terminal regions of primary sequence (Figure 16) then Hsp104 must
switch to a mechanism that requires collaboration from an increasing number of subunits.

2.11 Hsp104 switches mechanism to disaggregate disordered aggregates versus
prions
We confirmed that Hsp104 switches mechanism to disaggregate disordered
aggregates versus various NM prion strains using two strategies that do not employ
mutant subunits. First, we employed p370 a thirteen amino acid peptide that
competitively inhibits Hsp104 from engaging substrates [107]. Importantly, Hsp104catalyzed luciferase reactivation was insensitive to a 20-fold excess of p370 (Figure 18a).
In striking contrast, NM4 remodeling was inhibited and NM37 remodeling was abolished
by p370, whereas a control thirteen amino acid peptide, pSGG, which does not bind
Hsp104 [107], had no effect (Figure 18a). Thus, in keeping with our Hsp104DPL doping
experiments (Figure 11d, 15d) amyloid disaggregation by Hsp104 is more sensitive to
competitive inhibition of substrate binding than disaggregation of disordered aggregates.
Next, we assessed Hsp104 disaggregase activity against disordered aggregates
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Figure 18: Competitive peptide inhibitors and ATPgS affect amorphous and
amyloid disaggregation differently. (a) Luciferase aggregates, NM4 prions, or
NM37 prions were treated with Hsp104, Ssa1, and Sis1 plus buffer, p370, or
pSGG. Disaggregase activity was converted to % activity in the absence of
peptide. Values represent means ±SEM (n = 2). (b) Luciferase aggregates were
treated with Hsp104, Hsc70, and Hdj2 or Hsp104 alone plus various ATP:ATPγS
ratios. Disaggregase activity was converted to % activity of Hsp104, Hsc70, and
Hdj2 plus ATP. Values represent means ±SEM (n = 3). (c and d) NM4 prions (c)
or NM37 prions (d) were treated with Hsp104, Ssa1, and Sis1 or Hsp104 alone
plus various ATP:ATPγS ratios. Disaggregase activity was converted to % activity of Hsp104, Ssa1, and Sis1 plus ATP. Values represent means ±SEM (n = 3).
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and NM prion strains in the presence of various ratios of ATP and the slowly
hydrolyzable ATP analogue, ATPγS. We kept the total adenine nucleotide concentration
constant, but varied the ATP:ATPγS ratio from 12:0 to 0:12. In the presence of Hsp70
and Hsp40, luciferase reactivation was largely unaffected by increasing fractions of
ATPγS (Figure 18b). Indeed, optimal activity was observed at ratios of 7:5 or 6:6
ATP:ATPγS, and even a ratio of 4:8, ATP:ATPγS, supported luciferase reactivation
activity similar to reactions conducted in purely ATP (Figure 18b). Activity could even
be detected at a 1:11 ratio of ATP:ATPγS (Figure 18b). In the absence of Hsp70 and
Hsp40, Hsp104 was inactive against luciferase aggregates in the presence of ATP alone,
but addition of ATPγS stimulated activity, and at a 6:6 ATP:ATPγS ratio, we observed
the highest level of Hsp104 activity against luciferase (Figure 18b). Collectively, these
activity profiles illustrate the adaptability of the Hsp104 hexamer, which can effectively
promote luciferase reactivation when diverse mixtures of ATP and ATPγS populate its
NBDs. In vivid distinction, Hsp104-catalyzed remodeling of NM4 and NM37 was
sharply inhibited by even low fractions of ATPγS (Figure 18c, d). Consistent with our
mutant subunit doping experiments (Figure 17a-c, g-i), Hsp104-catalyzed remodeling of
NM37 was much more sensitive to ATPγS than NM4. Taken together, these findings
suggest that WT Hsp104 hexamers exploit a different mechanism to remodel disordered
aggregates versus amyloid.

2.12 Key residues in the MD and NBD2 enable Hsp104 to switch mechanism
How does Hsp104 switch reaction mechanism? We hypothesized that Hsp104
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variants that are functional in thermotolerance (disaggregation of amorphous aggregates),
but defective in prion propagation in vivo, might be unable to switch mechanism. We
focused on Hsp104D704N and Hsp104L462R, which confer WT levels of thermotolerance
but cannot propagate [PSI+], [RNQ+] or [URE3] prions [204, 205]. D704 is located
between the Walker B and sensor-1 motifs in NBD2, whereas L462 is located in helix 2
of the coiled-coil middle domain [1, 123]. D704 is predicted to be at a contact interface
between NBD2 and the coiled-coil middle domain, whereas L462 is predicted to be in
close proximity to nucleotide in NBD1 [133]. Thus, D704 and L462 are positioned to
play a crucial role in the interdomain or intersubunit communication necessary to switch
mechanism.
In vitro, Hsp104D704N and Hsp104L462R were hypomorphic. Hsp104D704N had
reduced ATPase activity, reduced ability to disaggregate disordered luciferase
aggregates, and could not remodel NM25 (Figure 19a). By contrast, Hsp104L462R had WT
levels of ATPase activity, but like Hsp104D704N, exhibited reduced disaggregase activity
against disordered luciferase aggregates, and could not disaggregate NM25 (Figure 19a).
Thus, Hsp104D704N and Hsp104L462R retain activity against disordered aggregates but are
inactive against amyloid, which explains their ability to confer thermotolerance but not
prion propagation in vivo [204, 205]. Very little functional Hsp104 is required for
thermotolerance in vivo [47, 213, 235]. Thus, the reduced activity of Hsp104D704N and
Hsp104L462R against disordered aggregates (Figure 19a) is likely sufficient to confer WT
levels of thermotolerance, especially when cells are given a conditioning pretreatment
[204, 205].
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Figure 19. Hsp104D704N and Hsp104L462R subunits selectively ablate amyloid disaggregation: (a) Comparison of ATPase activity, luciferase reactivation activity, and
NM25 disaggregase activity of WT Hsp104, Hsp104D704N, and Hsp104L462R. Observed
activity was converted to % WT activity. Values represent means ±SEM (n = 2–3). (b)
Luciferase aggregates were treated with Hsp104D704N, Hsc70, and Hdj2 plus increasing
fractions of Hsp104D704NDWA (gray markers) or Hsp104D704NDPLDWB (blue markers).
Luciferase reactivation was converted to % Hsp104D704N activity. Expected activity if six
(orange line), three or more (green line), or two or more (red line) mutant subunits ablate
hexamer activity. Values represent means ±SEM (n = 3). (c) Luciferase aggregates were
treated with Hsp104L462R, Hsc70, and Hdj2 plus increasing fractions of Hsp104L462RDWA
(gray markers) or Hsp104L462RDPLDWB (blue markers). Luciferase reactivation was
converted to % Hsp104L462R activity. Orange line indicates expected activity if six
mutant subunits are needed to ablate hexamer activity. Values represent means ±SEM (n
= 3). (d) Luciferase aggregates were treated with Hsp104, Hsc70, and Hdj2 plus increasing fractions of Hsp104D704N (purple markers) or Hsp104L462R (green markers). Luciferase reactivation was converted to % WT Hsp104 activity. Orange line indicates expected
activity if six mutant subunits are needed to ablate hexamer activity. Values represent
means ±SEM (n = 2). (e) NM25 was treated with Hsp104, Ssa1, and Sis1 plus increasing
fractions of Hsp104D704N or Hsp104L462R. Remodeling was monitored by ThT fluorescence. Activity was converted to %WT Hsp104 activity. Predicted activity (blue bars) if
one mutant subunit ablates hexamer activity. Values represent means ±SEM(n = 2).
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A trivial explanation for the inability of Hsp104D704N to remodel amyloid is its reduced
ATPase activity (Figure 19a). However, this would not seem to apply to Hsp104L462R,
which has WT levels of ATPase activity (Figure 19a). The limited ability of Hsp104D704N
and Hsp104L462R to remodel amyloid is reminiscent of ClpB (Figure 12c, d). Thus, we
hypothesized that Hsp104D704N and Hsp104L462R subunits might collaborate differently
than WT Hsp104 subunits to disaggregate disordered aggregates. To probe how
Hsp104D704N and Hsp104L462R subunits collaborate to reactivate aggregated luciferase, we
doped in mutant Hsp104D704N and Hsp104L462R subunits defective in ATP hydrolysis
(DWA) or ATP hydrolysis and substrate binding (DPLDWB). For Hsp104D704N, we
observed a sharp decline in activity upon doping Hsp104D704NDWA consistent with 2 or 3
mutant subunits being sufficient to inactivate the Hsp104D704N hexamer (Figure 19b).
Thus, Hsp104D704N exploits a subglobally co-operative mechanism of ATP hydrolysis to
reactivate luciferase, unlike WT Hsp104, which uses a probabilistic mechanism (Figure
11e). Indeed, Hsp104D704N responds to ATPase-defective subunits more like ClpB
(Figure 11e), which has limited amyloid-remodeling activity (Figure 12c, d). Doping in
subunits defective in ATPase activity and substrate-binding modalities
(Hsp104D704NDPLDWB) subunits elicited an approximately linear decline in Hsp104D704N
luciferase reactivation activity (Figure 19b), rather than the stimulation observed with
WT Hsp104 or sharp inhibition observed with ClpB (Figure 11g). Thus, in contrast to
WT Hsp104, Hsp104D704N subunits with compromised ATPase and substrate-binding
activity are not able to stimulate the activity of adjacent Hsp104D704N subunits. These data
suggest that the D704N mutation impairs intersubunit communication in a way that
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reduces plasticity and precludes amyloid disaggregation.
Hsp104L462R subunits collaborated differently than Hsp104D704N and WT Hsp104
subunits to resolve luciferase aggregates. An approximately linear decline in Hsp104L462R
disaggregase activity was observed upon doping Hsp104L462RDWA subunits (Figure 19c).
Thus, Hsp104L462R subunits responded like WT Hsp104 subunits upon doping ATPasedefective subunits (Figure 11e). These data suggest that Hsp104L462R exploits
probabilistic ATP hydrolysis to reactivate luciferase like WT Hsp104. In contrast to WT
Hsp104, however, doping in subunits defective in ATPase activity and substrate-binding
modalities (Hsp104L462RDPLDWB) subunits elicited an approximately linear decline in
Hsp104L462R luciferase reactivation activity (Figure 19c), rather than the stimulation we
observed with WT Hsp104 (Figure 11g). Thus, Hsp104L462R subunits with compromised
ATPase and substrate-binding activity are not able to stimulate the activity of adjacent
Hsp104L462R subunits. These data suggest that the Hsp104 hexamer is also altered by the
L462R mutation in a way that disrupts intersubunit communication and disables amyloidremodeling activity.
Unexpectedly, doping Hsp104D704N or Hsp104L462R subunits had very little effect
on luciferase reactivation catalyzed by WT Hsp104 (Figure 19d), even though
Hsp104D704N or Hsp104L462R hexamers are at least ~5-fold less active than WT hexamers
against luciferase (Figure 19a). These data reillustrate the robustness of the WT Hsp104
hexamer and its capacity to accommodate defective subunits and still effectively catalyze
the disaggregation of disordered aggregates. Even an average of one WT subunit per
Hsp104D704N or Hsp104L462R hexamer is capable of catalyzing the same amount of
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disaggregation as WT hexamers (Figure 19d). By contrast, Hsp104D704N or Hsp104L462R
subunits caused a sharp decline in Hsp104-catalyzed disaggregation of NM25 consistent
with one mutant subunit being sufficient to disrupt hexamer activity (Figure 19e). These
data suggest that D704 and L462 play a critical role in either transmitting or receiving the
signal that elicits recruitment of additional Hsp104 subunits during amyloid
disaggregation. Thus, we suggest that impairing intersubunit communication with
specific mutations, such as D704N or L462R, yields Hsp104 variants that dissolve
disordered aggregates but not amyloid.

2.13 Discussion
We have established for the first time that Hsp104 employs fundamentally distinct
modes of intersubunit collaboration to resolve stress-induced disordered aggregates
versus amyloid structures. For stress-induced disordered aggregates, Hsp104 subunits
employ a probabilistic mechanism of ATP hydrolysis similar to the mechanism defined
for the protein unfolding activity of ClpX [193, 194]. However, in striking contrast to
ClpX, Hsp104 is much more tolerant of subunits that are unable to engage substrate. For
example, ClpX unfolding and translocase activity is severely impaired by the introduction
of two subunits per hexamer that cannot engage substrate [203], whereas Hsp104 retains
~70% activity (Figure 11d). This sensitivity to subunits that are unable to engage
substrate might help explain why ClpX, which has a powerful unfoldase activity [236], is
unable to function as a protein disaggregase [212].
The permissive nature of Hsp104 hexamers to subunits that cannot hydrolyze
ATP or engage substrate enables a disaggregation mechanism with great flexibility. Thus,
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one WT subunit per hexamer is sufficient to catalyze disaggregation (Figure 20a). Indeed,
any opportunely positioned subunit within the hexamer that is able to engage the irregular
and heterogeneous aggregated structure and hydrolyze ATP can promote disaggregation.
Individual subunits do not have to co-ordinate ATPase events or substrate binding events
with neighboring subunits or wait until all subunits are engaged, which may be sterically
improbable. In this way, Hsp104 can systematically resolve the entire aggregated
proteome, comprised of diverse and unrelated proteins, after stress.
Surprisingly, ClpB, the E. coli homolog of Hsp104, is tuned very differently to
Hsp104. Like Hsp104, ClpB exploits probabilistic substrate binding to the disaggregation
of stress-induced aggregates. Thus, the ClpB hexamer is also remarkably tolerant of
subunits that are unable to engage substrate (Figure 11d, 20b). This ability of ClpB and
Hsp104 hexamers to tolerate subunits that cannot engage substrate is a shared feature of
these disaggregases, which distinguishes them from the protein unfoldase, ClpX.
In contrast to Hsp104, however, the probabilistic substrate interactions of ClpB
are coupled to a highly co-operative mode of ATP hydrolysis (Figure 20b).
Unexpectedly, this operating mode enables ClpB to disaggregate stress-induced,
disordered aggregates more effectively than Hsp104 (Figure 14). However, this enhanced
disaggregase activity comes at the expense of a robust disaggregase activity able to
accommodate subunits with compromised ATPase activity. Thus, in contrast to Hsp104,
ClpB hexamers are unable to tolerate a single subunit that is unable to hydrolyze ATP.
Moreover, our data suggest that unlike Hsp104, ClpB has limited ability to couple cooperative ATPase activity to co-operative substrate handling, which is necessary to
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Figure 20: Mechanisms of intersubunit collaboration for Hsp104 and ClpB. (a-d)
Hsp104 (a, c, d) or ClpB (b) subunits are depicted as spheres, and a single aggregated
conformer is displayed. Green subunits are engaged in productive disaggregation via
substrate binding (depicted by a lever) and/or ATP hydrolysis. Yellow subunits have
completed their role in disaggregation. Blue subunits are resting and do not need to
hydrolyze ATP or engage substrate for successful disaggregation. Red subunits recruit
resting subunits until a sufficient number are recruited to promote disaggregation. (a)
Hsp104 couples probabilistic ATPase activity and substrate binding to resolve disordered aggregates. Thus, a single subunit within a hexamer that can bind substrate and
hydrolyze ATP is sufficient to drive protein disaggregation. (b) ClpB exploits cooperative ATPase activity and probabilistic substrate binding to resolve disordered
aggregates. Five or six ClpB subunits per hexamer must hydrolyze ATP to disaggregate disordered aggregates. Cooperative ATPase activity is not coupled to cooperative
substrate handling, as one ClpB subunit capable of binding substrate can drive disaggregation provided five or six subunits can hydrolyze ATP. (c) Hsp104 switches to a
subglobal cooperative mechanism of ATP hydrolysis and substrate binding to resolve
NM4 prions. One subunit initially engages amyloid, but the localized structural
stability of the cross-b form antagonizes unfolding, which elicits a signal (red subunit)
that recruits additional subunits until a sufficient number are recruited that can
together unfold the cross-b structure. For NM4, three subunits per hexamer must
engage substrate and hydrolyze ATP. (d) Hsp104 switches to a global cooperative
mechanism of ATP hydrolysis and substrate binding to resolve more refractory amyloids, such as NM25 prions. Hsp104 subunits collaborate as in (c) except that the
local stability of the amyloid fold is even more antagonistic, such that six subunits
must be recruited to engage substrate and hydrolyze ATP for disaggregation.
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remodel amyloid. Indeed, ClpB appears unable to unfold stable protein domains during
disaggregation [210].
The increased robustness and plasticity of the Hsp104 hexamer is likely to be an
adaptation that enables the remodeling of amyloid and has allowed yeast to capture prion
conformers for beneficial purposes [56, 216, 224]. Indeed, ClpB and E. coli cytosol was
unable to remodel any of the 13 amyloid conformers tested in Figure 12. Amyloid
inclusions form in the E. coli cytoplasm upon gross protein overexpression [222, 237].
Yet, the limited ability of ClpB to remodel amyloid suggests that E. coli
compartmentalizes amyloid rather than disseminating it throughout the cytoplasm [222,
237]. By contrast, although yeast partition amyloid to specific compartments upon
protein overexpression [238, 239], they also actively disseminate infectious amyloid
conformers throughout the cytoplasm for a variety of beneficial purposes [216, 224]. The
profound selective advantages afforded by yeast prions are only made possible by the
ability of Hsp104 to remodel amyloid [56, 220].
We suggest that the default intersubunit collaboration mechanism of Hsp104 is
probabilistic (Figure 20a). However, this intersubunit collaboration mechanism can be
rapidly tuned to a suitable subglobal or global co-operative mechanism upon sensing
more stable substrates. Thus, extremely stable amyloid structures likely antagonize
unfolding and elicit a signal for Hsp104 subunits to work together in engaging substrate
and hydrolyzing ATP to promote disaggregation (Figure 20c, d). Indeed, for amyloid
conformers of α-synA30P and Ure2, 1-2 mutant subunits are sufficient to inactivate the
hexamer (Figure 20d). For synthetic NM prions (Figure 16), we decipher for the first time
80

that strains that are less chemically stable and possess a shorter cross-β core can be
resolved using a subglobal co-operative mechanism that is inactivated by three mutant
subunits per hexamer (Figure 20c). By contrast, NM prion strains of higher chemical
stability with longer cross-β cores are resolved by a global co-operative mechanism that
is inactivated by one mutant subunit (Figure 20d). Taken together, our data suggest that
Hsp104 hexamers possess sufficient plasticity to adapt a variety of mechanochemical
coupling mechanisms that are elicited by the specific physical demands of the precise
aggregated substrate. The adaptive value of operational plasticity lies in the fact that it
enables the Hsp104 hexamer to do the minimum work necessary to efficaciously
disaggregate any given substrate. Thus, if two Hsp104 subunits are sufficient to rapidly
disaggregate a substrate, then that is all that will be used. We suggest that various NTPfueled, multimeric ring-translocases that must remodel a diverse portfolio of substrates
could operate via similar adaptable repertoires of intersubunit collaboration.
We establish that an aspartate residue in NBD2 (D704) and a leucine residue in
helix 2 (L462) of the middle domain are essential for Hsp104 to switch to a mechanism
that enables amyloid remodeling. Hsp104D704N and Hsp104L462R are unable to remodel
amyloid, but maintain the ability to disaggregate disordered aggregates. Doping mutant
subunits into Hsp104D704N- and Hsp104L462R-catalyzed luciferase reactivation revealed
that Hsp104D704N and Hsp104L462R hexamers are tuned differently to WT Hsp104. Indeed,
Hsp104D704N couples subglobal ATP hydrolysis to luciferase disaggregation and in this
regard is more similar to ClpB. Like WT Hsp104, Hsp104L462R couples probabilistic
ATPase activity to luciferase disaggregation. In contrast to WT Hsp104, however, neither
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Hsp104L462R nor Hsp104D704N is stimulated by mutant subunits that are unable to engage
substrate but can bind but not hydrolyze ATP (i.e. DPLDWB subunits). This critical
difference suggests that intersubunit communication is impaired by the D704N and
L462R mutations. Importantly, Hsp104D704N or Hsp104L462R subunits poison prion
remodeling, but have no effect on luciferase reactivation catalyzed by WT Hsp104. Thus,
we suggest that D704 and L462 play a critical role in either transmitting or receiving the
signal that elicits recruitment of additional Hsp104 subunits during amyloid
disaggregation (Figure 7C, D). Indeed, Hsp104D704N and Hsp104L462R are functional in
thermotolerance and defective in prion propagation in vivo [204, 205]. We now provide a
mechanistic explanation for this previously puzzling observation: the D704N or L462R
mutations impair intersubunit communication in a way that reduces operational plasticity
and selectively precludes amyloid disaggregation.
Finally, these findings suggest that Hsp104 might be engineered or designed to be
more potent and selective against specific proteins, which could empower the facile
purification of diverse recombinant proteins for valuable basic and therapeutic purposes.
Moreover, Hsp104 might be developed to target select proteins that misfold and form
amyloid in diverse degenerative disorders [41, 240]. The intrinsic ability of Hsp104 to
remodel a diverse collection of disease-connected amyloid forms (see Figure 12) as well
as toxic oligomers (Figure 14a, d, g) raises optimism that this avenue warrants deeper
exploration. Here, it will be important to maintain or tune the operational plasticity of the
Hsp104 hexamer such that only the desired aggregated forms or strains of the target
protein are remodeled. Thus, a challenge will be to increase the specificity of the Hsp104
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hexamer for a target polypeptide while maintaining the operational plasticity of the
hexamer to a level that selectively eliminates toxic conformers. As just one example, in
specific circumstances where amyloid conformers are protective and disordered
aggregates are toxic then hypomorphic scaffolds based on Hsp104D704N or Hsp104L462R
might be explored.

2.14 Contributions
All constructs were generated by M.E.D. FRET experiments, luciferase
reactivation, and ATPase without substrate were performed by M.E.D. Biotinylation and
Ni-elution experiments, amyloid disaggregation, ATPase with substrate were performed
by J.S.
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CHAPTER 3: The distal loops of the Middle Domains of Hsp104 and
ClpB are crucial for collaboration with Hsp70 and Hsp40

3.1 Overview
Hsp104 and ClpB are homologous protein disaggregases that confer
thermotolerance by disaggregating misfolded substrates in either yeast or bacteria,
respectively [12, 90]. Both proteins require collaboration with the Hsp70 and Hsp40 (also
referred to as DnaK and DnaJ in bacteria) to function in this respect [12, 90]. The exact
nature of the collaboration between disaggregase and the Hsp70 chaperone system is not
fully elucidated. Recently, it has become apparent that the coiled coil MD (amino acids
411-538) of Hsp104 and ClpB play a key role in collaboration with Hsp70 and Hsp40.
Here, we determine that the distal loop portion of the MD (amino acids 430-446) is
especially important for this collaboration, as mutations in this region specifically ablate
the functional interaction between Hsp104 and Hsp70. It has been established that the
distal loop of Hsp104 does not directly interact with Hsp70 [186, 187, 189]. Instead the
distal loop of the MD appears to make an intra-protomer interface with the second NBD2
as revealed by disulfide cross-linking. Tryptophan fluorescence and hydroxyl-radical
foot-printing also suggest that the distal loop is partially shielded from solvent. The
distal-loop – NBD2 interaction may function to regulate disaggregation by Hsp104 in
response to Hsp70 and Hsp40. However, it appears that prolonged interaction between
the MD and NBD2 is inhibitory to Hsp104 activity. Finally, using a mutant-doping
strategy, we determined that ClpB has a more stringent requirement for Hsp70
collaboration than Hsp104.
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3.2 Mutations in the distal loop affect collaboration with Hsp70 and Hsp40
Recently, much attention has been focused on the role that the MD plays in
Hsp104 and ClpB activity [141, 159, 178]. However, research focused on the function of
the distal loop has been strikingly absent. Additionally, the placement of the MD within
the Hsp104 hexamer has been hotly debated [1, 123, 134]. Interestingly, while motif 2 is
similarly placed in each proposed model of Hsp104 structure, the distal loop portion of
the MD in motif 1 is in very different environments in both models [1, 123, 134] (Figure
3c, d). To determine the importance of the distal loop region of the MD of Hsp104, we
mutated several residues in this region and determined the effects on Hsp104
functionality (Figure 21). We chose the residues A430, L431, and D438 because they are
conserved, yet lie in the disordered loop-turn region that connects helix 1 to helix 2
(Figure 21). Initially we attempted to make the most severe mutation and we introduced
the bulky, hydrophobic tryptophan residue. We observed that Hsp104A430W, Hsp104L431W,
and Hsp104D438W were unable to disaggregate aggregated luciferase in an in vitro assay
when supplemented with Hsp70 and Hsp40 (Figure 22a, light grey bars). Remarkably,
these mutants did not lose generalized disaggregation activity, as they were as active, or
more active in some cases, than WT Hsp104 when supplemented with activating ratios of
ATP and ATPγS (Hsp104A430W = 128±17.6%, Hsp104L431W = 196±49.8%, and for
Hsp104D438W = 105±13.8% WT Hsp104 activity) (Figure 22a, dark grey bars). These are
the first mutants we have encountered that are unable to collaborate with Hsp70 and
Hsp40 yet retain Hsp70-independent disaggregation activity. As with the tryptophan
substitution, we found that mutation to tyrosine at positions A430, L431, and D438
yielded proteins that were deficient in Hsp70 collaboration but were active when
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Distal Loop in Hsp104
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Figure 21: Location and sequence of the distal loop. (a) Domain schematic of
Hsp104. N terminal is shown in purple, NBD1 in cyan, MD in yellow, NBD2 in dark
blue. (b) Hsp104 monomer with A430 (orange), L431 (teal), and D438 (blue) shown as
spheres. Domain coloring as in (a). (c) Alignment of the middle domains from several
Hsp104 homologues. The distal loop region is boxed in red.
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Figure 22: Distal loop mutants are deficient in Hsp70 collaboration: (a, b) WT
Hsp104 or variants or WT ClpB or ClpBA428W were incubated with urea-denatured
luciferase aggregates (50nM). Reactions with Hsp70 and Hsp40 included are shown in
light grey in part (a). Reactions where Hsp70 and Hsp40 are replaced with activating
ratios of ATP:ATPγS are shown in dark grey (a). Reactions with only ATP (and no
Hsp70, Hsp40 and no ATPγS) are shown in part (b). For WT Hsp104 and variant
catalyzed reactions, Hsp104 was 6µM and the co-chaperones Hsc70 (an Hsp70) and
Hdj2 (an Hsp40) were either omitted or at 1µM. When co-chaperones were omitted,
ATPγS:ATP were present in a ratio of 4mM:1.1mM (a) or ATP was present at 5mM
(b). Reactions were incubated at 25°C for 90min. For WT ClpB and ClpBA428W catalyzed reactions, ClpB was held at 1µM, DnaK and DnaJ were at 0.167µM, and GrpE
was held at 0.0167µM (a). Reactions were incubated at 25°C for 60min. When bacterial KJE was omitted, ATPγS:ATP were present in a ratio of 2.5mM:2.6mM or ATP
was present at 5mM (b) and reactions were incubated for 90min at 25°C. Error bars
represent SEM, n≥3. (c) W303-Δhsp104 yeast were transformed with either empty
pHSE vector or WT Hsp104, Hsp104A430W, Hsp104L431W, or Hsp104D438W. Each strain
was pre-treated at 37°C for 30min prior to heat shock at 50°C for 0, 5, 10, or 20min.
Cells were spotted on SD-ura ar plates and incubated at 30°C for two days. Each
column of yeast spots represents a 5-fold dilution of the column of colonies to the left.
(d) Western blot of homogenized cell lysates used in thermotolerance. Cell density was
normalized to OD600 = 0.55 before cells were lysed and loaded on gel. Top panel was
blotted with α-Hsp104 antibody and bottom panel is total protein visualized with
Coomasie. From left are Hsp104A430W, Hsp104L431W, Hsp104D438W, WT Hsp104 or
empty vector control.
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supplemented with ratios of ATPγS:ATP (Figure 22a). Interestingly, it appeared that
mutation to other residues did not specifically ablate Hsp70 collaboration at positions
A430 and L431. For example, Hsp104A430D and to a lesser extent, Hsp104A430L, were
inactive in both Hsp70-dependent and -independent luciferase disaggregation (Figure
22a). Hsp104A430V was as active as WT Hsp104 with the Hsp70 and Hsp40 system
(143.7±44.4% WT activity), but was unable to be activated by ATP:ATPγS (Figure 22a).
Mutation to Hsp104L431A resulted in lowered Hsp70-dependent disaggregation (33.5±6.8
% WT activity) and inhibited ATP:ATPγS activation (Figure 22a). The Hsp104L431D
variant had lowered Hsp70 mediated disaggregation activity (45.9±7.2% WT Hsp104
activity), was nearly activated to WT levels by ATP:ATPγS, and interestingly, had slight
disaggregation activity with ATP alone (12.2±2% of WT Hsp104 with Hsp70 and
Hsp40), a behavior that WT Hsp104 does not exhibit (Figure 22b) [12]. Remarkably,
mutation to any residue we tested at the D438 position inhibited Hsp70-dependent
activity without effecting Hsp70-independent activity (Figure 22a). It is not clear why, at
positions A430 and L431, only the tryptophan and tyrosine substitutions resulted in
Hsp70 collaboration deficiency. To test if incorporation of tryptophan or tyrosine at any
position in the distal loop yielded a protein that could not collaborate with Hsp70 and
Hsp40, we generated Hsp104A437W and Hsp104A437Y and tested in vitro luciferase
disaggregation. We conjectured that mutants at this position should behave similarly to
the 438 variants because of the close proximity of the two positions. However, we found
that Hsp104A437W and Hsp104A437Y behaved very differently than the other distal loop
mutants we had tested. Both variants were able to collaborate with Hsp70 and Hsp40 and,
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in fact, were significantly more active than WT Hsp104 (Hsp104A437W was 453.7±36.8%
more active and Hsp104A437Y was 363.7±57.9% more active) (Figure 22a, light grey
bars). Additionally, both variants were unable to be activated by ATPγS:ATP ratios and
both had significant luciferase disaggregation ability with just ATP (Hsp104A437W was
212% and Hsp104A437Y was 297% as active as WT Hsp104 with Hsp70 and Hsp40)
(Figure 22b). Not every variant at position A437 was hyperactive, as Hsp104A437D had
WT levels of activity in the presence of Hsp70 and Hsp40 and had slightly repressed
activity with ATPγS:ATP ratios (42.3±1.45% WT Hsp104 activity) (Figure 22a).
In sum, our results show that the effects of mutations in the distal loop are very
unpredictable and can alter collaboration with Hsp70 and Hsp40. Certain variants, like
Hsp104A430W/Y, Hsp104L431W/Y, and Hsp104D438A/L/W/Y are unable to collaborate with
Hsp70 and Hsp40, yet maintain disaggregase functionality. Other variants like
Hsp104A437W/Y were hyperactive with Hsp70 and Hsp40 and were unable to be activated
by ATPγS:ATP. To understand the role of the distal loop in Hsp70 and Hsp40
collaboration, we focused subsequent analysis on the tryptophan mutants Hsp104A430W,
Hsp104L431W, and Hsp104D438W which were specifically impaired in collaboration with
Hsp70 and Hsp40, could be activated by ATPγS:ATP like WT Hsp104, and were not
active in the absence of Hsp70 and Hsp40 in the presence of only ATP (Figure 22a, b).
The ability to collaborate with Hsp70 and Hsp40 is required for amorphous
substrate disaggregation and thus, for in vivo thermotolerance. Therefore, proteins that
are not competent in Hsp70 collaboration are predicted to be completely inactive in an in
vivo thermotolerance assay. As expected, Hsp104A430W, Hsp104L431W, and Hsp104D438W
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were all impaired in thermotolerance. Hsp104A430W and Hsp104L431W were completely
inactive with thermotolerance levels comparable to that conferred by an empty vector
control (Figure 22c). Hsp104D438W was able to confer marginal thermotolerance as
compared to WT Hsp104 (Figure 22c). Western blot confirmed that all proteins were
expressed at comparable levels (Figure 22d). These data suggest that the inability to
collaborate with Hsp70 and Hsp40 was maintained in an in vivo setting.
Our results thus far suggested that specific mutation in the distal loop can lead to
specific impairment in Hsp104’s ability to collaborate with Hsp70 and Hsp40. To
determine if this was conserved in other Hsp104 homologues, we tested ClpBA428W,
which is analogous to Hsp104A430W (Figure 21). Interestingly, this mutant also had
impaired KJE-collaboration in in vitro luciferase reactivation but was slightly more active
than WT ClpB in ATP:ATPγS mediated disaggregation (162.1±28.7% WT ClpB activity)
(Figure 22a). Therefore, mutation of this conserved alanine (A430 in Hsp104 and A428
in ClpB) to tryptophan specifically ablates Hsp70 collaboration in both S. cerevisiae and
E. coli.
None of the distal loop mutants resulted in secondary structure perturbation as
shown by circular dichroism (Figure 23a) and each distal loop mutant oligomerized like
the WT Hsp104 (Figure 23b) so the effects we observed were not due to gross structural
changes. Recently, it has become clear that Hsp104 and ClpB engage Hsp70 via motif 1
of the MD and not at the distal loop [186, 187, 189]. Therefore the distal loop mutants we
have identified which cannot collaborate with Hsp70 are not part of the interaction
interface between Hsp104 and Hsp70 [186, 187, 189].
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Figure 23: Distal loop mutants are well-folded and oligomerize like WT-Hsp104.
(a) Mean residue ellipticity from 260-200nm was obtained for WT Hsp104 (red),
Hsp104A430W(orange), Hsp104L431W(light blue), Hsp104D438W (dark blue). All variants
were dialyzed into CD buffer (see Methods) and protein concentration was adjusted to
1µM. (b) WT Hsp104 (red), Hsp104A430W(orange), Hsp104L431W (light blue), and
Hsp104D438W (dark blue) (30µM each) were fractionated on a Superose 6 10/300
column.
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3.3 ATPase activity of Hsp104 distal loop variants does not correlate with the ability
to collaborate with Hsp70
We determined the ATPase activity of each Hsp104 distal loop mutant, as well as
WT ClpB and ClpBA428W (Figure 24). Most distal loop mutants in Hsp104 had impaired
ATPase rates compared to WT Hsp104. It was initially tempting to claim that the defects
we observed in Hsp70-dependent disaggregation were because of altered ATPase activity
in these mutants. However, Hsp104D438A had an ATPase rate of 11.2±0.96 min-1 which is
comparable to WT Hsp104 (13.1±0.93 min-1) (Figure 24). Like many of the other distal
loop mutants, Hsp104D438A is unable to collaborate with Hsp70 and Hsp40 but is active
with ATPγS:ATP (Figure 22a). Additionally, ClpBA428W, which was also unable to
collaborate with the DnaK system but is active in luciferase disaggregation when
supplemented with ATPγS:ATP, did not have a lower ATPase rate than WT ClpB
(compare 3.2±0.57 min-1 for WT ClpB to 3.4±0.06 min-1) (Figure 24). In fact, if
decreased ATPase activity led to failed Hsp70 collaboration, we would expect all distal
loop mutants to be deficient in collaboration with Hsp70 and Hsp40. However, this was
not observed. In fact, we saw no correlation between ATPase activity and the ability to
disaggregate luciferase in either an Hsp70-dependent or Hsp70-independent manner
(Figure 25a, b).

3.4 The A430W mutation in the distal loop results in a more compact Hsp104
hexamer
To determine how the distal loop mutants may be affecting overall structure of
Hsp104, we performed small and wide-angle x-ray scattering (SAXS and WAXS) to
determine the maximum dimension (Dmax) and radius of gyration (Rg) the WT Hsp104
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Figure 25: There is no correlation between ATPase rate and luciferase
reactivation: (a) Reactivation of luciferase with Hsp104, Hsc70, and Hdj2 vs.
ATPase activity for WT Hsp104 and variants. For a linear fit, R square =
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0.1483.
95

and the Hsp104A430W hexamers (Figure 26). SAXS exploits the fact that X-rays which are
scattered by a particle at very low angles contain information about particle size and
shape. As can be seen by the pairwise distance distribution (P(r) curve), which represents
the distances between pairs of atoms within a given volume, the Hsp104A430W variant has
a smaller Dmax than WT Hsp104 (203±3Å compared to 223±2Å for WT Hsp104). Also,
the Rg, which represents the average distance of all the atoms from the center of a
particle, is tighter for Hsp104A430W than for WT Hsp104 (compare 63.6±0.45Å to
67.3±0.216Å) (Figure 26).. This suggests that the A430W mutation compresses the
Hsp104 hexamer. Oguchi et al. suggests that certain mutations in the distal loop of ClpB
(e.g. E432A) promote a tighter interaction between NBD1 and motif 2 of the MD [141].
However, by examining their data (Figure 5 in Oguchi, et al. [141]), we can see that
mutation in the distal loop also slows hydrogen exchange in NBD2. Thus, we wondered
if the slowed hydrogen exchange in NBD2 indicated that NBD2 can interact with the
distal loop in a way that is fortified by specific mutations (e.g. A430W). An interaction
between the distal loop and NBD2 would be intriguing since certain proposed models of
Hsp104 structure place the distal loop near NBD2 [133, 134], and not NBD1 as Oguchi
and colleagues suggest [141].

3.5 Tryptophan fluorescence and hydroxyl radical foot-printing reveals that the
distal loop of Hsp104 is partially shielded from solvent
To determine the orientation of the distal loop within the Hsp104 hexamer, we
exploited the fact that Hsp104 has no natural tryptophan residues and utilized tryptophan
fluorescence spectroscopy to learn about the orientation and solvation state of the MD.
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Figure 26: The Hsp104A430W hexamer is more compact than WT Hsp104. The
P(r) distribution, derived from SAXS data, is a measure of distances between pairs
of atoms within a given volume and contains information about the shape of each
particle The maximum distance along the y-axis represents the Dmax for a given
particle and is listed below. The Rg value listed for each variant was determined by
a Guinier approximation using a small sub-set of the SAXS data (See methods
section).
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Tryptophan fluorescence is a sensitive technique that measures the polarity of the local
microenvironment within 10Å of a Trp residue [241, 242]. Red-shifted maxima
(~350nm) indicate a polar microenvironment, e.g. solvated regions [241, 242]. By
contrast, blue shifted emission maxima (~330nm) indicate a more hydrophobic
environment, e.g. regions that are shielded from solvent [241, 242]. We determined the
fluorescence spectra of each mutant distal loop tryptophan mutant and because of the lack
of natural tryptophans, we could be sure that each specific spectrum we collected was
unique to that mutant and reflected the local environment of a tryptophan at that position.
We included the Hsp104Y466W position, which is predicted to be buried in two different
CryoEM models of the Hsp104 hexamer structure (Figure 3) and the Hsp104Y497W
position, which is predicted to be solvated in both models as controls to ensure that our
experiment could accurately determine solvation state of specific residues. As expected,
the Hsp104Y466W ‘buried control’ had a blue-shifted fluorescence maxima of ~330nm,
which is predicted for a buried region (Figure 27a-d). By contrast, the Hsp104Y497W
‘solvated control’ had a red-shifted fluorescence maxima of ~350nm, which is predicted
for a solvated region (Figure 26a-d). Each distal loop mutant had a wavelength of
maximum emission in each nucleotide state that is between 335 and 340nm, which is
indicative of a region that is partially buried (Figure 27a-d). While fluorescence intensity
changed in response to nucleotide, we saw very minor spectral shifts in response to
different nucleotides. Notably, the spectra of the distal loop mutants in the absence of
nucleotide and in the presence of ADP was more red-shifted while the spectra of ATP
and ATPγS were more blue-shifted (Figure 27a-d).
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Figure 27: The distal loop is partially solvent inaccessible. Tryptophan fluorescence spectra of Hsp104Y466W(green line), Hsp104Y497W(purple line),
Hsp104A430W(orange line), Hsp104L431W(light blue line), or Hsp104D438W(dark blue
line). All variants were left in the apo state (a) or incubated with ATP(b), ATPγS(c),
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While minor, these shifts may indicate that the distal loop in the vicinity of the distal loop
is more solvated in the apo and ADP state and more buried in the ATP and ATPγS state.
Tryptophan fluorescence is a bulk technique in which the obtained signal is an
average of the total protein in solution. Therefore, the intermediate spectra obtained for
the distal loop mutants can be interpreted in two ways. The first possibility is that the
distal loop is partially sequestered from solvent all of the time. The second interpretation
is that the distal loop moves between two different conformations, one of which is
solvated and one of which is buried, which results in an averaged fluorescence spectra
that reflects a region of intermediate solvation. Regardless, these data suggest that the
distal loop might interact with other domains of Hsp104 in a manner in which shields it
from solvent.
We confirmed that the distal loop of the MD of Hsp104 was partially buried using
a technique called hydroxyl radical foot-printing. Here, white x-rays are used to generate
hydroxyl radicals which then covalently modify amino acid side chains in a predictable
way [243-246]. Oxidation is subsequently quenched with ethanolamine and MS-MS is
used to identify oxidized peptides, which can be mapped onto the structure or a structural
model of the protein [246]. This technique is ideal for monitoring solvation states
because, with very short X-ray exposures, only amino acids which are solvated will be
oxidatively modified [246]. We found that the distal loop region of the MD (amino acids
431-455) is more protected from oxidation when Hsp104 is saturated with ATPγS
(oxidation rate = 202.16±18.95 sec-1), which indicates that the distal portion of the MD is
partially buried (Table 1). However, the distal loop becomes heavily oxidized when
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Hsp104 is ADP bound state, which indicates that it is more accessible to solvent
(oxidation rate =838.66±32.96 sec-1) (Table 1).
Table 1: Oxidative modification rates of key peptides as determined by hydroxyl
radical foot-printing
Peptide
Nucleotide State
Rate (sec-1)
ATPγS
202.16±18.95
431-455
ADP
838.66±32.96
ATPγS
unmodified
611-631
ADP
9±0.62
ATPγS
unmodified
789-809
ADP
modified. no rate.
unmodified: peptide is not modified for the duration of exposure
modified. no rate: peptide is modified but rate cannot be determined due to inconsistent modifications over
time.

3.6 Engineered disulfide cross-links demonstrate that the distal loop can contact
NBD2
Using two different techniques, we were able to observe that the distal loop of
Hsp104 can be partially shielded from solvent. We have evidence from dynamic light
scattering coupled to size exclusion chromatography that Hsp104 hexamers are
monodisperse in solution (data not shown). We surmised, then, that the distal loop of the
MD must be interacting with a domain within an Hsp104 hexamer, and not forming a
dimer-of-hexamers type arrangement where the MD can form a bridge between two
hexamers. Where, then, does the distal loop become buried? Oguchi et al. has suggested
that the distal loop interacts with NBD1 of an adjacent protomer [141], however, we
wanted to investigate if the distal loop could contact NBD2, as has been suggested [133,
134]. To answer this question, we looked to a structural model of Hsp104 where the
distal loop is in close proximity to NBD2 in the same subunit [133, 134, 247]. We
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mutated all naturally occurring Hsp104 cysteines to serine. This Hsp104 variant retains
wild-type levels of thermotolerance in vivo and luciferase reactivation in vitro (Figure
28a, b). Then, based upon the model [133, 134] (Figure 3d), we site-specifically
introduced cysteine residues at proposed contact points between the MD and NBD2 and
attempted to form disulfide cross-links. Disulfides were induced by diamide and detected
by reduced mobility on non-reducing SDS-PAGE and with Ellman’s reagent to quantify
free sulfhydryls [140]. We were able to observe disulfide cross-linking between the MD
residue A430C and the NBD2 residue F630C (Hsp104A430C:F630C) (Figure 29a, b). This
crosslink formed with 85% efficiency in the presence of AMP-PNP (a non-hydrolyzable
ATP analog) and with 50% efficiency in the presence of ADP. We also were able to
observe specific cross-links between MD residue K451C and NBD2 residue E790C
(Hsp104K451C:E790C). This crosslink formed with 75% efficiency in the presence of AMPPNP and with 40% efficiency in the presence of ADP (Figure 29a, b). The fact that both
cross-links formed with less efficiency in the presence of ADP as compared to an ATP
analog confirmed both the tryptophan fluorescence and hydroxyl-radical foot-printing
data which suggested that saturating ADP causes the distal loop to become more
solvated. Cross-links which form within a subunit manifest as a slight upshift in band
migration in non-reducing SDS-PAGE [140]. Conversely, cross-links which are formed
between two subunits result in dimer formation which is easily visualized via SDSPAGE. All of the cross-links we observed were intra-subunit bonds, ie the distal loop of
the MD interacts specifically with NBD2 of the same subunit.
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a.

b.

Figure 28: 6CS Hsp104 behaves like WT Hsp104. (a) Thermotolerance conferred
by 6CS Hsp104 (red), WT Hsp104 (blue), and an empty vector control (blue).
Values represesnt means ±SEM (n=3) (b) Luciferase aggregates were treated with
Hsc70, Hdj1, and either WT Hsp104 or 6CS Hsp104. Disaggregase activity was
converted to % WT activity.
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Figure 29: The distal loop can contact NBD2 in Hsp104 and ClpB: (a) Successful
cross-links formed between the MD (yellow) and NBD2 (blue) of Hsp104 (only one
monomer shown). Residue A430C (dark pink spheres) in the MD could crosslink to
F630C (light pink spheres) in NBD2. Residue K451C (dark green spheres) in the MD
could crosslink to E790C (light green spheres) in NBD2. (b) Crosslinks were visualized by band shift in SDS-PAGE. Single mutants did not show cross-linking (left).
Up-shift was seen only in double mutant constructs. Quantification of band intensity
is shown below (c) In ClpB, A428C (dark purple spheres) in the MD (yellow) was
able to crosslink with L817C (light purple spheres) in NBD2 (blue). (d) Crosslinks
were visualized by band shift in SDS-PAGE. Single mutants did not show crosslinking (left). Up-shift was seen in double mutant constructs in all nucleotide states.
All gels were stained with coomasie and quantified with ImageJ software
(http://rsbweb.nih.gov/ij/).
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If the distal loop has a greater propensity to interact with NBD2 in the presence of
ATPγS, as the cross-linking data suggests, we would expect the regions surrounding the
proposed NBD2 contacts to be more solvated in the presence of ADP. Hydroxyl radical
foot-printing confirmed that the regions surrounding residues F630 and E790 were
shielded from solvent more in the presence of ATPγS than ADP. The peptide
corresponding to amino acids 611-631 remained unmodified when Hsp104 was preincubated with ATPγS, but was modified at a rate of 9±0.62sec-1 in the presence of ADP
(Table 1). Similarly, the peptide 789-809 was unmodified in the ATPγS solution. This
peptide incurred some oxidative modifications in the presence of ADP, however because
of inconsistent modifications over time, we were not able to determine an accurate rate
(Table 1).
To determine if the contacts between the MD and NBD2 were conserved in
bacteria, we attempted to form the specific cross-links we observed with Hsp104 in the
ClpB background. While A428C (Hsp104A430C) and F625C (Hsp104F630C) did not form a
covalent bond, we were able to observe cross-linking between the MD residue A428C
and L817C, which is located in the small domain of NBD2 (ClpBA428C:L817C) (Figure 29c,
d). Contrary to Hsp104, we observed 100% cross-linking efficiency in all nucleotide
states.

3.7 Stabilization of the contact between the MD and NBD2 inhibits disaggregation.
The tryptophan fluorescence, foot-printing, and cross-linking data thus far
suggested that the MD can populate at least two different conformations that results in the
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distal loop being in two different environments. One of the conformations results in a
distal loop that is less solvent accessible and which can be juxta-NBD2 and thus able to
form a covalent cross-link between the two domains. The second conformation leaves the
distal loop more solvent accessible and not as tightly associated with NBD2. To learn
more about the functional relevance of the interaction between NBD2 and the MD we
tested cross-linked and uncross-linked Hsp104A430C:F630C and ClpBA428C:L817C in a
luciferase reactivation assay. Before the cross-linking protocol was performed, both
Hsp104A430C:F630C and ClpBA428C:L817C displayed luciferase reactivation levels comparable
to their WT counterparts (Figure 30a, b). After the cross-linking protocol was performed
in the absence of DTT (so that the covalent bond between the distal loop and NBD2
remains in the oxidized state), both Hsp104A430C:F630C and ClpBA428C:L817C had very low
luciferase reactivation abilities, suggesting that the cross-links inhibited the
disaggregation ability of Hsp104 and ClpB (Figure 30a, b). Furthermore, when
Hsp104A430C:F630C and ClpBA428C:L817C were incubated with 1mM DTT after the crosslinking procedure (thus reducing the formed cysteine bond) both Hsp104A430C:F630C and
ClpBA428C:L817C regained WT Hsp104 or ClpB disaggregation activity, indicating that the
cross-linking procedure itself does not result in impaired activity. We were unable to test
whether the cross-links inhibited Hsp70-independent reactivation since all ATPγS:ATP
activated disaggregation was inhibited in the absence of DTT for unknown reasons.
To determine how the crosslink between MD and NBD2 results in disaggregation
inhibition, we determined the ATPase activity of Hsp104A430C:F630C and ClpBA428C:L817C.
Hsp104A430C:F630C displayed an elevated ATPase rate compared to WT Hsp104 (compare
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Figure 30: Crosslinked constructs have diminished ATPase and luciferase
reactivation activities. (a) Luciferase aggregates were treated with Hsc70, Hdj1,
and WT Hsp104, 6CS Hsp104, or Hsp104A430C/F630C. Hsp104 variants were either
not cross-linked (red), cross-linked with no DTT (blue), or cross-linked and subsequently incubated with DTT (grey). Disaggregase activity was converted to % WT
activity. (b) Luciferase aggregates were treated with DnaK, DnaJ, GrpE, and WT
ClpB or ClpBA428C/L817C. not cross-linked (red), cross-linked with no DTT (blue), or
cross-linked and subsequently incubated with DTT (grey). Disaggregase activity
was converted to % WT activity. (c) ATPase activity (min-1) of Hsp104A430C/F630C
after no cross-linking (red), cross-linking with no DTT (blue), or cross-linking
followed by incubation with DTT (grey). (d) ATPase activity (min-1) of
ClpBA428C/L817C after no cross-linking (red), cross-linking with no DTT (blue), or
cross-linking followed by incubation with DTT (grey).
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25±0.67 min-1 to 13.13±0.93 min-1 for WT Hsp104) (Figure 24, Figure 30c). After the
cross-linking procedure was performed, Hsp104A430C:F630C hydrolysis was inhibited in the
absence of DTT; i.e. when the crosslink was left intact (9.54±1.63min-1) (Figure 30c).
Inhibition was relieved when Hsp104A430C:F630C was incubated with DTT (27±0.67min-1),
indicating that the MD-NBD2 covalent contact inhibits hydrolysis in the Hsp104
background (Figure 30c). In contrast, ClpBA428C:L817C both in the presence and absence of
DTT had nearly identical rates of ATP hydrolysis (compare 2.56±0.38min-1 with a
reduced crosslink to 2.65±0.46min-1 with an intact crosslink) (Figure 30d), indicating that
the presence of the crosslink between the distal loop and NBD2 does not impair
hydrolysis in ClpBA428C/L817C.

3.8 Doping analysis reveals Hsp104 has a less stringent requirement for Hsp70
collaboration than ClpB
Both Hsp104 and ClpB are dynamic hexameric assemblies where subunit
exchange occurs rapidly and randomly [95, 175, 206] (Figures 6-10). This means that we
can use a mutant-doping approach to answer questions about how many subunits are
required for a given aspect of Hsp104 or ClpB activity [95, 175, 206, 248]. In these types
of experiments, WT subunits are mixed with subunits that contain a mutation that
specifically abolishes one aspect of activity, like chaperone collaboration. As has been
established previously, these mixtures rapidly form heterohexamers, which are hexamers
that contain both WT and mutant subunits assembled according to a binomial probability
distribution (Figure 6a) By using these previously assembled heterohexamers in a
luciferase reactivation assays, we can get a measure of how many WT subunits are
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required for a specific activity (i.e. chaperone collaboration) during disaggregation of
aggregated luciferase (Figure 6b). For example, by mixing WT Hsp104 with
Hsp104A430W or WT ClpB with ClpBA428W in known and established ratios we were able
to determine how many WT subunits are required for Hsp104 or ClpB to successfully
collaborate with Hsp70 during disaggregation. We conducted doping experiments as
outlined (See Methods Section) with Hsp104A430W and ClpBA428W and found that WT
ClpB was far more sensitive to the Hsp70-collaboration deficient mutant than was WT
Hsp104. In fact, ClpB required between 3 and 4 WT subunits to successfully
disaggregate luciferase, while Hsp104-WT only required 2 WT subunits (Figure 31). We
were concerned that the differences observed between Hsp104 and ClpB in this assay
were due to GrpE, a nucleotide exchange factor which is included in the ClpB-mediated
reactivation experiments, but not in the Hsp104 experiments [90]. To determine if GrpE
could account for the observe differences, we repeated the ClpBA428W doping
experiments, but omitted GrpE. We observed an even more deleterious effect upon
titration of ClpBA428W. In the absence of GrpE, it appeared as if ClpB required between 5
and 6 WT subunits to accomplish disaggregation (Figure 31).

3.9 Discussion
Recently, the MD of Hsp104 and ClpB has been implicated as being crucial to
collaboration with Hsp70 [159, 178, 187]. However, the role of the distal loop portion of
the MD has been largely ignored. In this study, we determined the importance of the
distal loop portion of the MD of Hsp104. We exploited the fact that both Hsp104 and
ClpB can be activated to disaggregate substrates when supplemented with mixtures of
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Figure 31: ClpB requires more subunits that can collaborate with Hsp70 than
Hsp104. Luciferase aggregates were treated with Hsp104, Hsc70, and Hdj2 plus
increasing fractions of, Hsp104A430W (green markers). Alternatively, luciferase
aggregates were treated with ClpB, ClpBA428W, DnaK, and DnaJ. GrpE was
included (grey markers) or omitted (orange markers). Where error bars are not
visible, they are too small and are hidden by marker. Luciferase reactivation (%
WT activity) was then assessed. Values represent means ± SEM (n=3-4). Solid
lines represenent theoretical activity curves for situations where one or more
mutant subunits (blue), two or more mutant subunits (red), three or more mutant
subunits (green), four or more mutant subunits (purple), or five or more mutant
subunits (light blue) are required to eliminate hexamer activity.
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ATPγS and ATP. In this way, we were able to test disaggregation of aggregated
substrates in the absence of Hsp70 and Hsp40. No other study which has attempted to
elucidate the mechanism of Hsp70 collaboration has utilized this approach. We showed
for the first time that the distal loop region is crucial for Hsp70 and Hsp40 collaboration
in Hsp104 and that by introducing bulky aromatic residues at either the 430 or 431
positions or by introducing any mutation at the 438 position, Hsp70 collaboration can be
specifically ablated without affecting generalized disaggregation ability. Furthermore, we
showed that the role of the distal loop in collaboration with Hsp70 and Hsp40 has been
conserved across millions of years of evolution because introducing a large, bulky
tryptophan residue at the 428 position in ClpB (which is homologous to the 430 position
in Hsp104) results in a specific inhibition of Hsp70 collaboration. Remarkably, not every
substitution in distal loop results in Hsp70 and Hsp40 collaboration defects. The variants
Hsp104A437W and Hsp104A437Y are hyperactive and function even better than WT Hsp104
in luciferase disaggregation.
Why are some distal loop mutants unable to function in Hsp70 collaboration but
display activity in Hsp70-independent disaggregation? It is not because these mutants are
impaired structurally or in their ability to form hexamer, as we have shown that the distal
loop mutants retain WT secondary structure and oligomerize like WT Hsp104. Neither is
it because the distal loop mutants have a lowered ATPase rate, as there was no
discernible trend or correlation between ATPase rate and Hsp70 collaboration. It is also
improbable that the distal loop binds Hsp70 with high affinity as three recent studies have
determined that Hsp70 binds ClpB and Hsp104 via residues in motif 2 of the middle
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domain [141, 186, 189]. Though they were specifically probed for with cross-linking, no
interaction between Hsp70 and the distal loops in ClpB or Hsp104 were detected [186,
187]. It has been proposed that the distal loop portion of the MD interacts or is in close
proximity to NBD1 of an adjacent subunit [141, 187]. Using two different techniques, we
were able confirm that the distal loop is partially buried in an intra-Hsp104 interface in a
manner that is nucleotide-dependent. That is, when the NBDs are populated with ATP or
ATPγS, the distal loop of the MD is less solvent accessible and when ADP is present, the
distal loop is more solvent accessible. It is possible that the distal loop in Hsp104 does
interact with NBD1, however we did not specifically test this. Instead, using disulfide
cross-linking we were able to show that the MD in both Hsp104 and ClpB can contact
NBD2 in the same subunit of either protein, respectively. We hypothesize that this
interface is functionally relevant for Hsp70 collaboration and that the distal loop mutants
may mimic the cross-links effects by strengthening the interaction between the distal loop
and NBD2. In fact, we observed that the distal loop mutant Hsp104A430W is more compact
and has a maximum dimension that is 20Å shorter than WT Hsp104. It is possible that
the tightness of the Hsp104A430W particle could be due, in part, to a strengthened
interaction between the distal loop and NBD2. We also observed that cross-linking the
distal loop to NBD2 in Hsp104 results in inactivation of ATPase and disaggregase
activity. Curiously, only disaggregase activity was inhibited when the distal loop of ClpB
was cross-linked to NBD2; ATPase activity was comparable to WT ClpB when the
oxidized cross-link was left intact. Once covalent cross-links were reduced in both ClpB
and Hsp104, all activities were recovered. These data suggest that the interaction between
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the distal loop and NBD2 is inhibitory to Hsp70 collaboration and potentially that
movement of the MD is required for a functional interaction with Hsp70. We propose
that the MD-NBD2 interface is stronger in certain distal loop mutant constructs (i.e.
Hsp104A430W/Y, Hsp104L431W/Y, and Hsp104D438A/L/W/Y) which results in the MD
populating the juxta-NBD2 position more often. Again, if movement of the MD is
required for disaggregation or the interaction between distal loop and NBD2 is inhibitory
to Hsp70 collaboration, this would explain why the distal loop mutants cannot
functionally interface with the Hsp70 chaperone system.
While it is not exactly clear how the distal loop mutants impair Hsp70 and Hsp40
collaboration, we were still able to exploit the fact that they cannot collaborate with the
Hsp70 system. We used Hsp104A430W and ClpBA428W in a doping experiment against
aggregated luciferase to determine how many collaboration-competent subunits are
required in order to productively disaggregate substrate. We determined that Hsp104 only
requires 2 WT subunits to collaborate with Hsp70 (Figure 31). ClpB, conversely,
required between 3 and 4 WT subunits to promote Hsp70-dependent disaggregation
(Figure 30), suggesting that ClpB has a more rigid requirement for Hsp70 collaboration
than Hsp104. This result was surprising because it indicated that Hsp104 and ClpB differ
fundamentally in their mechanism of collaboration with Hsp70. One must take care not to
over-interpret the data presented in Figure 31. It is tempting to claim that these data
indicate that one ClpB hexamer forms a complex with 3 DnaK proteins or that one
Hsp104 hexamer forms a disaggregation complex with 2 Hsp70 proteins. However,
because Hsp70 has the capacity to function upstream of the disaggregase to facilitate
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threading into the central channel [115, 140, 152, 153], downstream of the disaggregase
to promote proper folding of the remodeled aggregate [46, 91], and in complex with the
disaggregase to form a protein remodeling complex [158, 189] we are unable to
determine why ClpB requires an additional Hsp70 to accomplish disaggregation. For
example, it is possible 3 DnaKs are required to successfully thread substrate into ClpB,
while only 2 Hsp70s are required to thread into Hsp104. It is also possible that the
products of ClpB disaggregation have more stringent refolding requirements than the
products of Hsp104 disaggregation, so more DnaK proteins are required downstream of
disaggregation.
GrpE is a nucleotide exchange factor (NEF) for bacterial DnaK [249, 250]. GrpE
can promote the dissociation of DnaK from either ADP or ATP [251, 252] but
preferentially recognizes the high affinity ADP-DnaK complex [250, 252]. Interestingly,
there is no eukaryotic protein with high sequence homology with GrpE [253]. However,
Hsp110 proteins are functional homologues of GrpE and act as Hsp70 NEFs in yeast
(Sse1) or metazoans (e.g. Apg1, Apg2, Hsp105) [51, 52]. To test if the differences we
observed in the doping experiments discussed above were due to the inclusion of the
GrpE NEF with the bacterial system, we omitted GrpE and repeated the doping
experiment with WT ClpB and ClpBA428W. Instead of observing a trend more similar to
Hsp104 (i.e. 2 WT subunits required to collaborate with Hsp70) we observed a more
stringent requirement for Hsp70 and Hsp40 in the absence of GrpE (between 5 and 6 WT
subunits were required for successful disaggregation). DnaK that is saturated with ADP
binds substrate with high affinity and GrpE promotes substrate release in Hsp70 by
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promoting the exchange of ADP for ATP [254]. It is possible that the role of GrpE in the
ClpB, DnaK, and DnaJ system is to promote nucleotide exchange such that DnaK can
pass substrate to ClpB more easily. However, it is not clear why Hsp104 and Hsp70
would not require an NEF to promote successful substrate handover. It would be
interesting to study the effects of the yeast or metazoan NEFs on Hsp104 disaggregation
and determine if inclusion of NEFs altered Hsp104 requirement for Hsp70.

3.10 Contributions
Constructs were generated by M.E.D., E.L., and D.S. Luciferase reactivation,
thermotolerance, circular dichroism, size exclusion chromatography, ATPase, and
tryptophan fluorescence were performed by M.E.D. Cross-linking experiments were
performed by M.E.D., E.L., J.S., and D.S. X-ray foot-printing and small angle X-ray
scattering were performed by E.A.S.

115

CHAPTER 4: Summary
4.1 Closing remarks
The work presented in this thesis focused on elucidating two unknown aspects of
Hsp104 activity. In Chapter 2, we investigated the role of subunit collaboration in
disaggregation of amorphous and amyloid aggregates by Hsp104. We found that more
stable substrates, like amyloid, require more communication between subunits to
accomplish disaggregation. The result does not only clarify an aspect of Hsp104
mechanism, but may potentially reveal a mechanistic detail that could be exploited by
any multimeric ATPase which must couple mechanical work to ATPase events occurring
in multiple subunits. Additionally, we found that both substrate binding and hydrolysis
during disaggregation are collaborative when Hsp104 encounters amyloid aggregates.
However, both substrate binding and hydrolysis are probabilistic processes during
amorphous substrate remodeling. Furthermore, the E. coli homologue ClpB appears to
operate very differently than Hsp104. While substrate handling is probabilistic, ClpB
employs collaborative ATP hydrolysis to disaggregate amorphous substrates. The fact
that ATPase activity and substrate binding are uncoupled in ClpB is compelling and may
indicate that Hsp104 and ClpB not only exploit different modes of inter-subunit
collaboration, but may utilize different mechanisms to translocate substrates.
Additionally, ClpB is unable to disaggregate amyloid, though it can bind the amyloid
structure with high affinity. Finally, we identified two Hsp104 mutants, L462R and
D704N, which appear to inhibit subunit collaboration. We posit that the regions
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surrounding these mutations may be crucial in relaying signals between Hsp104
protomers.
We also investigated the role of the distal loop portion of the MD of Hsp104 and
ClpB. While is has recently become clear that portions of the MD of ClpB and Hsp104
are crucial to collaboration with Hsp70, we identified that the distal loop is also key,
which was previously unknown. We found that this region is partially buried and is able
to contact NBD2 in the same subunit. Prolonging the interaction between the distal loop
and NBD2 or inhibiting MD movement via disulfide cross-linking inhibits Hsp104
ATPase and luciferase disaggregation ability. Covalently binding the distal loop of ClpB
to NBD2 only inhibits disaggregation activity; ATPase activity is left intact. It is not clear
why this difference exists between Hsp104 and ClpB. We propose that mutation in the
distal loop of both proteins inhibits the ability to interact with Hsp70 because of allosteric
changes that propagate up the MD to the Hsp70 interacting site on helices 2 and 3. The
mechanism of inhibition could be an increased affinity between motif 2 and NBD1 or a
decreased binding affinity between motif 2 and Hsp70. As has been shown previously,
these two phenomena are intricately tied [141, 187], so it is likely that we will not be able
to distinctly differentiate how the distal loop mutations affect co-chaperone collaboration.
Finally, we used the mutant doping approach outlined in Chapter 2 to try to understand
how many subunits are required to collaborate with Hsp70 in order to accomplish
disaggregation. We found that ClpB, on average required 3 subunits to interact with the
Hsp70 chaperone system while Hsp104 only required 2 subunits. Furthermore, when the
NEF, GrpE, was omitted from the bacterial disaggregation reactions, ClpB required
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between 5 and 6 WT subunits to productively interface with DnaK, suggesting that ClpB
has a greater requirement for Hsp70 and Hsp40 than Hsp104.

4.2 Future Directions
While the work presented here has expanded our understanding of how Hsp104
operates, there are a number of experiments that could answer some unresolved
questions. In Chapter 2, none of the data we presented can answer questions concerning
orientation of coordination around the Hsp104 hexamer. For example, while Hsp104 is
disaggregating NM25, six subunits are required to hydrolyze ATP. The doping
experiments cannot clarify whether hydrolysis must occur in a concerted fashion where
all subunits hydrolyze all at once or whether hydrolysis happens in one subunit at a time,
until all six subunits have hydrolyzed ATP. Similarly, if hydrolysis is not a concerted
event, then there could be a number of different sequential hydrolysis events which
promote disaggregation. For instance, hydrolysis could happen in one subunit at a time,
moving in a clock-wise or counter-clock-wise manner around the ring, as has been
observed with the E1 helicase [199]. Additionally, ATP hydrolysis could occur in paired
subunits, where subunits directly adjacent to each other or directly across the channel
from each other hydrolyze at the same time. Pairing of subunits has been observed the
protease-regulatory AAA+ complex, PAN [271]. In order to conclusively determine the
spatial requirements of inter-subunit coordination in Hsp104, we propose to construct a
linked Hsp104 hexamer, where each subunit is covalently linked to the adjacent subunit
by a disordered floppy linker. This approach has been utilized to define specific spatial
orientation of hydrolysis events around the AAA+ protein, ClpX [193, 195, 203]. To do
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this, we will attempt initially to construct a linked dimer, where two Hsp104 subunits are
connected by a linker similar to the one utilized by the Sauer lab with ClpX [193]. If a
dimer can be constructed, we will attempt to construct a linked trimer or hexamer
comprised of 3 or 6 Hsp104 subunits. Once the linked Hsp104 constructs can be
constructed, the mutations we exploited in the doping studies in Chapter 2, like
Hsp104DWA or Hsp104DPL can be introduced in specific subunits to discern if Hsp104 has
a spatial requirement for inter-subunit coordination with respect to ATP or substrate
binding.
In Chapter 3, we proposed that the distal loop of Hsp104 is important for
collaboration with Hsp70. However we do not fully understand how the distal loop
functions in interaction with Hsp70. A number of experiments could be performed to
clarify how the distal loop mutants specifically inhibit Hsp70 collaboration. Oguchi et al.
observed a close association between NBD1 and motif 2, while Seyffer et al. found that
stabilizing this interaction precludes DnaK from activating ClpB [141, 187]. In fact,
Seyffer and colleagues even suggest that mutations in the distal loop of ClpB (E432A in
ClpB) results in a strengthened interaction between motif 2 and NBD1 [187]. It would be
illuminating to test how the distal loop mutants we identified which result in specific
inhibition of Hsp70 collaboration (e.g. Hsp104A430Y/W, Hsp104L431Y/W, of
Hsp104D438A/L/Y/W) change or alter the association of motif 2 and NBD1. It is possible that
the distal loop mutants identified in this work strengthen the interaction between motif 2
and NBD1 of Hsp104. It would also be prudent to test if the repressed ClpB distal loop
mutant (E432A in ClpB) identified by Oguchi et al. [141] and discussed above, had the
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same phenotype in Hsp104 (Hsp104D434A). Additionally, we want to determine how distal
loop mutations that result in Hsp70 collaboration defects affect the interaction with
Hsp70. To do this, we could use a photo-activatable cross-linking approach [141, 186] in
the Hsp104A430W background. If distal loop mutation inhibits interaction with Hsp70, we
would expect that Hsp104A430W would have a weaker interaction with Hsp70 than WT
Hsp104.
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CHAPTER 5: Methods

5.1 Mutagenesis
All Hsp104 and ClpB mutants were constructed using the QuickChange
Lightening Mutagenesis Kit (Agilent).

5.2 Protein expression and purification
ClpB variants were C-terminally His6-tagged in a pDS56-Rll parent plasmid with
an ampicillin selectable marker. Plasmids were transformed into M15 competent cells
(New England Biolabs) and allowed to grow in at 37°C in 2-XYT media (USB. Recipe:
16g/L casein peptone, 10g/L yeast extract, 5g/L NaCl, pH 7.0) supplemented with
100µg/ml ampicillin till mid log phase was reached. Protein expression was induced with
1mM isopropylthio-β-galactoside (IPTG) for 15-18 hours at 15°C with shaking at
250rpm. Cells pellets were harvested via (4,000rpm, 4°C , 25min in a Sorvall RC 3BP+)
and respuspended in 10ml of lysis buffer (40mM HEPES-KOH pH 7.4, 500mM KCl,
20mM MgCl2, 2.5% (w/v) glycerol, 20mM imidazole, 5μM pepstatin A, complete
protease inhibitor cocktail (1 EDTA-free tablet/50mL) (Roche), 2mM βmercaptoethanol). Lysis was accomplished via a 30min treatment with 2mg Hen Egg
Lysozyme per 1L of cells followed by sonication. The lysate was clarified via
centrifugation (16,000rpm, 4°C, 25min in a Sorvall RC5C+ centrifuge), mixed with
lysis-buffer equilibrated Ni-sepharose beads (GE) (2ml beads per 1L of cells), and
incubated at 4°C with slow rotation for 3 hours. Beads were washed with 25 column
volumes of wash buffer (40mM HEPES-KOH pH 7.4, 150mM KCl, 20mM MgCl2, 2.5%
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(w/v) glycerol, 20mM imidazole, 2mM β-mercaptoethanol), 5 column volumes of wash
buffer with 1M KCl, then washed again with 25 column volumes of wash buffer. ClpB
was eluted with 1 column volume of elution buffer (40mM HEPES-KOH pH 7.4,
150mM KCl, 20mM MgCl2, 2.5% (w/v) glycerol, 350mM imidazole, 2mM βmercaptoethanol). After elution, ClpB was buffer exchanged into Storage Buffer (40mM
HEPES-KOH pH 7.4, 150mM KCl, 20mM MgCl2, 2.5% (w/v) glycerol, 1mM DTT).
Purity was assessed with SDS-PAGE analysis.
Hsp104 variants were expressed and purified as either N-terminally His6-tagged
constructs (pPROEX-HTb parent plasmid) as described [255] and generally as outlined
above or as tagless constructs as detailed subsequently. Hsp104 in the pNOTAG vector
(gift from Lindquist lab) was expressed in BL21-DE3 Ril cells and allowed to grow till
the cells reached mid-log phase. Expression was induced with 1mM IPTG for 15-18
hours at 15°C. Cells were then harvested via centrifugation (4,000 rpm, 4°C, 20min),
resuspended in lysis buffer (50mM Tris, pH 8, 10mM MgCl2, 2.5% glycerol (w/v), 5μM
pepstatin A, complete protease inhibitor cocktail (1 EDTA-free tablet/50mL) (Roche),
2mM β-mercaptoethanol), and lysed via treatment with lysozyme and sonication as
described above. Cell debris was removed via centrifugation (16,000rpm, 4°C, 25min)
and supernatant was applied to 3ml of lysis buffer equilibrated Affi-Gel Blue Media resin
(Bio-Rad) per 1L of starting cell culture. Supernatent and resin were rotated at 20rpm at
4°C for 3 hours. Resin was then washed 4 times with wash buffer (50mM Tris, pH 8,
10mM MgCl2, 100mM KCl, 2.5% glycerol (w/v), 2mM β-mercaptoethanol) before
Hsp104 was eluted with high-salt buffer (wash buffer with 1M KCl). After elution from
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Ni-sepharose or Affi-Blue resin, both 6His-tagged and tagless constructs, respectively,
were buffer exchanged into Buffer Q (20mM Tris-HCl pH 8, 0.5mM EDTA, 5mM
MgCl2, 50mM NaCl), filtered with a PES membrane 0.2µM syringe-driven filter
(Millipore), and purified via anion exchange chromatography with a 6ml Resource Q
column (GE). Weakly bound proteins were eluted with 2 column volumes of 20% Buffer
Q+ (20mM Tris-HCl pH 8, 0.5mM EDTA, 5mM MgCl2, 1M NaCl). Hsp104 was eluted
with a linear gradient (20%-50% Buffer Q+) over 5 column volumes. WT Hsp104 and
variants typically elute around 34% Buffer Q+ (~31mS/cm). Hsp104 was buffer
exchanged into storage buffer and purity was assessed by SDS-PAGE analysis. All
tagged Hsp104 vectors contain a TEV protease cleavage site downstream from the His6tag. Prior to use, all the His6-tag was cleaved off with proTEV protease (Promega) or
AcTEV protease (Invitrogen) according to manufacturer’s instructions. Full cleavage
was assessed with SDS-PAGE analysis.
Ssa1, Sis1, NM, Hsp26, Sup35 and Ure2 were lab stocks that were purified as
described [54, 55, 256]. Hsc70, Hdj2, DnaK, DnaJ and GrpE were from Enzo Life
Sciences. Full-length WT Rnq1 was purified as described [257]. pSGG
(SGGSGGSGGSGGS) and p370 (KLSFDDVFEREYA) peptides were from Genscript.
Aβ42 was synthesized and purified by the W.M. Keck Facility (Yale University School
of Medicine, New Haven, CT) as described [258]. The longest WT human tau isoform
(T40; amino acids 1-441), which contains the four microtubule-binding domains of tau,
and the fibrillogenic tau fragment (K18) consisting of the microtubule-binding region of
tau (amino acids 244-372, numbering of amino acids is according to T40) were purified
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as described [259]. α-Synuclein and variants were purified as described [260].
Polyglutamine (Q62 or Q81) was purified as GST-tagged proteins as described [261].
Amylin was from Anaspec. Photinus pyralis (firefly) luciferase and citrate synthase
(porcine heart) were from Sigma. Creatine kinase was from Roche. Purity of all proteins
was determined by SDS-PAGE and Coomassie staining to be >95%. Unless otherwise
indicated, Hsp104 and ClpB concentrations refer to the hexamer concentration.

5.3 Luciferase reactivation
Luciferase reactivation was performed as described[12]. To assemble aggregates,
firefly luciferase (50µM) in luciferase refolding buffer (LRB: 25mM HEPES-KOH pH
7.4, 150mM KAOc, 10mM MgAOc, 10mM DTT) with 6M urea was incubated at 30°C
for 30min. The sample was then rapidly diluted 100-fold into LRB and aliquoted into
100µl volumes. Aliquots were then frozen and stored at -80°C until use. For reactivation
assays, aggregated luciferase (50nM) was incubated with Hsp104 (1µM), Hsc70 (1µM)
and Hdj2 (1µM) plus ATP (5.1mM) and an ATP regeneration system (1mM creatine
phosphate, 0.25µM creatine kinase [Roche]) for 90min at 25°C. All co-chaperones
purchased from Enzo Life Sciences. In some experiments, Hsc70 and Hdj2 were omitted
and ATPγS and ATP ratios were included instead, as indicated. In Chapter 3, a ration of
4mM ATPγS:1mM ATP was used For luciferase reactivation by ClpB, Hsp104, Hsc70
and Hdj2 were replaced with ClpB (0.167µM), DnaK (0.167µM), DnaJ (0.033µM) and
GrpE (0.0167µM) and incubation was shortened to 60min. All co-chaperones were
purchased from Enzo Life Sciences. In some experiments, DnaK, DnaJ, and GrpE were
replaced by 2.5mMATPγS and 2.6mM ATP. Reactivated luciferase activity was assessed
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with a luciferase assay system (Promega). Recovered luminescence was monitored using
a Tecan Safire2 or Infinite M1000 plate reader. For doping experiments, total Hsp104 was
comprised of either WT Hsp104 or ClpB and mutant in a 1:5, 2:4, 3:3, 4:2, 5:1 mixture of
the two as indicated. For doping experiments, with Hsp104A430W and ClpBA428W, the
conditions for ClpB and Hsp104 were kept as similar as possible. To that end 6µM ClpB,
1µM DnaK, 1µM DnaJ, and 0.167µM GrpE were used. In some cases GrpE was omitted
from the reaction. Hsp104, Hsc70, and Hdj2 were used as described above. Total Hsp104
or ClpB was comprised of either WT or mutant or a 1:5, 2:4, 3:3, 4:2, 5:1 mixture of the
two as indicated. WT and mutant Hsp104 or ClpB mixtures were allowed to equilibrate
for 15min on ice prior to addition to the reaction.

5.4 In vivo thermotolerance assay
W303 Δhsp104 yeast were transformed with a centromeric plasmid, pHSE,
containing WT Hsp104, Hsp104A430W, Hsp104L431W, Hsp104D438W, or empty vector
according to previously established protocol [262]. Briefly, a few colonies of W303
Δhsp104 (MATa, can1-100, his3-11,15, leu2-3,112, trp1-1, ura3-1, ade2-1,
hsp104:kanMX4) yeast were grown overnight at 30°C with rotation in YPD (2% Bacto
Peptone and 1% Yeast Extract). The culture was diluted to an OD600 of 0.2 in a 100ml
volume and grown for 4 more hours at 30°C with shaking at 200rpm. Cells were pelleted
(4,000rpm, 5min, 25°C in a Sorvall RC 3BP+) and resuspended in sterile water. This
wash step was repeated 3 times. For each plasmid to be transformed, a 360µl
transformation mix (240µl of 50% PEG3350(w/v), 36µl of 1M Lithium Acetate, 10µl of
sonicated salmon sperm that was boiled at 99°C for 5min, and 72µl of sterile water) was
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prepared. Cell pellet was dissolved in all of the transformation mix and separated into 5
different epinodorf tubes. Then, ~100ng of plasmid DNA (WT Hsp104, Hsp104A430W,
Hsp104L431W, Hsp104D438W in pHSE, or empty pHSE vector) was added. Cells were heat
shocked at 42°C for 20min in a water bath, then centrifuged at 16,000rpm for 1min. The
resulting cell pellets were dissolved in sterile water, plated on SD-Ura (0.67% yeast
nitrogen base without amino acids, 2% glucose, 0.078% CSM-ura, 2% Agar) plates for
selection, and incubated at 30°C for 2 days.
For thermotolerance assay, a scraping of each strain trains was grown in SD-ura
media until an optical density of 0.55 was reached. Each strain was then incubated at
37°C for 30min to induce expression of Hsp104 variants. Cells were then heat-shocked at
50°C for between 0-20min. Immediately after heat-shock, cells were placed on ice for
2min. Cells were plated on SD-ura. Each column of cells represents a 5fold dilution.
Plates were incubated at 30°C for 2 days prior to analysis.
For immunoblotting, 3mL of cells of were adjusted to an optical density of 0.55
and heat shocked for 20min, harvested, and treated with 0.1M NaOH for 5 min at room
temperature. Cell pellets were then resuspended into 1x SDS sample buffer (60mM
TrisHCl, pH6.8, 5% glycerol, 2% SDS, 4% β-mercaptoethanol, 0.0025% bromophenol
blue) and boiled for 4 min. Lysates were cleared by centrifugation at 14,000 rpm for 2
min and then separated by SDS-PAGE (4-20% gradient, BioRad), and transferred to a
PVDF membrane. Gel was stained with Coomasie to visualize total protein. Membranes
were blocked in 10% omniblock in PBS for 1 h at room temperature. Primary α-Hsp104
(Enzo Life Sciences) antibody incubation was performed at 4ºC overnight. Secondary
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antibody was HRP conjugated (Invitrogen). Blots were visualized with SuperSignal West
Pico kits (Thermo Scientific).

5.5 ATPase
Hsp104 of ClpB (0.25µM monomer) 12min at 25°C (for Hsp104) or 20min at
25°C (for ClpB) in the presence of ATP (1mM). ATPase activity was determined by the
amount of inorganic phosphate released, which was determined using a malachite green
phosphate detection kit (Innova) according to manufacturer’s instruction. Background
hydrolysis at time zero was subtracted.

5.6 Circular Dichroism (CD) and Size Exclusion Chromatography (SEC)
For CD data collection, Hsp104 variants were dialyzed into CD buffer (50mM
Na3PO4, 50mM K3PO4, and 10mM Mg2OAC2) and the concentration was adjusted to
1µM monomer. Data was collected on an Aviv Biomedial Inc CD (Mode 410). Samples
were scanned from 260-190nm with a 1nm step-size and a 15s averaging time at 25°C.
Mean residue ellipticity (MRE) was calculated as follows: 𝑀𝑅𝐸 =

𝜃𝑜𝑏𝑠(𝑚𝑑𝑒𝑔)
10∗𝑙∗𝑐∗𝑛

, where

θobs(mdeg) is observed ellipticity at wavelength, l is pathlength (cm), n is number of amino
acids, and c is protein concentration (M). For SEC, Hsp104 variants were buffer
exchanged into running buffer (40mM HEPES pH 7.4, 150mM KCl, 10mM MgCl2, and
1mM DTT). Concentration was adjusted to 35µM and 100µl of sample was fractionated
by a Superose 6 10/300 column (GE Healthcare).

5.7 Small Angle X-Ray Scattering
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SAXS and WAXS data were collected simultaneously at beamline X9 at the
National Synchrotron Light Source (NSLS, Upton, NY) at 10°C by two overlapping
detectors, a Mar 165 CCD SAXS detector 3.4 m from the sample, and a custom built
Photonic Science CCD WAXS detector. The two-dimensional images were converted
into one-dimensional scattering profiles using software developed at the beamline. The
X-ray wavelength was 0.855 Å and the angular range collected was 0.00550 ≤ Q ≥
1.0060. The sample cell contained a glass capillary sealed across the evacuated chamber.
The protein samples and matching buffer solutions were flowed through the capillary
during exposure to reduce radiation damage. For data collection 30µL of the protein
sample or matching buffer solution was exposed for 180s, subdivided into 3 60s
exposures of 10µL. After each measurement the capillary was washed thoroughly and
purged with compressed nitrogen.
Data were collected at concentrations between 1.5 mg/mL and 6.0 mg/mL. The
two-dimensional scattering images were collected on CCD detectors, and circularly
averaged using software developed at the individual beamlines to yield one-dimensional
scattering profiles as a function of momentum transfer Q (Q=4πsin(θ)/λ, where 2π is the
scattering angle and λ is the wavelength). The raw scattering data were scaled and buffer
subtracted using the program PRIMUS [263]. Each individual scattering curve was
visually inspected for radiation damage and aggregation prior to averaging, including
Guinier and Kratky plot analysis. For data collected at NSLS, where both SAXS and
WAXS data are collected on separate detectors simultaneously, averaged scattering
curves from the SAXS and WAXS detectors were scaled and merged in PRIMUS to yield
128

a low-noise composite curve. The radii of gyration (Rg) were initially calculated using
Guinier plots [264]. Distance distribution functions P(r) were calculated by the program
GNOM [265] using an indirect Fourier transform. The maximum dimension of the
particle (Dmax) was determined by examining the quality of fit to the experimental data
for a Dmax range of 180 Å to 280 Å, varied in 5 Å increments. Values for Rg were
computed from the second moment of the P(r) and compared favorably to those
calculated by Guinier plots.

5.8 Tryptophan Fluorescence
Hsp104 variants were dialyzed overnight into Low Salt Buffer (20mM HEPES
pH 7.4, 20mM NaCl, 10mM MgCl2, 1mM DTT) to ensure that all proteins were
hexameric, even in the absence of nucleotides [110]. Concentration was then adjusted to
5.5uM monomer and samples were either left apo or incubated with 5mM ATP, ADP,
ATPγS, or AMP-PNP (a non-hydrolysable ATP analog). Samples were excited at 295nm
(4mm bandwidth) and emission was collected from 305-505nm (3mm bandwidth) with a
1nm step size on a GCK using a Fluorolog-3–21 Jobin-Yvon Spex Instrument SA
(Edison, NJ). Spectra shown are the average of two separate trials. Spectra of buffer
controls for each nucleotide state were subtracted from spectra for each protein.

5.9 Hydroxyl Radical Footprinting
Purified Hsp104 was buffer exchanged via gel filtration with a Superdex 200
column (GE) equilibrated in 20mM phosphate pH 7.5, 125mM NaCl, 20mM MgCl2.
Samples were kept on ice and transported to Brookhaven National Laboratory (Upton,
NY). Samples were kept on ice. Ten minutes prior to use samples were diluted to 10µM
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and 2mM ADP or ATPγS was added. Exposure times were predetermined by monitoring
the dose-dependent degradation of the fluorescent compound Alexa 488 (Invitrogen,
Carlsbad, CA) in the presence of the various samples in the given reaction buffers. The
samples were exposed to a mirror-focused synchrotron X-ray beam (5.5 mrad angle,
focus value or 6mm) at the X28C beamline of the National Synchrotron Light Source at
Brookhaven National Laboratory for 0-20ms. The exposure time of the samples was
controlled by flow rate through the flow cell of a KinTek (Austin, TX) stopped flow
apparatus [266]. Oxidation was immediately quenched by the addition of 10mM
methioninamide, and samples were frozen with dry ice, transported to the University of
Pennsylvania and stored at -80°C. Irradiated protein samples were thawed on ice, diluted
to 1µM in 5mM HEPES NaOH pH 7.0, 140mM KCl, 10mM MgCl2, 1mM DTT, 1%
TFA, and immediately injected into an on-line fragmentation-separation/MS analysis
system. Samples passed through an immobilized pepsin column onto a C18 trap column.
Following a 3 minute wash the peptides were eluted with a shaped elution gradient
optimized for the highly charged Hsp104 peptide fragments (6µL/min non-linear 2-50%
acetonitrile gradient with 0.1% formic acid at pH 2 and 0°C) onto and through an
analytical C18 HPLC column and injected by ESI into an LTQ Orbitrap XL mass
spectrometer (ThermoScientific). To enhance peptide identification, selected peptide ions
(the four most abundant in each scan) were fragmented by CID and measured in the LTQ
stage. Each sample was run in duplicate, eluted over a 45min gradient with extensive
washing of the trap and analytical columns between samples. A “peptide pool” of
unmodified peptides was obtained by combining high probability peptides identified from
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a number of 0ms timepoint runs. A program used for the identification of H/D exchange
data, ExMS was modified to identify oxidatively modified peptides. A list of theoretical
modified peptides was created using the unmodified peptide pool and the list of potential
modifications for each amino acid [267], and the MS spectra was searched for the
theoretical masses. Results were confirmed by searching the spectra with a modified
EXMS [268] analysis against the Hsp104 protein sequence. To date, not all of the
specifically modified residues have been confirmed/identified, which may require an
additional MSMS analysis that specifically looks for the modified peptides (which may
not be abundant enough to be automatically chosen for fragmentation).

5.10 Disulfide cross-linking
For Hsp104 crosslinking constructs, all native cysteines were mutated to serine
before engineered cysteines were introduced. For ClpB, native cysteines were not
mutated to serine. All constructs were purified as outlined above. After purification,
samples were buffer exchanged into running buffer without DTT. Protein concentrations
were then adjusted to 60µM and were incubated with 1mM diamide for 30min at room
temperature. Samples were buffer exchanged back into running buffer without DTT to
remove excess diamide. Cross-links were visualized on a Coomasie stained 4-20% TrisHCl SDS gel (BioRad) as an upshift in band migration. Quantification of band intensities
was determined by densitometry. In some cases, Ellman’s Reagent (Pierce) was used to
quantify the amount of free-sulfhydryls present according to manufacturer’s instructions.
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For all activity assays with cross-linked proteins, DTT was omitted unless
specifically stated. Luciferase aggregates (see Section 5.3 Luciferase reactivation
above) were assembled without DTT in any of the buffers.

5.11 Mathematical modeling of heterohexamer ensemble activity
We employed the approach of Reinstein and colleagues to simulate the
distribution of WT and mutant subunits within a given population of Hsp104 (or ClpB)
hexamers [206]. Thus, we employed the binomial distribution:

n 
P(x) =   p x (1 − p)n−x
x
where P is the probability that a hexamer (therefore, n=6) contains x mutant subunits and
p is the probability that a mutant subunit is incorporated. Experiments demonstrated that
mutant and WT subunits have a similar probability of being incorporated into a hexamer
(Figure S1D-I, S2J). Consequently, p is calculated as the molar ratio of mutant and WT
protein present:

p=

Hsp104 mut
(Hsp104 mut + Hsp104 WT )

Therefore, for any specified percentage of mutant subunits the probability distribution of
Hsp104 hexamers containing 0, 1, 2, 3, 4, 5 or 6 mutant subunits can be derived (Figure
6a). Activity versus p plots (Figure 6b) could then be generated assuming each WT
subunit makes an equal contribution to the total activity (one-sixth per subunit).
Consequently, if subunits within the hexamer operate independently then activity should
decline in a linear manner upon incorporation of defective mutant subunits. Conversely,
if subunits are coupled then a specific number of subunits will be sufficient to eliminate
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activity. Thus, zero activity is assigned to hexamers that are in breach of a specific
threshold number of mutant subunits. In this way, we can generate activity versus p plots
if we assume that 1 or more, 2 or more, 3 or more, 4 or more, or 5 or more mutant
subunits are required to eliminate activity.
To model the effect of Hsp104DPLDWB subunits on WT Hsp104 activity we
employed the binomial distribution as above, but imposed an additional rule whereby a
mutant subunit stimulates the activity of an adjacent WT subunit by a factor of s, but
exerts an inhibitory effect if it is adjacent to a mutant subunit [196]. To model this
behavior, we scored each subunit-subunit interface of every possible hetero-hexamer in
each possible configuration as follows: interfaces were scored as 1/6 if at a WT-WT
junction, s/6, if at a WT-mutant junction, or 0 if at a mutant-mutant junction. Activity
was then normalized to the predicted hetero-hexamer population as defined by the
binomial distribution above. Figure 1M shows the effect of increasing amounts of
stimulation denoted by the variable s.

5.12 Biotinylation of Hsp104 and subunit mixing
WT Hsp104 or Hsp104 variants were biotinylated by incubation on ice for 15min
with a 3-fold molar excess of the primary amine reactive EZ-Link NHS-LC-biotin
(Pierce) to obtain an average of 1-2 biotin moieties per Hsp104 molecule as determined
with the HABA (2-[4’-hydroxyazobenzene]-benzoic acid) reagent (Pierce). In mixing
experiments, the indicated fraction of bio-Hsp104 was mixed with unlabeled WT Hsp104
(5µM total Hsp104) for 5min on ice in luciferase refolding buffer (LRB; 25mM HEPESKOH pH 7.4, 150mM KAOc, 10mM MgAOc, 10mM DTT) in the presence of ATP
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(5mM). Reactions were then rapidly depleted of bio-Hsp104 using Ultralink immobilized
Neutravidin spin columns. The amount of unlabeled Hsp104 in the flow through was
determined by immunoblot in comparison to known quantities of unlabeled Hsp104.
Depletion of bio-Hsp104 from flow through fractions was confirmed with the HABA
reagent and by probing blots with neutravidin-HRP and comparing to known quantities of
bio-Hsp104. A similar approach was employed using his-tagged Hsp104 in place of bioHsp104. Here, his-tagged Hsp104 variants were rapidly depleted using Ni-sepharose. Nisepharose was then eluted with an empirically determined imidazole step gradient with
increments of 40mM imidazole. The flow through and eluate fractions were then TCAprecipitated and processed for SDS-PAGE and Coomassie staining. The amount of
untagged and his-tagged Hsp104 in each fraction was determined by densitometry in
comparison to known quantities of his-tagged or untagged Hsp104.

5.13 Alexa Fluor labeling of Hsp104
Hsp104 (WT and mutants) in storage buffer (SB; 40mM HEPES-KOH pH 7.4,
150mM KCl, 20mM MgCl2, 10% glycerol) was incubated with DTT (10mM) for 15min
on ice to ensure cysteine residues were reduced. Samples were then buffer exchanged
into SB plus 1mM TCEP using Micro Bio-Spin 6 columns (Bio-Rad). The Hsp104
concentration was adjusted to 100µM. The thiol-reactive dye, 5mM Alexa-Fluor-488 C5
maleimide (AF488) or 5mM Alexa-Fluor 546 C5 maleimide (AF546) (Invitrogen), was
then added drop-wise to Hsp104 samples to achieve a 20-fold molar excess over Hsp104.
Samples were then rotated slowly at 4°C in the dark. After 16h, the labeling reaction was
quenched with 1% β-mercaptoethanol and samples were rotated slowly for 15min at 4°C.
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Labeled Hsp104 samples were then exchanged into storage buffer with 1mM DTT using
Micro Bio-Spin 6 columns (Bio-Rad). To ensure that all unreacted dye was removed, the
buffer exchange step was repeated at least twice. Concentrations and labeling efficiency
were determined by UV/Vis spectrometry according to the manufacturer’s instructions
(Invitrogen). Typically, ~1-2 molecules of dye incorporated per monomer and mass
spectrometry confirmed that Cys643 and/or Cys876 became modified.

5.14 Fluorescence resonance energy transfer (FRET) and subunit mixing
Donor (Alexa-Fluor 488) labeled Hsp104 (AF488-Hsp104), Acceptor (AlexaFluor 546) labeled Hsp104 (AF546-Hsp104), or unlabeled Hsp104 were mixed in equal
stoichiometric parts to a final total Hsp104 concentration of 1µM in LRB. ATP (5mM)
was included unless otherwise indicated. In some experiments, additional NaCl was
added to LRB. Prior to any measurements, samples were allowed to equilibrate for 15min
on ice. Mixed and equilibrated samples were excited at the donor excitation wavelength
of 475nm. To monitor FRET, fluorescence was observed from 500nm-650nm, a range
which includes both donor (~525nm) and acceptor fluorescence (~572nm) maxima.
Apparent FRET efficiency (Figure S2J) was calculated from corrected AF488-Hsp104
emission (525nm) as 1-(FDA/FD), where FDA is the measured AF488-Hsp104 fluorescence
in the presence of AF546-Hsp104 (acceptor) and FD is the AF488-Hsp104 fluorescence
in the presence of unlabeled Hsp104.
For the size-exclusion chromatography experiments, AF488-Hsp104, AF546Hsp104 or unlabeled Hsp104 were mixed in equal stoichiometric parts to a final total
Hsp104 concentration of 8.3µM in size exclusion buffer (40mM HEPES-KOH pH7.4,
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150mM KCl, 20mM MgCl2, 1mM DTT and 1mM ATP). Samples were first allowed to
equilibrate for 15min on ice. After equilibration, 20µl was fractionated by TSK4000 sizeexclusion chromatography and the elution profile was followed by absorbance at 280nm
and fluorescence at 572nm (excitation 475nm) using an inline Varian Prostar Fluorimeter
with a Xe lamp. FRET was observed by exciting samples at 475nm and observing
fluorescence at 572nm, which is the predicted wavelength of maximum fluorescence for
the acceptor dye, Alexa Fluor 546.

5.15 GFP disaggregation assay
GFP disaggregation was as described [46]. Briefly, to assemble aggregates, GFP
(4.5µM) in buffer A (20mM Tris-HCl, pH 7.5, 100mM KCl, 20mM MgCl2, 5mM DTT,
0.1mM EDTA, 10% (v/v) glycerol) was incubated for 15min at 85°C. Under these
conditions, GFP forms a continuum of aggregated structures of ~500kDa and greater in
size, which are detergent soluble and completely resolved by 1% SDS at 25°C. Circular
dichroism revealed that these aggregates are dominated by random coil and beta
secondary structure. GFP aggregates (0.45µM) were incubated with Ssa1 (1µM) and Sis1
(1µM) in buffer A plus ATP (5mM) and an ATP regeneration system (as above for
luciferase reactivation). Disaggregation was initiated with WT Hsp104 (1µM) and after
8min a 5-fold molar excess of Hsp104DPL, Hsp104DWA, Hsp104DWB or Hsp104DPLDWB
was added. Disaggregation and refolding of GFP was monitored for 0-60min at 25°C by
measuring fluorescence at 510nm upon excitation at 395nm.

5.16 Hsp104 and ClpB aggregate binding
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Due to rapid ATP hydrolysis, Hsp104 and ClpB engage substrates transiently
[132, 214]. Thus, to assess Hsp104-aggregate or ClpB-aggregate interactions we
employed conditions were ATP hydrolysis was limited. Thus, we employed either WT
protein in the presence of ATPγS (1mM) or the double Walker B mutant in the presence
of ATP (1mM). Increasing amounts of Hsp104 or ClpB were incubated with the
aggregated protein (0.5µM monomer) in binding buffer (40mM HEPES-KOH pH 7.4,
150mM KCl, 20mM MgCl2 and 1mM DTT) for 10min on ice. Aggregated protein was
then rapidly recovered by centrifugation at 100,000g for 10min. Pellets were washed
gently twice with binding buffer and the amount of Hsp104 or ClpB recovered in the
pellet fraction was determined by quantitative immunoblot and densitometry in
comparison to Hsp104 or ClpB reference curves. Binding isotherms were fitted to obtain
apparent Kd estimates using Prism 5 software (Graphpad).

5.17 Amyloid assembly
Amyloid forms of full-length Sup35 and Ure2 (10µM) were generated by
incubation in assembly buffer (AB; 40mM HEPES-KOH pH 7.4, 150mM KCl, 20mM
MgCl2 and 1mM DTT) plus 10% (v/v) glycerol for 16h with rotation (80rpm on a minirotator, Glas-Col) at 25°C [55]. For Sup35, GTP (1mM) was included to stabilize the Cterminal GTP binding domain. Rnq1 (80µM) fibers were assembled in AB plus 1M NaCl
for 7 days with agitation (1,400rpm in an Eppendorf Thermomixer) at 25°C. Rnq1 fibers
were recovered by centrifugation and resuspended in AB for disaggregation assays. Aβ42
(10µM) fibers were assembled in AB for 24h with agitation (1,400rpm in an Eppendorf
Thermomixer) at 37°C. Tau (50µM) fibers were assembled in AB plus arachidonic acid
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(75µM) for 7 days with agitation (1,400rpm in an Eppendorf Thermomixer) at 37°C. K18
(20µM) fibers were assembled in AB plus arachidonic acid (75µM) for 16h with
agitation (1,400rpm in an Eppendorf Thermomixer) at 37°C. WT and mutant α-Synuclein
(80µM) were assembled in AB for 48h with agitation (1,400rpm in an Eppendorf
Thermomixer) at 37°C. For polyglutamine, GST-Q62 (5µM) or GST-Q81 (5µM) were
cleaved with thrombin to specifically remove the GST tag and incubated in AB for 16h
with agitation (1,400rpm in an Eppendorf Thermomixer) at 25°C. Phenylmethylsulfonyl
fluoride was then added to inhibit thrombin, and Q81 or Q62 fibers were recovered by
centrifugation and resuspended in AB for disaggregation assays. Amylin (20µM) fibers
were assembled in AB for 24h with agitation (1,400rpm in an Eppendorf Thermomixer)
at 25°C. NM (5µM) fibers were assembled in AB for 16h with agitation (1,400rpm in an
Eppendorf Thermomixer) at 4°C to yield NM4, at 25°C to yield NM25 or at 37°C to
yield NM37 [234]. All fiber preparations were assessed by Thioflavin-T (ThT)
fluorescence and electron microscopy. Fibers were diluted to the requisite concentration
for subsequent remodeling reactions.

5.18 Amyloid remodeling
Amyloid forms of Sup35, Ure2, Rnq1 (2.5µM monomer) or Aβ42, tau, K18, αsynWT, α-synA53T, α-synA30P, α-synE46K, Q62, Q81 and amylin fibers (1µM monomer)
were incubated with the indicated combination of Hsp104 (20µM), Ssa1 (6µM), Sis1
(6µM), or Hsp104DWA (20µM) or ClpB (20µM), DnaK (3.33µM), DnaJ (0.67µM) and
GrpE (0.33µM) in AB in the presence of ATP (5mM) and an ATP regeneration system
for 6h at 37°C. Alternatively, the indicated yeast cytosol or E. coli cytosol was added to a
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final concentration of 10mg/ml. Fiber integrity was then determined by either ThT
fluorescence or by determining the amount of the appropriate protein in the pellet fraction
by sedimentation analysis (100,000g, 10min, 25°C) and immunoblot [54, 55, 269]. In
mutant doping experiments, α-synA30P, Ure2, NM4, NM25 or NM37 fibers (1µM
monomer) were incubated with Hsp104 (10µM), Ssa1 (3µM) and Sis1 (3µM) in the
presence of ATP (5mM) and an ATP regeneration system for 1h at 37°C (for α-synA30P)
or 25°C (for Ure2, NM4, NM25 and NM37). Total Hsp104 was comprised of either WT
or mutant Hsp104 or a 1:5, 2:4, 3:3, 4:2, 5:1 mixture of the two as indicated. In some
reactions, the total adenine nucleotide concentration was kept constant at 5mM, but the
ATP:ATPγS was varied from 12:0 to 0:12. Fiber integrity was then determined by ThT
fluorescence [54, 55, 269].

5.19 Alpha-synuclein oligomer purification and disassembly
α-SynA30P preamyloid oligomers were purified by gel filtration [270].
Disassembly reactions were as described [172]. Briefly, α-SynA30P preamyloid oligomers
(1µM monomer) were incubated with Hsp104 (10µM), Ssa1 (3µM) and Sis1 (3µM) in
AB plus ATP (5mM) and an ATP regeneration system for 1h at 37°C. Total Hsp104 was
comprised of either WT or mutant Hsp104 or a 1:5, 2:4, 3:3, 4:2, 5:1 mixture of the two
as indicated. Reactions were fractionated through a Microcon YM-100 (100kDa
molecular weight cut off) filter (Milllipore) and the amount of α-SynA30P in the filtrate
was determined by immunoblot in comparison to know quantities of α-SynA30P.
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